0001144204-19-034306.txt : 20190710 0001144204-19-034306.hdr.sgml : 20190710 20190710161406 ACCESSION NUMBER: 0001144204-19-034306 CONFORMED SUBMISSION TYPE: 424B5 PUBLIC DOCUMENT COUNT: 12 FILED AS OF DATE: 20190710 DATE AS OF CHANGE: 20190710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EYENOVIA, INC. CENTRAL INDEX KEY: 0001682639 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 471178401 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B5 SEC ACT: 1933 Act SEC FILE NUMBER: 333-229365 FILM NUMBER: 19949486 BUSINESS ADDRESS: STREET 1: 8748 TECHNOLOGY WAY CITY: RENO STATE: NV ZIP: 89521 BUSINESS PHONE: 813-766-9539 MAIL ADDRESS: STREET 1: 8748 TECHNOLOGY WAY CITY: RENO STATE: NV ZIP: 89521 424B5 1 tv524860-424b5.htm 424B5 tv524860-424b5 - none - 7.1946122s
 Filed Pursuant to Rule 424(b)(5)
 Registration Number 333-229365​
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting an offer to buy these securities, in any jurisdiction where the offer and sale is not permitted.
Subject to completion, dated July 10, 2019
Preliminary prospectus supplement
(To prospectus dated February 12, 2019)
[MISSING IMAGE: lg_eyenovia.jpg]
     Shares
Common Stock
We are offering        shares of our common stock. Our common stock is listed on the Nasdaq Capital Market under the symbol “EYEN”. The last reported sale price of our common stock on July 9, 2019 was $3.60 per share.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-11 of this prospectus supplement and on page 12 of the accompanying prospectus, as well as the documents incorporated by reference into this prospectus supplement and accompanying prospectus, to read about factors you should consider before investing in our securities.
Per share
Total
Price to the public
$      $     
Underwriting discounts and commissions(1)
$ $
Proceeds to us (before expenses)
$ $
(1)
We have agreed to reimburse the underwriters for certain expenses which are not reflected in the table above. See “Underwriting”.
We intend to grant the underwriters an option to purchase up to          additional shares of common stock at the public offering price, less underwriting discounts and commissions, within 30 days from the date of this prospectus supplement. See “Underwriting” for more information.
Our Chief Executive Officer and two additional members of our Board of Directors and an executive officer have indicated an interest in purchasing up to an aggregate of approximately 10% of the number of shares of common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to these individuals than they indicated an interest in purchasing or sell no shares to these individuals, and these individuals could determine to purchase fewer shares than they indicated an interest in purchasing or purchase no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these individuals as they will on any other shares sold to the public in this offering. See “Underwriting” for more information.
As of July 9, 2019, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $42,243,740, which was calculated based on 7,172,112 shares of our outstanding common stock held by non-affiliates and at a price of  $5.89 per share, the last reported sale price for our common stock on May 13, 2019. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding one-third of our public float in any 12-month period unless our public float subsequently rises to $75.0 million or more. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus supplement.
Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares of common stock to purchasers on or about           , 2019.
Sole Book-running Manager
Oppenheimer & Co.
Lead Manager
Ladenburg Thalmann
Prospectus supplement dated            , 2019.

TABLE OF CONTENTS
Prospectus Supplement
S-1
S-1
S-2
S-9
S-11
S-16
S-18
S-19
S-20
S-25
S-25
S-25
S-25
Prospectus
1
2
3
12
13
15
16
19
21
23
25
26
28
30
30
30
31
S-i

ABOUT THIS PROSPECTUS SUPPLEMENT
On January 25, 2019, we filed a Registration Statement on Form S-3 with the United States Securities and Exchange Commission (the “SEC”) using a shelf registration process. The Registration Statement on Form S-3 was declared effective by the SEC on February 12, 2019.
This prospectus supplement describes the specific terms of an offering of our common stock and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The accompanying prospectus provides more general information. If the information in this prospectus supplement is inconsistent with the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement.
The rules of the SEC allow us to incorporate by reference information into this prospectus supplement. This means that important information is contained in other documents that are considered to be a part of this prospectus supplement. Additionally, information that we file later with the SEC will automatically update and supersede this information. You should carefully read both this prospectus supplement and the accompanying prospectus together with the additional information that is incorporated or deemed incorporated by reference in this prospectus supplement before making an investment in our common stock. See “Incorporation of Documents by Reference” before making an investment in our common stock. This prospectus supplement contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. Copies of the documents referred to herein have been filed or will be filed or incorporated by reference as exhibits to the Registration Statement of which this prospectus supplement is a part. The Registration Statement, including the exhibits and documents incorporated or deemed incorporated by reference in this prospectus supplement, can be read on the SEC website mentioned under the heading “Where You Can Find Additional Information”.
Neither the delivery of this prospectus supplement or the accompanying prospectus, nor any sale made using this prospectus supplement or the accompanying prospectus implies that there has been no change in our affairs or that the information in this prospectus supplement or in the accompanying prospectus is correct as of any date after their respective dates. You should not assume that the information included in or incorporated by reference in this prospectus supplement or the accompanying prospectus, or any future prospectus supplement or free writing prospectus prepared by us, is accurate as of any date other than the date(s) on the front covers of those documents. Our business, financial condition, results of operations and prospects may have changed since those dates.
You should rely only on the information contained in or incorporated by reference in this prospectus supplement, the accompanying prospectus and any related free writing prospectus prepared by us. Neither we nor the underwriters have authorized anyone to give you different information, and if you are given any information that is not contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any related free writing prospectus prepared by us, you must not rely on that information. We are not making an offer to sell securities in any jurisdiction where the offer or sale of such securities is not permitted.
Unless otherwise indicated in this prospectus supplement or the context otherwise requires, all references to “we”, “us”, “our”, “the Company”, and “Eyenovia” refer to Eyenovia, Inc.
INDUSTRY AND MARKET DATA
We obtained the industry, statistical and market data in this prospectus supplement from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. In presenting this information, we have made assumptions based on such data and other similar sources, and on our knowledge of, and our experience to date in, the potential markets for our product candidates. Although we believe the data from these third-party sources is reliable, we have not independently verified any third-party information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled “Risk Factors”. These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.
S-1

PROSPECTUS SUPPLEMENT SUMMARY
This summary highlights information contained elsewhere in this prospectus supplement, or incorporated by reference into this prospectus supplement and the accompanying prospectus. It might not contain all the information that is important to you. You should carefully read the entire prospectus supplement, the accompanying prospectus, any applicable additional prospectus supplement or free writing prospectus we file with the SEC and the information incorporated herein by reference, including the financial data and related notes and the sections entitled “Risk Factors”.
Our Business
Overview
We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing our patented piezo-print delivery technology, branded the Optejet™. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, Optejet has demonstrated up to a 75% reduction in ocular drug and preservative exposure, with successful topical delivery that is consistent with the efficacy of traditional eye drop administration. Using our proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Our products are not classified by the FDA as medical devices or drug-device combination products.
Eyenovia has completed its Phase III trials for MicroStat and announced positive results from those studies, known as MIST-1 and MIST-2. MicroStat is a fixed combination formulation of phenylephrine-tropicamide for mydriasis (pupil dilation), designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States. In each trial, MicroStat was shown to be safe and effective for pharmacologic mydriasis achieving clinically and statistically superior mean pupil dilation. Collective results show approximately 94% of treated eyes achieved pupil dilation of at least 6mm at 35 minutes post-instillation. Dilation was rapid in most patients, with up to 64% of fixed-combination treated eyes achieving 6mm or greater dilation as early as 20 minutes post-installation. Adverse events were infrequent (~3% of subjects), transient, and generally mild in nature. With the primary objectives of our Phase III program for MicroStat met, we plan to submit to the FDA an NDA in 2020 for marketing approval in the United States. In February 2019, the FDA accepted Eyenovia’s investigational new drug application (“IND”) to initiate our Phase III registration trial of MicroPine (the CHAPERONE study) to reduce the progression of myopia in children. We enrolled our first patient in the CHAPERONE study in June 2019. MicroPine is a first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately 5 million people in the United States.
Additionally, we have received clear feedback from the FDA regarding the requirements for Phase III trials for our MicroProst program. MicroProst is a novel latanoprost formulation for lowering intraocular pressure (“IOP”) in patients with any one or more of: ocular hypertension (“OHT”), primary open angle glaucoma (“POAG”) and chronic angle closure glaucoma (“CACG”). MicroTears, our over-the-counter (“OTC”) product candidate for dry eye, will not require Phase III trials. We plan to launch MicroTears concurrently with our potential commercialization of MicroStat.
Results from our three Phase II clinical trials have been published in peer-reviewed literature. Two studies evaluating our mydriatic agents demonstrated how the Optejet consistently delivered precision dosing at the volume of the eye’s natural tear film capacity of 6 – 8 µL, which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional eye drops with fewer side effects. In the third study, we evaluated usability, patient tolerability and IOP lowering of microdosed latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved
S-2

IOP reduction consistent with published literature on latanoprost eye drops, and administration of the medication was successful in a single attempt in more than 90% of cases. Based on the results from these clinical trials, we are able to advance MicroStat, MicroPine and MicroProst into Phase III utilizing the 505(b)(2) pathway. Where possible, we also intend to use this pathway for future clinical trials in new indications with significant unmet needs.
Our Solution
Ophthalmic drugs delivered as eye drops can fail to provide the prescribed dose more than 50% of the time and, even when the prescribed dose is delivered to the ocular surface, eye drops can overdose the ocular surface by more than 300%. The average tear volume of the eye is 6 – 8 µL, yet conventional eye drops deliver fluid volume of approximately 30 – 50 µL. Even among bottles of the same size and shape, eye drop sizes vary significantly depending on the angle of the bottle and the amount of ophthalmic solution remaining. The large drop size can result in overflow from the eye into the nasolacrimal canal, where the active drug product becomes available systemically. Ocular drugs that are absorbed by the nasolacrimal mucosa mimic intravenous injection delivery insofar as they are not susceptible to first-pass hepatic metabolism. Additionally, ocular medication in swallowed nasolacrimal secretions is theoretically available for absorption in the gastrointestinal tract. As such, only a small fraction of the applied medication is actually absorbed directly into the eye, while there remain multiple opportunities for unintended local and systemic exposure. Additionally, excess drug (and preservative in some instances) in the eye is more likely to cause ocular surface toxicity and tolerability issues and spillage to the periorbital skin can cause dermatological changes.
Instillation of eye drops also stimulates lacrimation, and can increase tear turnover rate from 16% per minute to 30% per minute once eye drops have been instilled, thereby diluting the drug product. If the eye drop stings, the loss rate can be even higher. Approximately 80% of a medication instilled as an eye drop is lost to drainage during the first 15 – 30 seconds after instillation.
The Optejet
[MISSING IMAGE: tv524860_img-optejet1.jpg]
S-3

[MISSING IMAGE: tv524860_img-optejet2.jpg]
The Optejet delivers doses of 6 – 8 µL, directly coating the corneal surface where 80% of intraocular drug penetration occurs. We believe that microdosing may reduce drug and toxic preservative exposure by more than 75%, thus reducing ocular irritation, and resulting in potentially gentler treatments without compromising the desired clinical effect. Our approach could also reduce inadvertent waste associated with poor administration of conventional macrodose drops.
We believe that we are one of the only companies with clinical stage technology for targeted microdosing of ophthalmic investigational therapies. The Optejet is based on piezo-print technology, which is also used for pixel-sharp high-precision inkjet printing. The technology is optimized for and applied in ophthalmic delivery to achieve microdosing that can be many times more precise than conventional eye droppers. In addition, our smart, electronic system provides the capability to track when patients administer their medications and deliver this information to patients and physicians via Bluetooth connectivity. Thus, physicians can make decisions regarding therapeutic regimens with knowledge of patient compliance.
The FDA has provided written feedback that our clinical development activities will be treated as drug development programs, because only the drug comes into contact with the eye. Consequently, we do not anticipate needing separate FDA approval for the Optejet or being required to comply with FDA medical device regulations.
Microdose administration of topical ophthalmic drugs with the Optejet has been tested in preclinical models and clinical trials and shown to provide many advantages over administrations of eye drops. Key advantages of the Optejet include:

Dose reduction:   Our microdose delivery technology is designed to achieve precise volumetric control at the microliter level to deliver 6 – 8 µL, which is the physiologic capacity of the tear film. This compares favorably to the volume of an eye drop (30 – 50 µL), which can result in overdosing, ocular toxicity and systemic leaching into the plasma.

Targeted dose instillation:   The Optejet allows for targeted delivery to the ocular surface and cornea, avoiding the conjunctival cul-de-sac. The micro-jet spray created by the piezo-electric vibrations is columnated and focused to provide precise delivery to the corneal surface where the majority of ocular penetration occurs. Additionally, the Optejet is designed with an LED targeting mechanism to facilitate proper positioning and objective alignment, thus increasing the likelihood of successful dose delivery.

Speed of delivery:   Our piezo-print technology is similar to pixel-sharp precision ink jet printing. Unlike a simple aerosolized mechanism, the OpteJet is designed with ejection control that creates a fast and targeted micro-jet delivery. Solution is dispensed to the ocular surface in approximately 80 milliseconds beating the eye’s 100-millisecond blink reflex.

Smart electronics:   Our smart electronics and mobile e-health technology are designed to track when a patient administers treatment. This enables physicians to objectively monitor patient compliance. We believe this technology will improve compliance and chronic disease management by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm.
S-4

Our Pipeline
The following summarizes our product pipeline and expected milestones:
Product Candidate
Indication
Next Expected Milestones
MicroStat
Mydriasis (Pupil Dilation)
NDA filing 2020
MicroPine
Pediatric Myopia Progression
(Near Sightedness)
Enrollment completion end of 2020
MicroProst
Chronic Angle Closure
Glaucoma
Phase III start end of 2019
MicroTears
Dry Eye
Launch concurrent with MicroStat
MicroStat
MicroStat is the potentially first-in-class fixed combination micro-formulation product candidate for mydriasis (eye dilation) intended to facilitate the estimated 80 million office-based comprehensive and diabetic eye exams and four million ophthalmic surgical dilations performed every year in the United States. Our fixed combination product has been developed to help achieve efficient pupil dilation while reducing unintended effects of conventionally administered mydriatic agents. We believe the market for MicroStat exceeds $250 million in the United States alone.
Phase III Clinical Development Program
We initiated Phase III clinical trials of fixed-combination microdosed phenylephrine 2.5% and tropicamide 1% administered for mydriasis in November 2018.
The MicroStat program consisted of two Phase III randomized, controlled, cross-over clinical studies evaluating pupil dilation in a total of 134 subjects with our fixed combination product (MicroStat) in comparison with the individual drug components (phenylephrine 2.5% and tropicamide 1%, respectively) (the MIST-1 study), and with a placebo (the MIST-2 study). The primary endpoint for each study was the mean change in pupil diameter at 35 minutes post-drug administration. In each trial, MicroStat was shown to be safe and effective for pharmacologic mydriasis achieving clinically and statistically superior mean pupil dilation. Collective results show approximately 94% of treated eyes achieved pupil dilation of at least 6mm at 35 minutes post-instillation. Dilation was rapid in most patients, with up to 64% of fixed- combination treated eyes achieving 6mm or greater dilation as early as 20 minutes post-installation. Adverse events were infrequent (~3% of subjects), transient, and generally mild in nature. With the primary objectives of our Phase III program for MicroStat met, we plan to submit to the FDA an NDA in 2020 for marketing approval in the United States. Outside of the United States, we have entered into a licensing partnership for MicroStat with one of our largest stockholders and a leading ophthalmology company in Japan, Senju Pharmaceuticals, Co. Ltd. (“Senju Pharmaceuticals”), for commercialization in Asia, including China, Japan and India.
MicroPine
A key therapeutic program for Eyenovia is our first-in-class topical treatment for progressive myopia, a back-of-the-eye disease. Progressive myopia is estimated to affect close to 5 million patients in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment.
S-5

[MISSING IMAGE: tv524860_img-retinal.jpg]
Progressive Myopia with Retinal Atrophy Changes
[MISSING IMAGE: tv524860_img-macular.jpg]
Fundus photographs showing the progression of myopic maculopathy from (A) category 2 (diffuse atrophy) to (B) category 4 (macular atrophy) Ophthalmology 2018;-:1e11
Academic groups have demonstrated that high efficacy with low dose atropine reduces myopia progression 60 – 70%, with sustained effect through three years. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology, indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399). While atropine 1% ophthalmic solution is commercially available, we believe the significant side effects associated with its use in the pediatric population make its use undesirable for the treatment of progressive myopia.
[MISSING IMAGE: tv524860_chrt-line.jpg]
Ophthalmology 2012;119:347-354
Phase III Clinical Development Program
MicroPine is Eyenovia’s clinical development program involving the formulation and the Optejet microdose administration of low-dose atropine for reduction of progressive myopia. In June 2019, we initiated the CHAPERONE study, a single required Phase III trial enrolling children and adolescents who will use
S-6

MicroPine therapy daily. The primary assessment of efficacy is based on reduction in myopia progression at three years, at which point the data will be analyzed and submitted in an NDA for FDA review, with a follow-up in the fourth year required to assess any rebound effects associated with a change in the medication regimen.
MicroProst
MicroProst is our proprietary latanoprost formulation product candidate, which we are developing as a first-line treatment for reduction of IOP in patients with OHT, POAG and CACG. Currently, there are no FDA-approved therapies for CACG, even though it accounts for an estimated 10% and 50% of all glaucoma diagnoses in the United States and China, respectively. We estimate that the addressable market for MicroProst exceeds $1.5 billion in the United States alone.
Phase III Clinical Development Program
Subsequent to the completion of early phase clinical trials, we met with the FDA to discuss our Phase III plans for MicroProst. The FDA outlined the necessary clinical trials for approval and we are preparing to initiate a Phase III registration program for MicroProst relying on the 505(b)(2) pathway at the end of 2019. If approved, we believe MicroProst could have the widest indication of commercially available IOP-lowering therapies, including the first FDA-approved treatment for CACG. Based on the results of our earlier study of Optejet-administered latanoprost (EYNPG-21), we believe MicroProst will achieve similar clinical efficacy without the adverse effects seen with conventional drops, which overdose the eye with potentially harmful preservatives and active pharmaceutical ingredient.
We anticipate that the MicroProst clinical program will require a single Phase III randomized controlled clinical trial involving patients with OHT, POAG and/or CACG, with a three-month primary endpoint evaluating IOP reduction and follow-up through six months for safety. We have entered into a licensing partnership for our MicroProst program with Senju Pharmaceuticals for Asia, including China where CACG accounts for up to 50% of all glaucoma.
MicroTears
MicroTears is a micro-droplet ocular hyperemia (red eye), pruritis (itch) and ocular lubrication product candidate for an estimated $850 million ocular OTC market in the United States. The Optejet can enable accurate delivery of MicroTears directly to the ocular surface, which we believe enhances its effectiveness. The lower volume of MicroTears could also lower the incidents of droplet overflow and potentially reduce the risk of therapeutic rebound from the ocular decongestant, where over time these products may lose their effectiveness. While no FDA studies are required for registration of a monograph formulation, we expect to conduct multiple Phase IV post-marketing studies to demonstrate the benefits of MicroTears. We plan to complete formulation and manufacturing scale-up activities for an expected market introduction to coincide with potential MicroStat commercialization.
Our Strategy
Our goal is to become a leading ophthalmic biopharmaceutical company focused on developing and commercializing a strong pipeline of first-in-class microdose therapeutics and a digital health platform for interactive patient care. The key elements of our strategy to achieve this goal are:
Establish a portfolio of first-in-class piezo-print micro-therapeutic products for multiple eye treatments through the 505(b)(2) pathway with the FDA.   We are initially focused on integrating our next-generation technology with therapeutic compounds already well-established in the topical treatment of ophthalmic indications. We believe that the 505(b)(2) registration pathway, which reduces development risk compared to new molecular entity programs by working with known compounds that have well-established safety and efficacy profiles, will be available for our initial development pipeline. We believe our pipeline of patented micro-therapeutic product candidates will be highly differentiated by our improved tolerability and enhanced compliance profile, and our late-stage development programs could lead to NDA submissions in novel indications where the products can have unique dosing and therapeutic profiles. We believe that this could lead to favorable pricing and reimbursement, and a reduced risk of generic substitution.
S-7

Improve clinical outcomes and patient experiences while providing an improved tolerability profile with our micro-therapeutics.   We believe the Optejet will allow for high-precision targeted microdosing for front-of-the-eye treatments, while eliminating ophthalmic over-dosing and reducing ocular exposure to toxic preservatives and pharmacologic ingredients compared to conventional eye drop delivery mechanisms. Our clinical trials have demonstrated similar efficacy to eye drops, improved side effect profile and enhanced patient experience with the Optejet as compared to conventional eye drops.
Leverage our electronic, smartphone-enabled “e-health” technology to introduce and develop patient-specific compliance monitoring program.   The mobile e-health technology within the Optejet is designed to track when a patient administers treatments, allowing physicians to track patient compliance more accurately. We believe this may enhance patient compliance and improve compliance monitoring by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent, informed and personalized therapeutic paradigm.
Develop microdose treatments for other ophthalmic diseases independently or in collaboration with third parties.   The Optejet may also be suitable for new molecular entities and applications. Leveraging our existing platform technology, we plan to continue developing, either independently or through strategic relationships with third parties, other product candidates for various eye diseases that can be administered using the Optejet and additional applications for the Optejet. We have entered into an exclusive agreement with Senju Pharmaceuticals for the Asian development and commercial rights to our therapies and technology.
Develop solutions for ophthalmic conditions with high unmet needs and no approved therapy.   We plan to target chronic ophthalmic conditions with a high unmet medical need. By leveraging our piezo-print microdosing technology, we aim to reach conditions where there are no approved drug therapies. For example, our MicroPine program involves a proprietary formulation of low-dose atropine intended to slow myopia progression in the pediatric population. There are currently no commercially available therapies in the United States to treat this indication.
Preliminary Financial Estimate
Set forth below is a preliminary estimate of our cash and cash equivalents as of June 30, 2019. This estimate is subject to the completion of our quarterly financial procedures and review and is not a comprehensive statement of our financial position as of June 30, 2019. We advise you that our actual holdings of cash and cash equivalents as of June 30, 2019 may differ materially from this estimate as a result of the completion of our quarterly financial procedures, review adjustments, and risks and uncertainties, many of which are not within our control, and other developments which may arise between now and the time that our quarterly financial results are finalized. This preliminary estimate has been prepared by, and is the responsibility of, our management and has not been reviewed, audited, compiled or subject to any other procedures by our independent registered public accounting firm. Accordingly, our independent registered public accounting firm does not express an opinion or any other form of assurance with respect to this estimate.
As of June 30, 2019, we had approximately $9.3 million in cash and cash equivalents.
Corporate Information
We were organized as a corporation under the laws of the State of Florida on March 12, 2014 under the name “PGP Holdings V, Inc.” On May 5, 2014, we changed our name to Eyenovia, Inc. On October 6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation. Our principal executive office is located at 295 Madison Avenue, Suite 2400, New York, NY 10017, and our phone number is 917-289-1117. Our website is http://www.eyenoviabio.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus supplement, does not constitute part of this prospectus supplement and should not be relied upon in connection with making any investment in our securities.
S-8

THE OFFERING
Common stock offered by us
         shares of common stock.
Option to purchase additional
shares
The underwriters will be granted an option to purchase up to an additional          shares of common stock from us. This option is exercisable, in whole or in part, for a period of 30 days following the date of this prospectus supplement.
Common stock to be outstanding immediately after this offering
         shares (or          shares if the underwriters exercise their option to purchase additional shares in full).
Use of proceeds
We estimate the net proceeds from this offering to be approximately $     million, after deducting underwriting discounts and commissions and estimated offering expense payable by us. We expect to use the proceeds of this offering, together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate purposes. See the section of this prospectus supplement titled “Use of Proceeds” for a more complete description of the intended use of proceeds from this offering.
Risk factors
See “Risk Factors” beginning on page S-11 of this prospectus supplement and on page 12 of the accompanying prospectus, as well as the documents incorporated by reference into this prospectus supplement and accompanying prospectus, to read about factors you should consider before investing in our securities.
Nasdaq Capital Market symbol
“EYEN”.
Insider Participation
Our Chief Executive Officer and two additional members of our Board of Directors and an executive officer have indicated an interest in purchasing up to an aggregate of approximately 10% of the number of shares of common stock in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to these individuals than they indicated an interest in purchasing or sell no shares to these individuals, and these individuals could determine to purchase fewer shares than they indicated an interest in purchasing or purchase no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these individuals as they will on any other shares sold to the public in this offering. See “Underwriting”.
The number of shares of our common stock to be outstanding following this offering is based on 12,053,963 shares of our common stock outstanding as of June 30, 2019 and excludes:

1,563,366 shares of our common stock underlying outstanding options to purchase common stock under our 2014 Equity Incentive Plan (the “2014 Plan”) and 2018 Omnibus Stock Incentive Plan (the “2018 Plan”) with a weighted average exercise price of $3.69 per share; and

835,669 shares of our common stock reserved for future issuance under our 2014 Plan and 2018 Plan.
S-9

Unless otherwise noted, the information in this prospectus supplement reflects and assumes the following:

no exercise of outstanding options; and

no exercise of the underwriters’ over-allotment option to purchase additional shares.
S-10

RISK FACTORS
Investing in our securities involves a high degree of risk. You should consider carefully the risks and uncertainties, as well as other information, in this prospectus supplement and the accompanying prospectus, including the risks described under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 which is incorporated herein by reference, and as updated by any other document that we subsequently file with the SEC and that is incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering. The risks set forth in this prospectus supplement and incorporated herein by reference are those which we believe are the material risks that we face. These risks are not the only ones facing us and there may be additional matters that we are unaware of or that we currently consider immaterial. The occurrence of any of such risks may materially and adversely affect our business, financial condition, results of operations and future prospects. In such an event, the market price of our common stock could decline, and you could lose part or all of your investment.
RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK
Our management and members of our Board of Directors have the ability to substantially influence all matters submitted to stockholders for approval.
As of June 30, 2019, our management and members of our Board of Directors, in the aggregate, beneficially owned shares representing approximately 26.0% of our capital stock, and some of these individuals have indicated an interest in purchasing up to an aggregate of approximately 10% of the number of shares of common stock in this offering. As a result, they can substantially influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons would substantially influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders desire or result in management of our company that our public stockholders disagree with.
A significant portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is performing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to certain restrictions. As of June 30, 2019, we had 12,053,963 shares of common stock outstanding, all of which may be resold in the public market immediately without restriction, other than shares owned by our affiliates, which may only be sold pursuant to Rule 144. In this offering we are selling      shares of common stock, which represents approximately     % of our outstanding common stock as of June 30, 2019, after giving effect to the sale of the shares of common stock in this offering. Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock on the NASDAQ Capital Market. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock.
If securities analysts do not continue to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.
The trading market for our common stock will rely, in part, on the research and reports that industry or financial analysts publish about us or our business. If securities analysts do not continue coverage of us, the trading price of our stock could decrease. Additionally, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.
The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
The stock market historically has experienced extreme price and volume fluctuations. As a result of this volatility and because the public market for our stock is new, you might not be able to sell your common
S-11

stock at or above the price at which you purchase it. From our IPO in January 2018 through July 9, 2019, the per share trading price of our common stock has been as high as $10.74 and as low as $2.40. It might continue to fluctuate significantly in response to various factors, some of which are beyond our control. These factors include:

delays in the regulatory approval of any of our product candidates;

our ability to establish and maintain an adequate manufacturing infrastructure;

our ability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;

our ability to successfully proceed to and conduct clinical trials for any of our product candidates;

results of clinical trials of our product candidates or those of our competitors;

the success of competitive products or technologies;

commencement or termination of collaborations;

the recruitment or departure of key personnel;

regulatory or legal developments in the United States and other countries;

developments or disputes concerning patent applications, issued patents or other proprietary rights;

the level of expenses related to any of our product candidates or clinical development programs;

the results of our efforts to discover, develop, acquire or in-license additional product candidates;

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

significant lawsuits, including patent or stockholder litigation;

variations in our financial results or those of companies that are perceived to be similar to us;

changes in the structure of healthcare payment systems;

market conditions in the pharmaceutical and biotechnology sectors;

general economic, industry and market conditions; and

the other factors described in this “Risk Factors” section.
Our business is subject to changing regulations regarding corporate governance, disclosure controls, internal control over financial reporting, and other compliance areas that will increase both our costs and the risk of noncompliance.
As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), the Dodd-Frank Act, and the rules and regulations of our stock exchange. The requirements of these rules and regulations will increase our legal, accounting, and financial compliance costs, will make some activities more difficult, time-consuming, and costly, and may also place undue strain on our personnel, systems, and resources.
The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Commencing with our fiscal year ending December 31, 2018, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our compliance with Section 404 of the
S-12

Sarbanes-Oxley Act will require that we incur substantial accounting expense and expend significant management efforts. Prior to our IPO, we had never been required to test our internal controls within a specified period, and, as a result, we may experience difficulty in meeting these reporting requirements in a timely manner.
We are required to disclose changes made to our internal control and procedures on a quarterly basis. However, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until we are no longer an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act), if we take advantage of the exemption available under the JOBS Act to the auditor attestation requirement in Section 404(b) of the Sarbanes-Oxley Act. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC, or other regulatory authorities, which would require additional financial and management resources.
Failure to develop and maintain adequate financial controls could cause us to have material weaknesses, which could adversely affect our operations and financial position.
As previously reported, in the fourth quarter of 2017, we identified certain material weaknesses in internal controls including regarding insufficient segregation of duties in our finance and accounting function because of our limited personnel, properly identifying all related party relationships and transactions so that they could be evaluated for disclosure in our public filings, properly communicating the terms of certain agreements entered into by us to the Board of Directors in order for the Board to take the appropriate actions, and adequately recording research and development expenses in our internal books and records to permit timely and accurate financial reporting. While we have remedied these weaknesses, we might in the future discover other material weaknesses that require additional remediation. In addition, an internal control system, no matter how well-designed, cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we might not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC, or other regulatory authorities.
Any failure to develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating results or cause us to fail to meet our reporting obligations. Any failure to implement and maintain effective internal controls also could adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control over financial reporting that we are required to include in our periodic reports filed with the SEC under Section 404 of the Sarbanes-Oxley Act. Ineffective disclosure controls and procedures or internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the trading price of our common stock. Implementing any appropriate changes to our internal controls may require specific compliance training of our directors, officers, and employees, entail substantial costs in order to modify our existing accounting systems, and take a significant period of time to complete. Such changes may not be effective, however, in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business. In the event that we are not able to demonstrate compliance with Section 404 of the Sarbanes-Oxley Act in a timely manner, that our internal controls are perceived as inadequate, or that we are unable to produce timely or accurate financial statements, investors may lose confidence in our operating results and our stock price could decline.
We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.
We are an emerging growth company. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards.
S-13

For as long as we continue to be an emerging growth company, we intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved, and exemptions from the requirements of auditor attestation reports on the effectiveness of our internal control over financial reporting. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
We will remain an emerging growth company until the earliest of  (i) the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700 million as of June 30 of that fiscal year, (ii) the end of the fiscal year in which we have total annual gross revenue of  $1.07 billion or more during such fiscal year, (iii) the date on which we issue more than $1 billion in non-convertible debt in a three-year period, or (iv) December 31, 2023.
Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our certificate of incorporation, and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board. Among other things, these provisions:

allow the authorized number of our directors to be changed only by resolution adopted by a majority of our Board;

limit the manner in which stockholders can remove directors from the Board, as may be permitted by law;

establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board;

limit who may call stockholder meetings;

authorize our Board to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called “poison pill”, that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board; and

require all stockholder action to take place at duly called stockholder meetings and disallow the ability of our stockholders to act by majority written consent.
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.
Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is, to the fullest extent permitted by law, the sole and exclusive forum for substantially all disputes between us and our stockholders. These choice of forum provisions could limit the ability of stockholders to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
Unless we consent to the selection of an alternative forum, our certificate of incorporation provides that the Court of Chancery of the State of Delaware (the “Court of Chancery”) will be, to the fullest extent
S-14

permitted by law, the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees or agent to the Company or our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; any action to enforce or determine the validity of our certificate of incorporation or bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Since the choice of forum provisions are only applicable to “the fullest extent permitted by law”, as provided in our certificate of incorporation, the provisions do not designate the Court of Chancery as the exclusive forum for any derivative action or other claim for which the applicable statute creates exclusive jurisdiction in another forum. As such, the choice of forum provisions do not apply to any actions arising under the Securities Act or the Exchange Act.
These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results.
Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
ADDITIONAL RISKS RELATED TO THIS OFFERING
Investors in this offering will pay a higher price than the book value of our common stock.
If you purchase common stock in this offering, you will pay more for your shares than the amounts paid by existing stockholders for their shares. You will incur immediate and substantial dilution of  $     per share, representing the difference between our net tangible book value per share after giving effect to this offering and an offering price of  $     per share. To the extent any outstanding options are ultimately exercised, you will sustain further dilution. For further information, see the section entitled “Dilution”.
We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.
Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our business, financial condition or results of operations or enhance the value of our common stock. We intend to use the proceeds of this offering, together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate purposes.
The failure by our management to apply these funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.
S-15

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement and accompanying prospectus contain a number of forward-looking statements. Specifically, all statements other than statements of historical facts included in this prospectus supplement and accompanying prospectus, or incorporated by reference into this prospectus supplement and accompanying prospectus, regarding our financial position, business strategy, development timelines and plans and objectives of management for future operations are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this prospectus supplement, accompanying prospectus and the documents incorporated by reference herein and therein, the words “anticipate”, “believe”, “estimate”, “expect”, “may”, “will”, “continue” and “intend”, and words or phrases of similar import are intended to identify forward-looking statements. These statements are subject to risks, uncertainties and assumptions related to various factors.
You should understand that the following important factors, in addition to those discussed in our periodic reports filed with the SEC under the Securities Exchange Act of 1934, as amended, or the Exchange Act, could affect our future results and could cause those results to differ materially from those expressed in such forward-looking statements:

risks involved in clinical trials, including, but not limited to, the costs, initiation, timing, progress and results of such trials;

our ability to timely develop and implement manufacturing, commercialization, and marketing capabilities and strategies for our existing product candidates;

our expectations related to the use of proceeds from our offerings;

our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash on hand and proceeds from any offering;

our estimates regarding expenses, future revenue, timing of any future revenue, capital requirements and needs for additional financing;

the potential advantages of our product candidates;

our estimates regarding the potential market opportunity for our product candidates;

the rate and degree of market acceptance and clinical utility of our products;

our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;

our intellectual property position;

our ability to attract and retain key personnel;

the impact of government laws and regulations;

our competitive position;

developments relating to our competitors and our industry;

our ability to maintain and establish collaborations or obtain additional funding;

general or regional economic conditions;

changes in U.S. GAAP; and

changes in the legal, regulatory and legislative environments in the markets in which we operate, and the impact of these changes on our ability to obtain regulatory approval for our products.
S-16

Although we believe that our expectations (including those on which our forward-looking statements are based) are reasonable, we cannot assure you that those expectations will prove to be correct. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described in our forward-looking statements as anticipated, believed, estimated, expected or intended.
Except for our ongoing obligations to disclose material information under the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or any other reason.
All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this prospectus supplement, accompanying prospectus and the documents incorporated by reference herein and therein might not occur.
S-17

USE OF PROCEEDS
We estimate that we will receive net proceeds from the sale of shares of common stock in this offering of approximately $     million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us (or $     million if the underwriters exercise in full their option to purchase additional shares), at a price of  $     per share in this offering.
We expect to use the proceeds of this offering, together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate purposes.
The expected net proceeds of this offering will not be sufficient for us to fund commercialization of any of our product candidates (including marketing and sales). Therefore we will need to raise substantial additional capital to complete the commercialization of our product candidates, as well as to establish an in-house manufacturing facility and sales and marketing operation.
The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials, registration activities and other development and commercialization efforts for our product candidates, as well as the amount of cash used in our operations. Although we have no present intention or commitment to do so, we may use a portion of the net proceeds for the acquisition of, or investment in, technologies, intellectual property or businesses that complement our business.
Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus supplement, we cannot predict with complete certainty all of the particular uses for the net proceeds to be received upon the completion of this or the actual amounts that we will spend on the uses set forth above. We may find it necessary or advisable to use the net proceeds for other purposes, and our management will retain broad discretion over the allocation of the net proceeds of this offering. Pending the uses described above, we plan to invest the net proceeds from this offering in corporate savings accounts with top tier commercial banks, short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
S-18

DILUTION
If you purchase shares of common stock in this offering you will experience dilution to the extent of the difference between the public offering price per share in this offering and our pro forma net tangible book value per share immediately after this offering.
Net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding. Our historical net tangible book value as of March 31, 2019 was $12,459,533, or $1.04 per share of common stock. After giving effect to the sale of       shares of common stock in this offering at the offering price of  $     per share, and the receipt of an estimated $     million of net proceeds therefrom, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding any additional shares of common stock that may be issuable upon the exercise of the underwriters’ option to purchase additional shares, our net tangible book value as of March 31, 2019 would have been $    , or $     per share. This represents an immediate increase in net tangible book value of  $     per share to existing stockholders and an immediate dilution in net tangible book value of  $     per share to investors in this offering. The following table illustrates this dilution on a per share basis:
Public offering price per share
$
Historical net tangible book value per share as of March 31, 2019
$ 1.04
Increase in net tangible book value per share attributable to this offering
$
As adjusted tangible book value per share, after giving effect to this offering
$
Dilution per share to investors in this offering
$     
If the underwriters exercise in full their option to purchase additional shares of common stock in this offering, the net tangible book value per share after giving effect to this offering would be $     per share, which amount represents an immediate increase in net tangible book value of   $     per share of our common stock to existing stockholders and an immediate dilution in net tangible book value of  $     per share of our common stock to investors purchasing shares in this offering.
The above discussion and tables are based on 12,019,148 shares of common stock outstanding as of March 31, 2019 and excludes the following:

1,598,181 shares of our common stock underlying outstanding options to purchase common stock with a weighted average exercise price of $3.65 per share as of March 31, 2019; and

335,669 shares of our common stock reserved for future issuance under our 2014 Plan and 2018 Plan.
To the extent that any of these options are exercised, new options are issued under our 2018 Plan or we issue additional shares of common stock or other equity securities in the future, there may be further dilution to investors participating in this offering.
S-19

UNDERWRITING
We entered into an underwriting agreement with the underwriters named below on July   , 2019. Oppenheimer & Co. Inc. is acting as representative of the underwriters. Subject to the terms and conditions of the underwriting agreement, each of the underwriters named below has severally agreed to purchase the number of shares of our common stock set forth opposite its name below:
Underwriter
Number of
Shares of Common Stock
Oppenheimer & Co. Inc.
Ladenburg Thalmann & Co. Inc.
Total
        
The underwriters have agreed to purchase all of the shares of common stock offered by this prospectus supplement (other than those covered by the option described below), if any are purchased.
The underwriters are offering the shares of common stock subject to various conditions and may reject all or part of any order. The representative has advised us that the underwriters propose initially to offer the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus supplement and to other dealers at such price less a concession not in excess of  $     per share of common stock to brokers and dealers. After the shares of common stock are released for sale to the public, the representative may change the offering price and other selling terms at various times.
Our Chief Executive Officer and two additional members of our Board of Directors and an executive officer have indicated an interest in purchasing up to an aggregate of approximately 10% of the number of shares of common stock to be sold in this offering at the public offering price and on the same terms as the other purchasers in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters could determine to sell fewer shares to these individuals than they indicated an interest in purchasing or sell no shares to these individuals, and these individuals could determine to purchase fewer shares than they indicated an interest in purchasing or purchase no shares in this offering. The underwriters will receive the same underwriting discount on any shares purchased by these individuals as they will on any other shares sold to the public in this offering.
We have granted the underwriters an option to purchase additional shares. This option, which is exercisable for up to 30 days after the date of this prospectus supplement, permits the underwriters to purchase a maximum of additional shares of common stock from us. If the underwriters exercise all or part of this option, they will purchase shares of common stock covered by the option at the public offering price that appears on the cover page of this prospectus supplement, less the underwriting discounts and commissions. The underwriters have severally agreed that, to the extent the option is exercised, they will each purchase a number of additional shares proportionate to the underwriter’s initial amount reflected in the foregoing table.
The following table provides information regarding the amount of the discount to be paid to the underwriters by us, before expenses.
Per
Share of
Common Stock
Total Without
Exercise of
Underwriters’
Option
Total With Full
Exercise of
Underwriters’
Option
Public offering price
$      $      $     
Underwriting discounts and commissions
$ $ $
Proceeds, before expenses, to us
$ $ $
We estimate that our total expenses of the offering, excluding the estimated underwriting discounts and commissions, will be approximately $    . We have agreed to reimburse the underwriters for expenses related to this offering, including up to $90,000 of the underwriters’ reasonable, documented out-of-pocket costs and expenses incident to the performance of their obligations under the underwriting agreement (including, without limitation, the reasonable fees and expenses of the underwriters’ outside counsel).
S-20

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933.
We and each of our executive officers and directors and certain stockholders have agreed to a 90-day “lock-up” with respect to shares of our common stock and other of our securities that they beneficially own, including securities that are convertible into shares of common stock and securities that are exchangeable or exercisable for shares of common stock. This means that, subject to certain exceptions, for a period of 90 days following the date of this prospectus supplement, we and such persons may not offer, sell, pledge or otherwise dispose of these securities without the prior written consent of the representative.
Rules of the U.S. Securities and Exchange Commission may limit the ability of the underwriters to bid for or purchase shares of common stock before the distribution is completed. However, the underwriters may engage in the following activities in accordance with the rules:

Stabilizing transactions — The representative may make bids or purchases for the purpose of pegging, fixing or maintaining the price of the common stock, so long as stabilizing bids do not exceed a specified maximum.

Over-allotments and syndicate covering transactions — The underwriters may sell more shares of common stock in connection with this offering than the number of shares of common stock that they have committed to purchase. This over-allotment creates a short position for the underwriters. This short sales position may involve either “covered” short sales or “naked” short sales. Covered short sales are short sales made in an amount not greater than the underwriters’ over-allotment option to purchase additional shares of common stock in this offering described above. The underwriters may close out any covered short position either by exercising its over-allotment option or by purchasing shares of common stock in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things, the price per share of common stock available for purchase in the open market, as compared to the price at which they may purchase shares of common stock through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing shares of common stock in the open market. A naked short position is more likely to be created if the underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price per share of common stock that could adversely affect investors who purchase shares of common stock in this offering.

Penalty bids — If the representative purchases shares of common stock in the open market in a stabilizing transaction or syndicate covering transaction, it may reclaim a selling concession from the underwriters and selling group members who sold those shares of common stock as part of this offering.

Passive market making — Market makers in the common stock who are underwriters or prospective underwriters may make bids for or purchases of shares of common stock, subject to limitations, until the time, if ever, at which a stabilizing bid is made.
Similar to other purchase transactions, the underwriters’ purchases to cover the syndicate short sales or to stabilize the market price of our common stock may have the effect of raising or maintaining the market price of our common stock or preventing or mitigating a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the common stock if it discourages resales of our shares of common stock.
Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may occur on the Nasdaq Capital Market or otherwise. If such transactions are commenced, they may be discontinued without notice at any time.
S-21

Electronic Delivery of Prospectus Supplement
A prospectus supplement in electronic format may be delivered to potential investors by one or more of the underwriters participating in this offering. The prospectus supplement in electronic format will be identical to the paper version of such prospectus supplement. Other than the prospectus supplement in electronic format, the information on any underwriter’s website and any information contained in any other website maintained by an underwriter is not part of this prospectus supplement or the registration statement of which this prospectus supplement forms a part.
Notice to Non-U.S. Investors
European Economic Area
In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a Relevant Member State), an offer to the public of our common shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of our common shares may be made at any time under the following exemptions under the Prospectus Directive:

To any legal entity which is a qualified investor as defined in the Prospectus Directive;

To fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the representatives for any such offer; or

In any other circumstances falling within Article 3(2) of the Prospectus Directive;
provided that no such offer or shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive.
For the purposes of this provision, the expression an “offer to public” in relation to our common stock in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common stock to be offered so as to enable an investor to decide to purchase our common stock, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression “Prospectus Directive” means Directive 2003/71/EC (as amended), including by Directive 2010/73/EU and includes any relevant implementing measure in the Relevant Member State.
This European Economic Area selling restriction is in addition to any other selling restrictions set out below.
United Kingdom
In the United Kingdom, this prospectus is only addressed to and directed as qualified investors who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (Order); or (ii) high net worth entities and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). Any investment or investment activity to which this prospectus relates is available only to relevant persons and will only be engaged with relevant persons. Any person who is not a relevant person should not act or relay on this prospectus or any of its contents.
Canada
This document constitutes an “exempt offering document” as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the securities described herein, or the Securities. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this document or on the merits of the Securities and any representation to the contrary is an offence.
S-22

Canadian investors are advised that this document has been prepared in reliance on section 3A.3 of National Instrument 33-105 Underwriting Conflicts, or NI 33-105. Pursuant to section 3A.3 of NI 33-105, this document is exempt from the requirement to provide investors with certain conflicts of interest disclosure pertaining to “connected issuer” and/or “related issuer” relationships as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.
Resale Restrictions
The offer and sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement to prepare and file a prospectus under applicable Canadian securities laws. Any resale of Securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the securities outside of Canada.
Representations of Purchasers
Each Canadian investor who purchases the securities will be deemed to have represented to the issuer and to each dealer from whom a purchase confirmation is received, as applicable, that the investor (i) is purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii) is an “accredited investor” as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions, or NI 45-106, or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii) is a “permitted client” as such term is defined in section 1.1 of National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.
Taxation and Eligibility for Investment
Any discussion of taxation and related matters contained in this document does not purport to be a comprehensive description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the securities or with respect to the eligibility of the securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations.
Rights of Action for Damages or Rescission
Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum, including where the distribution involves an “eligible foreign security” as such term is defined in Ontario Securities Commission Rule 45-501 Ontario Prospectus and Registration Exemptions and in Multilateral Instrument 45-107 Listing Representation and Statutory Rights of Action Disclosure Exemptions, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a “misrepresentation” as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defences under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor.
S-23

Language of Documents
Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu’il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d’achat ou tout avis) soient rédigés en anglais seulement.
Israel
This prospectus does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the common stock is directed only at, investors listed in the first addendum to the Israeli Securities Law, or the Addendum, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and “qualified individuals”, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.
Switzerland
The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the offering, us, or the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.
S-24

LEGAL MATTERS
The validity of the securities being offered hereby will be passed upon for us by Wyrick Robbins Yates & Ponton LLP, Raleigh, North Carolina. Goodwin Procter LLP, New York, New York, is representing the underwriters in connection with the offering. Certain partners of Wyrick Robbins Yates & Ponton LLP have indicated an interest in purchasing shares of common stock in this offering.
EXPERTS
The financial statements of Eyenovia, Inc. included in the Company’s Annual Report on Form 10-K as of December 31, 2018 and and for the two years in the period ended December 31, 2018 have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance on such report given upon the authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
This prospectus supplement, which constitutes a part of the registration statement on Form S-3 that we have filed with the SEC under the Securities Act, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus supplement, you should refer to the registration statement and the exhibits filed as part of that document. Statements contained in this prospectus supplement as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement.
We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings and the documents incorporated by reference and any exhibits, including the registration statement, over the Internet at the SEC’s website at http://www.sec.gov. We also maintain a website at http://www.eyenoviabio.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus supplement.
INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file later with the SEC will automatically update and supersede this information. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of any offering, except as to any portion of any future report or document that is not deemed filed under such provisions:

our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 27, 2019;


our Current Reports on Form 8-K filed with the SEC on January 30, February 6, February 13, February 19, February 25, June 4, June 12, and June 28, 2019;


S-25

Any statement contained in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or other subsequently filed document that also is or is deemed to be incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.
We will furnish without charge to you, on written or oral request, a copy of any filing or report incorporated by reference, including exhibits to the document. You should direct any requests for documents to Eyenovia, Inc., 295 Madison Avenue, Suite 2400, New York, NY 10017, (917) 289-1117, Attention: Corporate Secretary.
You should rely only on information contained in, or incorporated by reference into, this prospectus supplement. We have not authorized anyone to provide you with information different from that contained in this prospectus supplement or incorporated by reference in this prospectus supplement. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.
S-26

Prospectus
[MISSING IMAGE: lg_eyenovia.jpg]
$75,000,000 of
Common Stock
Preferred Stock
Debt Securities
Warrants
Units and/or
Rights
We may offer and sell from time to time up to $75,000,000 of our shares of common stock; shares of preferred stock; debt securities; warrants; rights to purchase common stock, preferred stock, debt securities or units; and units that include any of these securities, in one or more offerings in amounts, at prices and on terms that we will determine at the time of offering.
This prospectus provides you with a general description of the securities we may offer. A prospectus supplement containing specific information about the terms of the securities being offered and the offering, including the compensation of any underwriter, agent or dealer, will accompany this prospectus. Any prospectus supplement may also add, update or change information contained in this prospectus. If information in any prospectus supplement is inconsistent with the information in this prospectus, then the information in that prospectus supplement will apply and will supersede the information in this prospectus.
Our common stock is listed on the Nasdaq Capital Market under the symbol “EYEN”. The last reported sale price of our common stock on January 22, 2019 was $2.91 per share. We recommend that you obtain current market quotations for our common stock prior to making an investment decision.
As of January 22, 2019, the aggregate market value of our outstanding common stock held by non-affiliates, or the public float, was approximately $20,441,193, which was calculated based on 7,024,465 shares of our outstanding common stock held by non-affiliates and on a price of  $2.91 per share, the last reported sale price for our common stock on January 22, 2019. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell our common stock in a public primary offering with a value exceeding one-third of our public float in any 12-month period unless our public float subsequently rises to $75.0 million or more. We have not offered any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to and including the date of this prospectus.
This prospectus may not be used by us to consummate a sale of securities unless accompanied by the applicable prospectus supplement. You should carefully read both this prospectus and any prospectus supplement, together with additional information described in “Where You Can Find More Information” and “Incorporation of Certain Information by Reference”, before you invest in our securities.
Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 12 of this prospectus, in any accompanying prospectus supplement and in the documents incorporated by reference into this prospectus, to read about factors you should consider before investing in our securities.
Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.
Prospectus dated February 12, 2019.

TABLE OF CONTENTS
1
2
3
12
13
15
16
19
21
23
25
26
28
30
30
30
31
i

ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a shelf registration process. Under this shelf registration process, we may offer shares of our common stock; shares of our preferred stock; debt securities; warrants for such securities; rights to purchase common stock, preferred stock, debt securities or units; and units that include any of these securities, in one or more offerings, up to a total dollar amount of  $75,000,000. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering.
We may sell the securities (a) through agents; (b) through underwriters or dealers; (c) directly to one or more purchasers; or (d) through a combination of any of these methods of sale. We and our agents reserve the sole right to accept and to reject in whole or in part any proposed purchase of securities. See “Plan of Distribution” below. A prospectus supplement (or pricing supplement), which we will provide to you each time we offer securities, will provide the names of any underwriters, dealers, or agents involved in the sale of the securities, and any applicable fee, commission or discount arrangements with them.
This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. Prospectus supplements may also add, update or change information contained or incorporated by reference in this prospectus. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable prospectus supplements and the documents incorporated by reference into this prospectus, will include material information relating to the offering. You should carefully read this prospectus, the applicable prospectus supplement, the information and documents incorporated herein by reference and the additional information under the heading “Where You Can Find Additional Information About Us” before making an investment decision.
You should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus or any prospectus supplement. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained or incorporated by reference in this prospectus or any prospectus supplement. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any prospectus supplement is accurate only as of the date on the front of the document and that any information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of a security.
To the extent there are inconsistencies between this prospectus, any prospectus supplement and any documents incorporated by reference, the document with the most recent date will control.
This prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement.
Unless otherwise indicated in this prospectus or the context otherwise requires, all references to “we,” “us,” “our,” “the Company,” and “Eyenovia” refer to Eyenovia, Inc.
1

INDUSTRY AND MARKET DATA
We obtained the industry, statistical and market data in this prospectus from our own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. In presenting this information, we have made assumptions based on such data and other similar sources, and on our knowledge of, and our experience to date in, the potential markets for our product candidates. Although we believe the data from these third-party sources is reliable, we have not independently verified any third-party information. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled “Risk Factors”. These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.
2

PROSPECTUS SUMMARY
This summary highlights information contained elsewhere in this prospectus, or incorporated by reference into this prospectus. It might not contain all the information that is important to you. You should read the entire prospectus carefully, including the section entitled “Risk Factors” and our financial statements and the related notes included elsewhere in this prospectus or incorporated by reference into this prospectus, before making an investment decision to purchase shares of our securities.
Our Business
Overview
We are a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing our patented piezo-print delivery technology, which we recently branded the Optejet™. Eyenovia aims to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, which has the potential to replace conventional eyedropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. In the clinic, Optejet has demonstrated up to a 75% reduction in ocular drug and preservative exposure, with successful topical delivery that generally exceeded the efficacy of traditional eyedrop administration. Using our proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration (the “FDA”). Eyenovia’s microdose therapeutics follow the FDA-designated pharmaceutical registration and regulatory process. Our products are not classified by the FDA as medical devices or drug-device combination products.
Eyenovia recently initiated Phase III trials for MicroStat. MicroStat is a fixed combination formulation of phenylephrine-tropicamide for mydriasis (pupil dilation), designed to be a novel approach for the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States. Additionally, we have received clear feedback from the FDA regarding the requirements for Phase III trials for our MicroPine and MicroProst programs. MicroPine is a first-in-class topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching affecting approximately 5 million people in the United States. MicroProst is a novel latanoprost formulation for lowering intraocular pressure (“IOP”) in patients with ocular hypertension (“OHT”), primary open angle glaucoma (“POAG”) and chronic angle closure glaucoma (“CACG”). MicroTears, our over-the-counter (“OTC”) product candidate for dry eye, will not require Phase III trials. We plan to proceed with registration activities for MicroTears this year.
We have completed three Phase II trials, with results from two published in peer-reviewed literature and a third in press publication. In two studies evaluating mydriatic agents, the Optejet consistently delivered precision dosing at the volume of the eye’s natural tear film capacity of 6 – 8 µL, which reduced ocular and systemic drug and preservative exposure, while demonstrating pupil dilation comparable to conventional eyedrops with fewer side effects. In the third study, we evaluated usability, patient tolerability and intraocular pressure lowering of microdosed latanoprost administered with the Optejet. In this study, eyes receiving microdosed latanoprost achieved IOP reduction consistent with published literature on eyedrops and administration of the medication was successful in a single attempt in more than 90% of cases. Based on the results from these clinical trials, we have advanced MicroStat into Phase III utilizing the 505(b)(2) pathway and plan to do the same with MicroPine and MicroProst. Where possible, we also intend to use this pathway for future clinical trials in new indications with significant unmet needs.
Our Solution
Ophthalmic drugs delivered as eyedrops can fail to provide the prescribed dose more than 50% of the time and, even when the prescribed dose is delivered to the ocular surface, eyedrops can overdose the ocular surface by more than 300%. The average tear volume of the eye is 6 – 8 µL, yet conventional eyedrops deliver fluid volume of approximately 30 – 50 µL. Even among bottles of the same size and shape, eyedrop sizes vary significantly depending on the angle of the bottle and the amount of ophthalmic solution
3

remaining. The large drop size can result in overflow from the eye into the nasolacrimal canal, where the active drug product becomes available systemically. Ocular drugs that are absorbed by the nasolacrimal mucosa mimic intravenous injection delivery insofar as they are not susceptible to first-pass hepatic metabolism. Additionally, ocular medication in swallowed nasolacrimal secretions is theoretically available for absorption in the gastrointestinal tract. As such, only a small fraction of the applied medication is actually absorbed directly into the eye, while there remain multiple opportunities for unintended local and systemic exposure. Additionally, excess drug (and preservative in some instances) in the eye is more likely to cause ocular surface toxicity and tolerability issues and spillage to the periorbital skin can cause dermatological changes.
Instillation of eyedrops also stimulates lacrimation, and can increase tear turnover rate from 16% per minute to 30% per minute once eyedrops have been instilled, thereby diluting the drug product. If the eyedrop stings, the loss rate can be even higher. Approximately 80% of a medication instilled as an eyedrop is lost to drainage during the first 15 – 30 seconds after instillation.
The Optejet
[MISSING IMAGE: tv511296_img-optejet1.jpg]
[MISSING IMAGE: tv511296_img-optejet2.jpg]
The Optejet delivers doses of 6 – 8 µL, directly coating the corneal surface where 80% of intraocular drug penetration occurs. We believe that microdosing may reduce drug and toxic preservative exposure by more than 75%, thus reducing ocular irritation, and resulting in potentially gentler treatments without compromising the desired clinical effect. Our approach could also reduce waste associated with conventional macrodose drops — a problem that has been highlighted by recently introduced legislation in the U.S. Senate to address this specific concern.
We believe that we are one of the only companies with clinical stage technology for targeted microdosing of ophthalmic investigational therapies. The Optejet is based on piezo-print technology, which is also used for pixel-sharp high-precision inkjet printing. The technology is optimized for and applied in
4

ophthalmic delivery to achieve microdosing that can be many times more precise than conventional eyedroppers. In addition, our smart, electronic system provides the capability to track when patients administer their medications and deliver this information to patients and physicians via Bluetooth connectivity. Thus, physicians can make decisions regarding therapeutic regimens with knowledge of patient compliance.
The FDA has provided written feedback that our clinical development activities will be treated as drug development programs, because only the drug comes into contact with the eye. Consequently, we do not anticipate needing separate FDA approval for the Optejet or being required to comply with FDA medical device regulations.
Microdose administration of topical ophthalmic drugs with the Optejet has been tested in preclinical models and clinical trials and shown to provide many advantages over administrations of eyedrops. Key advantages include:

Dose reduction:   Our microdose delivery technology achieves precise volumetric control at the microliter level to deliver 6 – 8 µL, which is the physiologic capacity of the tear film. This compares favorably to the volume of an eyedrop (30 – 50 µL), which can result in overdosing, ocular toxicity and systemic leaching into the plasma.

Targeted dose instillation:   The Optejet allows for targeted delivery to the ocular surface and cornea, avoiding the conjunctival cul-de-sac. The micro-jet spray created by the piezo-electric vibrations is columnated and focused to provide precise delivery to the corneal surface where the majority of ocular penetration occurs. Additionally, the Optejet is designed with an LED targeting mechanism to facilitate proper positioning and objective alignment, thus increasing the likelihood of successful dose delivery.

Speed of delivery:   Our piezo-electric technology is similar to pixel-sharp precision ink jet printing. Unlike a simple aerosolized mechanism, our patented technology is designed with ejection control that creates a fast and targeted micro-jet delivery. Solution is delivered to the ocular surface in less than 80 milliseconds beating the typical eye’s 100-millisecond blink reflex.

Smart electronics:   Our smart electronics and mobile e-health technology are designed to track when a patient administers treatment. This enables physicians to objectively monitor patient compliance. We believe this technology will improve compliance and chronic disease management by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm.
Our Pipeline
The following summarizes our product pipeline and expected milestones:
Product Candidate
Indication
Next Expected Milestones
MicroStat
Mydriasis (Pupil Dilation)
Report Phase III Trial Results H1 2019
MicroPine
Pediatric Myopia Progression (Near Sightedness)
Initiate Phase III Trial H1 2019
MicroProst
Chronic Angle Closure Glaucoma
Initiate Phase III Trial H1 2019
MicroTears
Dry Eye
OTC Registration H1 2019
MicroStat
MicroStat is the potentially first-in-class fixed combination micro-formulation product candidate for mydriasis (eye dilation) intended to facilitate the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States. Our fixed combination product has been developed to help achieve efficient pupil dilation while reducing unintended effects of conventionally administered mydriatic agents. We believe the market exceeds $150 million annually in the United States alone.
5

Phase III Clinical Development Program
Our New Drug Application (“NDA”) has been accepted by the FDA and we initiated Phase III clinical trials of fixed-combination microdosed phenylephrine 2.5% and tropicamide 1% administered for mydriasis in November 2018.
The MicroStat program consists of two Phase III randomized, controlled, cross-over clinical studies evaluating pupil dilation with our fixed combination product in comparison with the individual drug components (phenylephrine 2.5% and tropicamide 1%, respectively), and with a placebo. The primary endpoint for each study is the mean change in pupil diameter at 35 minutes post-drug administration. If the primary objectives of our Phase III program are met, we plan to submit an NDA to the FDA for marketing approval in the United States. Outside of the United States, we have entered into a licensing partnership for MicroStat with one of our largest stockholders and a leading ophthalmology company in Japan, Senju Pharmaceuticals, Co. Ltd. (“Senju Pharmaceuticals”), for commercialization in Asia, including China, Japan and India.
MicroPine
A key therapeutic program for Eyenovia is our first-in-class topical treatment for progressive myopia, a back-of-the-eye disease. Progressive myopia is estimated to affect close to 5 million patients in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment.
[MISSING IMAGE: tv511296_img-retinal.jpg]
Progressive Myopia with Retinal Atrophy Changes
[MISSING IMAGE: tv511296_img-macular.jpg]
Fundus photographs showing the progression of myopic maculopathy from (A) category 2 (diffuse atrophy) to (B) category 4 (macular atrophy) Ophthalmology 2018;-:1e11
Academic groups have demonstrated that high efficacy with low dose atropine reduces myopia progression 60 – 70%, with sustained effect through three years. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology, indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399). While atropine 1% ophthalmic solution is commercially available, we believe the significant side effects associated with its use in the pediatric population make its use undesirable for the treatment of progressive myopia.
6

[MISSING IMAGE: tv511296_chrt-line.jpg]
Ophthalmology 2012;119:347–354
Phase III Clinical Development Program
MicroPine is Eyenovia’s clinical development program involving the formulation and the Optejet microdose administration of low-dose atropine for reduction of progressive myopia. Based on FDA feedback, we anticipate initiation of the single required Phase III trial enrolling children and adolescents who will use MicroPine therapy daily. The primary assessment of efficacy is based on reduction in myopia progression at three years, at which point the data will be analyzed and submitted in an NDA for FDA review, with a follow-up in the fourth year required to assess any rebound effects associated with a change in the medication regimen.
MicroProst
MicroProst is our proprietary latanoprost formulation product candidate, which we are developing as a first-line treatment for reduction of IOP in patients with OHT, POAG and CACG. Currently, there are no FDA-approved therapies for CACG, even though it accounts for an estimated 10% and 50% of all glaucoma diagnoses in the United States and China, respectively. We believe that the market for MicroProst exceeds $700 million annually in the United States alone.
Phase III Clinical Development Program
Subsequent to the completion of early phase clinical trials, we met with the FDA to discuss our Phase III plans for MicroProst. The FDA outlined the necessary clinical trials for approval and we are preparing to initiate a Phase III registration program for MicroProst relying on the 505(b)(2) pathway in the first half of 2019. If approved, we believe MicroProst could have the widest indication of commercially available IOP-lowering therapies, including the first FDA-approved treatment for CACG. Based on the results of our earlier study of Optejet-administered latanoprost (PG-21), we believe MicroProst will achieve similar clinical efficacy without the adverse effects seen with conventional drops, which overdose the eye with potentially harmful preservatives and active pharmaceutical ingredient.
We anticipate that the MicroProst clinical program will require a single Phase III randomized controlled clinical trial involving patients with OHT, POAG and/or CACG, with a three-month primary endpoint evaluating IOP reduction and follow-up through six months for safety. We plan to begin the clinical trial for MicroProst in the first half of 2019. We have entered into a licensing partnership for our MicroProst program with Senju Pharmaceuticals for Asia, including China where CACG accounts for up to 50% of all glaucoma.
MicroTears
MicroTears is a micro-droplet ocular surface tear replenishment product candidate for the estimated $2 billion-plus (200 million units) annual OTC artificial tear market. The Optejet can enable accurate
7

delivery of MicroTears directly to the ocular surface, which we believe will enhance its effectiveness. The lower volume of MicroTears could also lower the incidents of droplet overflow. While no FDA studies are required for registration of a monograph formulation, we expect to conduct multiple Phase IV post-marketing studies to demonstrate the benefits of MicroTears. We plan to complete formulation and manufacturing scale-up activities for an expected market introduction in mid-to-late 2019.
Our Strategy
Our goal is to become a leading ophthalmic biopharmaceutical company focused on developing and commercializing a strong pipeline of first-in-class microdose therapeutics and a digital health platform for interactive patient care. The key elements of our strategy to achieve this goal are:
Establish a portfolio of first-in-class piezo-print micro-therapeutic products for front-of-the-eye treatments through the 505(b)(2) pathway with the FDA.   We are initially focused on integrating our next-generation technology with therapeutic compounds already well-established in the topical treatment of ophthalmic indications. We believe that the 505(b)(2) registration pathway, which reduces development risk compared to new molecular entity programs by working with known compounds with well-established safety and efficacy profiles, will be available for our initial development pipeline. We believe our pipeline of patented micro-therapeutic product candidates will be highly differentiated by our improved tolerability and enhanced compliance profile, and our late-stage development programs could lead to NDA submissions in novel indications where the products can have unique dosing and therapeutic profiles. We believe that this could lead to favorable pricing and reimbursement, and a reduced risk of generic substitution.
Improve clinical outcomes and patient experiences while providing an improved tolerability profile with our micro-therapeutics.   We believe the Optejet will allow for high-precision targeted microdosing for front-of-the-eye treatments, while eliminating ophthalmic over-dosing and reducing ocular exposure to toxic preservatives and pharmacologic ingredients compared to conventional eyedrop delivery mechanisms. Our clinical trials have demonstrated equivalent efficacy to eyedrops, improved side effect profile and enhanced patient experience with the Optejet as compared to conventional eyedrops.
Leverage our electronic, smartphone-enabled “e-health” technology to introduce and develop patient-specific compliance monitoring program.   The mobile e-health technology within the Optejet is designed to track when a patient administers treatments, allowing physicians to track patient compliance more accurately. We believe this may enhance patient compliance and improve compliance monitoring by empowering patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent, informed and personalized therapeutic paradigm.
Develop microdose treatments for other ophthalmic diseases independently or in collaboration with third parties.   The Optejet is also suitable for new molecular entities. Leveraging our existing platform technology, we plan to continue developing, either independently or through strategic relationships with third parties, other product candidates for front-of-the-eye diseases that can be administered using the Optejet. We have entered into an exclusive agreement with Senju Pharmaceuticals for the Asian development and commercial rights to our therapies and technology.
Develop solutions for ophthalmic conditions with high unmet needs and no approved therapy.   We plan to target chronic ophthalmic conditions with a high unmet medical need. By leveraging our piezo-print microdosing technology, we aim to reach conditions where there are no approved drug therapies. For example, our MicroPine program involves a proprietary formulation of low-dose atropine intended to slow myopia progression in the pediatric population. There are currently no commercially-available therapies in the United States to treat this indication.
Our Team
Our management team is a critical component to the execution of our overall strategy and business model and is led by our Chief Executive Officer and Chief Medical Officer, Dr. Tsontcho Ianchulev. Dr. Ianchulev has over 15 years of experience in public health, life-science and medical technology. He is a physician-executive and public health expert who has been at the core of developing medical products and technologies that have transformed the ophthalmic field and impacted medical care for thousands of
8

patients each year. His intellectual property was a core asset to WaveTec’s (acquired by Alcon) technology for intraoperative aberrometry. He is currently a Professor of Ophthalmology at the New York Eye and Ear Infirmary and sits on the Boards of Kurobe Pharmaceuticals and The American Society of Cataract and Refractive Surgery Foundation. Dr. Ianchulev spent five years at Genentech, where he headed the ophthalmology research group and directed the development and FDA approval of Lucentis, a successful specialty biologic in the field of ophthalmology with more than $4 billion of annual sales in 2015. Most recently, he headed all clinical development of Transcend Medical’s (acquired by Alcon) micro-stent for glaucoma. We believe Dr. Ianchulev’s clinical experience, combined with development and commercial work in both biopharmaceuticals and medical devices make him well suited to lead Eyenovia. Dr. Ianchulev is a graduate of Harvard Medical School and has an MPH degree from the Harvard School of Public Health.
In addition to Dr. Ianchulev, the management team includes professionals with significant experience in translational science, drug evaluation, clinical development, regulatory affairs, finance, marketing and business development. Our management team is supported by our Board of Directors, which has extensive professional experience in strategic development, executive, operational and financial leadership in the pharmaceutical and healthcare industries, including several successful ophthalmology companies.
Corporate Information
We were organized as a corporation under the laws of the State of Florida on March 12, 2014 under the name “PGP Holdings V, Inc.” On May 5, 2014, we changed our name to Eyenovia, Inc. On October 6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation. Our principal executive office is located at 295 Madison Avenue, Suite 2400, New York, NY 10017, and our phone number is 917-289-1117. Our website is http://www.eyenoviabio.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, does not constitute part of this prospectus and should not be relied upon in connection with making any investment in our securities.
Offerings Under This Prospectus
We may offer shares of our common stock; shares of our preferred stock; debt securities; warrants for such securities; rights to purchase common stock, preferred stock, debt securities or units; and units that include any of these securities, with a total value of up to $75,000,000 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of any offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities.
The prospectus supplement also may add, update or change information contained in this prospectus or in documents we have incorporated by reference into this prospectus. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described in this prospectus at the time of its effectiveness.
This prospectus may not be used to consummate a sale of any securities unless it is accompanied by a prospectus supplement.
We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we offer securities through agents or underwriters, we will include in the applicable prospectus supplement:

the names of those agents or underwriters;

applicable fees, discounts and commissions to be paid to them;

details regarding over-allotment options, if any; and

the net proceeds to us.
9

Common Stock
Our Third Amended and Restated Certificate of Incorporation, as amended, or certificate of incorporation, authorizes the issuance of 90,000,000 shares of common stock, of which 11,782,682 shares were issued and outstanding as of January 22, 2019. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends declared by our Board of Directors, subject to any preferential dividend rights of outstanding preferred stock.
In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.
Preferred Stock
Our certificate of incorporation authorizes the issuance of 6,000,000 shares of blank check preferred stock with such designation, rights and preferences as may be determined from time to time by our Board of Directors. No shares of preferred stock are currently designated and outstanding. Our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights, which could adversely affect the voting power or other rights of the holders of common stock. We may issue some or all of the preferred stock to effect a business transaction. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing a change in control of us.
If we sell any series of preferred stock under this prospectus and applicable prospectus supplements, we will fix the rights, preferences, privileges and restrictions of the preferred stock of such series in a certificate of amendment to our certificate of incorporation relating to that series. We will also incorporate by reference from reports that we file with the SEC, the form of any certificate of amendment that describes the terms of series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the applicable prospectus supplement related to the series of preferred stock being offered, as well as the complete certificate of amendment that contains the terms of the applicable series of preferred stock.
Warrants
We may issue warrants for the purchase of common stock, preferred stock and/or debt securities (described below) in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. We will evidence each series of warrants by warrant certificates that we will issue under a separate agreement. We may enter into warrant agreements with a bank or trust company that we select to be our warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants.
In this prospectus, we have summarized certain general features of warrants. We urge you, however, to read the applicable prospectus supplement related to the particular series of warrants being offered, as well as the warrant agreements and warrant certificates that contain the terms of the warrants. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement and warrant certificate containing the terms of the warrants we are offering before the issuance of the warrants.
Debt Securities
We may offer debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any
10

other unsecured and unsubordinated debt. Any subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Any convertible debt securities will be convertible into or exchangeable for our common stock or our other securities. Conversion may be mandatory or at your option or both and would be at prescribed conversion rates.
With respect to any debt securities that we issue, we will issue such debt securities under an indenture, which we would enter into with the trustee named in the indenture. The form of indenture is filed as an exhibit to the registration statement of which this prospectus is a part and is incorporated herein by reference. Any indenture would be qualified under the Trust Indenture Act of 1939, as amended.
Units
We may issue units consisting of some number and/or combination of shares of our common stock; shares of our preferred stock; debt securities; warrants for such securities; or rights for the purchase of common stock, preferred stock, debt securities or units, in one or more series. In this prospectus, we have summarized certain general features of units. We urge you, however, to read the applicable prospectus supplement related to the series of units being offered, as well as the unit agreements that contain the terms of the units. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference reports that we file with the SEC, the form of unit agreement, unit certificate, as may be applicable, and any supplemental agreements that describe the terms of the units we are offering before the issuance of the units.
Rights
We may offer rights to our existing stockholders to purchase additional shares of our common stock, shares of our preferred stock, debt securities or units. For any particular subscription rights, the applicable prospectus supplement will describe the terms of such rights, including the period during which such rights may be exercised, the manner of exercising such rights, the transferability of such rights and the number of shares of common stock, shares of preferred stock, debt securities or units that may be purchased in connection with each right and the subscription price for the purchase of such common stock, preferred stock, debt securities or units. In connection with a rights offering, we may enter into a separate agreement with one or more underwriters or purchasers to purchase any shares of our common stock, preferred stock, debt securities or units not subscribed for in the rights offering by existing stockholders, which will be described in the applicable prospectus supplement.
In this prospectus, we have summarized certain general features of rights. We urge you, however, to read the applicable prospectus supplement related to the rights being offered and the rights agreement that contains the terms of the rights, and the rights certificate. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of rights agreement containing the terms of the rights and rights certificate we are offering before the issuance of rights.
Listing
If any securities are to be listed or quoted on a securities exchange or quotation system, the applicable prospectus supplement will so indicate. Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “EYEN”.
11

RISK FACTORS
Investing in our securities involves a high degree of risk. You should consider carefully the risks and uncertainties described in “Risk Factors” in our most recently filed Annual Report on Form 10-K filed with the SEC, in each case as these risk factors are amended or supplemented by subsequent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, or Current Reports on Form 8-K that have been or will be incorporated by reference in this prospectus. The prospectus supplement relating to a particular offering of our securities may also discuss certain risks of investing in that offering. The risks set forth in any prospectus supplement and incorporated herein by reference are those which we believe are the material risks that we face. The occurrence of any of such risks may materially and adversely affect our business, financial condition, results of operations and future prospects. In such an event, the market price of our common stock could decline, and you could lose part or all of your investment.
12

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains a number of forward-looking statements. Specifically, all statements other than statements of historical facts included in this prospectus, or incorporated by reference into this prospectus, regarding our financial position, business strategy, development timelines and plans and objectives of management for future operations are forward-looking statements. These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions made by and information currently available to management. When used in this prospectus and the documents incorporated by reference herein, the words “anticipate”, “believe”, “estimate”, “expect”, “may”, “will”, “continue” and “intend”, and words or phrases of similar import are intended to identify forward-looking statements. These statements are subject to risks, uncertainties and assumptions related to various factors.
You should understand that the following important factors, in addition to those discussed in our periodic reports filed with the SEC under the Securities Exchange Act of 1934, as amended, or the Exchange Act, could affect our future results and could cause those results to differ materially from those expressed in such forward-looking statements:

risks involved in clinical trials, including, but not limited to, the costs, initiation, timing, progress and results of such trials;

our estimates regarding the potential market opportunity for our product candidates;

our ability to develop and implement our commercialization, marketing and manufacturing capabilities and strategies;

our expectations related to the use of proceeds from any offering;

our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash on hand and proceeds from any offering;

the potential advantages of our product candidates;

the rate and degree of market acceptance and clinical utility of our products;

our intellectual property position;

our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives;

our estimates regarding expenses, future revenue, timing of any future revenue, capital requirements and needs for additional financing;

our ability to attract and retain key personnel;

the impact of government laws and regulations;

our competitive position;

developments relating to our competitors and our industry;

our ability to maintain and establish collaborations or obtain additional funding;

general or regional economic conditions;

changes in U.S. GAAP; and

changes in the legal, regulatory and legislative environments in the markets in which we operate, including impacts of U.S. government shut-downs on our ability to raise money and obtain regulatory approval for our products.
Although we believe that our expectations (including those on which our forward-looking statements are based) are reasonable, we cannot assure you that those expectations will prove to be correct. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described in our forward-looking statements as anticipated, believed, estimated, expected or intended.
13

Except for our ongoing obligations to disclose material information under the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or any other reason. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this prospectus and the documents incorporated by reference herein might not occur.
14

USE OF PROCEEDS
We cannot assure you that we will receive any proceeds in connection with securities offered by us pursuant to this prospectus. Unless otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of our securities by us under this prospectus for general corporate purposes, including to cover expenses related to our clinical trials and development programs and our operating expenses. We will set forth in the applicable prospectus supplement our intended use for the net proceeds received from the sale of any securities by us. Pending the application of the net proceeds, we intend to invest the net proceeds generally in corporate savings accounts with top tier commercial banks, short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
15

PLAN OF DISTRIBUTION
We may sell securities offered under this prospectus:

through underwriters or dealers;

through agents;

directly to one or more purchasers; or

through a combination of any of these methods for sale.
The distribution of the securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be changed from time to time, or at negotiated prices. For each type and series of securities offered, the applicable prospectus supplement will set forth the terms of the offering, including, without limitation:

the names of any underwriters, dealers or agents;

the purchase price of the securities;

the use of proceeds to us from the sale of the securities;

any underwriting discounts, agency fees or other compensation payable to underwriters or agents;

any discounts or concessions allowed or re-allowed or repaid to dealers; and

the securities exchanges on which the securities will be listed, if any.
If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. If we use underwriters in any sale of securities offered under this prospectus, the underwriters will buy the securities for their own account. The underwriters may then resell the securities in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale or thereafter. The underwriters may sell the securities directly or through underwriting syndicates managed by managing underwriters. The obligations of the underwriters to purchase the securities will be subject to certain conditions. The underwriters will be obligated to purchase all the securities offered if they purchase any securities. The offering price and any discounts or concessions allowed or re-allowed or paid to dealers may be changed from time to time. In connection with an offering, underwriters and their affiliates may engage in transactions to stabilize, maintain, or otherwise affect the market price of the securities in accordance with applicable law.
Underwriters or agents may make sales in privately negotiated transactions and/or any other method permitted by law, including sales deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act, which includes sales made directly on the Nasdaq Capital Market, the existing trading market for our common stock, or sales made to or through a market maker other than on an exchange.
If we use dealers in any sale of securities offered under this prospectus, the securities will be sold to such dealers as principals. The dealers may then resell the securities to the public at varying prices to be determined by such dealers at the time of resale. If agents are used in any sale of securities offered under this prospectus, they will generally use their reasonable best efforts to solicit purchases for the period of their appointment. If securities offered under this prospectus are sold directly, no underwriters, dealers or agents would be involved. We are not making an offer of securities in any state that does not permit such an offer.
Underwriters, dealers and agents that participate in any distribution of securities may be deemed to be underwriters as defined in the Securities Act. Any discounts, commissions or profit they receive when they resell the securities may be treated as underwriting discounts and commissions under the Securities Act. We expect that any agreements we may enter into with underwriters, dealers and agents will include provisions indemnifying them against certain civil liabilities, including certain liabilities under the Securities Act, or providing for contributions with respect to payments that they may be required to make.
16

We may authorize underwriters, dealers or agents to solicit offers from certain institutions whereby the institution contractually agrees to purchase the securities offered under this prospectus from us on a future date at a specific price. This type of contract may be made only with institutions that we specifically approve. Such institutions could include banks, insurance companies, pension funds, investment companies, and educational and charitable institutions. The underwriters, dealers or agents will not be responsible for the validity or performance of these contracts.
Sales of securities offered under this prospectus also may be effected by us from time to time in one or more types of transactions (which may, without limitation, include block transactions, special offerings, exchange distributions, secondary distributions, purchases by a broker or dealer, or other direct sales by us to one or more purchasers) on the Nasdaq Capital Market or any other national securities exchange or automated trading and quotation system on which our common stock or other securities are listed, in the over-the-counter market, in transactions otherwise than on such exchanges and systems or the over-the-counter market, including negotiated transactions, through options transactions relating to the shares, or a combination of such methods of sale, at market prices prevailing at the time of sale, at negotiated prices, or at fixed prices. Such transactions may or may not involve brokers or dealers. Any shares of our common stock offered under this prospectus will be listed on the Nasdaq Capital Market, subject to notice of issuance.
Each issue of a new series of debt securities, preferred stock, warrants, units and rights will be a new issue of securities with no established trading market. It has not been established whether the underwriters, if any, of the securities offered under this prospectus will make a market in these securities. If a market in any series of debt securities, preferred stock, warrants, units and rights is made by any such underwriters, such market-making may be discontinued at any time without notice. We can give no assurance as to the liquidity of the trading market of these securities.
In order to facilitate the offering of any of the securities offered under this prospectus, the underwriters with respect to any such offering may, as described in the prospectus supplement, engage in transactions that stabilize, maintain, or otherwise affect the price of the securities or any other securities the prices of which may be used to determine payments on these securities. Specifically, the underwriters may over-allot in connection with the offering, creating a short position in these securities for their own accounts. In addition, to cover over-allotments or to stabilize the price of these securities or of any other securities, the underwriters may bid for, and purchase, these securities or any other securities in the open market. Finally, in any offering of the securities offered under this prospectus through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing these securities in the offering, if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions, or otherwise. Any of these activities may stabilize or maintain the market price of these securities above independent market levels. The underwriters are not required to engage in these activities, and may end any of these activities at any time, all as described in the applicable prospectus supplement.
If so indicated in the applicable prospectus supplement, one or more firms, which we refer to as “remarketing firms”, acting as principals for their own accounts or as agents for us, may offer and sell the securities offered under this prospectus as part of a remarketing upon their purchase, in accordance with their terms. We will identify any remarketing firm, the terms of its agreement, if any, with us and its compensation in the applicable prospectus supplement.
Remarketing firms, agents, underwriters and dealers may be entitled under agreements with us to indemnification by or contribution from us against some civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.
Any person participating in the distribution of securities will be subject to applicable provisions of the Exchange Act, and the rules and regulations under the Exchange Act, including without limitation, Regulation M, which may limit the timing of transactions involving the securities offered under this prospectus. Furthermore, Regulation M may restrict the ability of any person engaged in the distribution of such securities to engage in market-making activities with respect to the particular securities being distributed. All of the above may affect the marketability of the securities offered under this prospectus and the ability of any person or entity to engage in market-making activities with respect to such securities.
17

Under the securities laws of various states, the securities offered under this prospectus may be sold in those states only through registered or licensed brokers or dealers. In addition, in various states the securities offered under this prospectus may not be offered and sold unless such securities have been registered or qualified for sale in the state or an exemption from such registration or qualification is available and is complied with.
18

DESCRIPTION OF OUR CAPITAL STOCK
Common Stock
Our certificate of incorporation, authorizes the issuance of 90,000,000 shares of common stock, of which 11,782,682 shares were issued and outstanding as of January 22, 2019. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive proportionately any dividends declared by our Board of Directors, subject to any preferential dividend rights of outstanding preferred stock.
In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.
The transfer agent for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent’s address is American Stock Transfer & Trust Company, LLC 6204 15th Avenue, Brooklyn, New York 11219 and its telephone number is 800-937-5449.
Options
As of January 22, 2019, options to purchase an aggregate of 1,924,432 shares of our common stock, with a weighted average exercise price of  $3.27 per share, were outstanding under our 2014 Equity Incentive Plan and 2018 Omnibus Stock Incentive Plan.
Preferred Stock
Our certificate of incorporation authorizes the issuance of 6,000,000 shares of blank check preferred stock with such designation, rights and preferences as may be determined from time to time by our Board of Directors. No shares of preferred stock are currently designated and outstanding. Our Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights, which could adversely affect the voting power or other rights of the holders of common stock. We may issue some or all of the preferred stock to effect a business transaction. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing a change in control of us.
If we issue preferred stock, we will fix the rights, preferences, privileges, qualifications and restrictions of the preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in a certificate of amendment to our certificate of incorporation relating to that series. We will also incorporate by reference into the registration statement, of which this prospectus is a part, the form of any certificate of amendment that describes the terms of series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you to read the prospectus supplement related to any series of preferred stock we may offer, as well as the complete certificate of amendment that contains the terms of the applicable series of preferred stock.
It is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of our common stock until our board of directors determines the specific rights of the holders of the preferred stock. However, these effects might include restricting dividends on the common stock, diluting the voting power of the common stock, impairing the liquidation rights of the common stock, and delaying or preventing the completion of a merger, tender offer or other takeover attempt. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock.
All shares of preferred stock offered will, when issued, be fully paid and nonassessable, including shares of preferred stock issued upon the exercise or exchange of any other securities described in this prospectus.
19

Registration Rights
We are subject to an Investor’s Rights Agreement, as amended (the “Rights Agreement”), between us and the previous holders of our Series A preferred stock, Series A-2 preferred stock and Series B preferred stock, which shares were all converted to shares of our common stock immediately following the January 2018 initial public offering of our common stock (“IPO”). Under the Rights Agreement, beginning in July 2018, the holders of approximately 4,301,946 shares of our common stock are entitled to demand registration rights. At any time, the holders of more than specified amounts of these shares can, on not more than two occasions, request that we register all or a portion of their shares. We will not be required to effect a demand registration during the period beginning 60 days prior to our good faith estimate of the date of filing and 180 days following the effectiveness of a company-initiated registration statement relating to a public offering of our securities, such as our registration statement on Form S-1, filed with the SEC on December 12, 2018 and effective December 18, 2019.
In addition, in the event that we propose to register any of our securities under the Securities Act of 1933, as amended (“Securities Act”), either for our own account or for the account of other security holders, the holders of approximately 4,301,946 shares of our common stock are entitled to certain “piggyback” registration rights allowing such holders to include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to a registration related to employee benefit plans, debt securities or corporate reorganizations, the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in the registration. The holders of these rights have waived them with respect to this Registration Statement.
We will pay the registration expenses of the holders of the shares registered pursuant to the registrations described above.
The registration rights described above will expire upon the earlier of (i) January 2021, or (ii) with respect to any particular stockholder, the date on which such stockholder can sell all of its shares under Rule 144 of the Securities Act during any 90-day period.
20

DESCRIPTION OF WARRANTS
The following description, together with the additional information we may include in any applicable prospectus supplement, summarizes the material terms and provisions of the warrants that we may offer under this prospectus and any related warrant agreement and warrant certificate. While the terms summarized below will apply generally to any warrants that we may offer, we will describe the specific terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms described below. Specific warrant agreements will contain additional important terms and provisions as follows and will be filed, along with a form of warrant certificate, as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC:

the specific designation and aggregate number of, and the price at which we will issue, the warrants;

the currency or currency units in which the offering price, if any, and the exercise price are payable;

if applicable, the exercise price for shares of our common stock or preferred stock and the number of shares of common stock or preferred stock to be received upon exercise of the warrants;

in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise;

the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants;

whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit;

any applicable material U.S. federal income tax consequences;

the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or other agents;

the proposed listing, if any, of the warrants or the common stock issuable upon exercise of the warrants on any securities exchange;

if applicable, the date from and after which the warrants and the common stock or preferred stock will be separately transferable;

if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;

information with respect to book-entry procedures, if any;

the anti-dilution provisions of the warrants, if any;

the redemption or call provisions, if any;

whether the warrants are to be sold separately or with other securities as parts of units; and

any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.
Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:

in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or
21


in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
Each warrant will entitle the holder of the warrant to purchase for cash, or via net exercise, an amount of securities at the exercise price set forth in the applicable prospectus supplement. Holders may exercise warrants at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will be void.
The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement.
22

DESCRIPTION OF DEBT SECURITIES
The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the material terms and provisions of any debt securities that we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we offer, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities we may offer under a prospectus supplement may differ from the terms described below. For any debt securities that we offer, an indenture (and any relevant supplemental indenture), if required, will contain additional important terms and provisions, the form of which we filed as an exhibit to the registration statement of which this prospectus is a part and is incorporated therein by reference. We will file any definitive indenture as an exhibit to reports that we file with the SEC and incorporate by reference in this prospectus and the applicable prospectus supplement. Any indenture would be qualified under the Trust Indenture Act of 1939, as amended.
With respect to any debt securities that we issue, we will describe in each prospectus supplement the following terms relating to a series of debt securities:

the title;

the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding;

any limit on the amount that may be issued;

whether or not we will issue the series of debt securities in global form, and if so, the terms and who the depository will be;

the maturity date;

the principal amount due at maturity;

whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;

the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;

whether or not the debt securities will be convertible into shares of our common stock or our preferred stock and, if so, the terms of such conversion;

whether or not the debt securities will be secured or unsecured by some or all of our assets, and the terms of any secured debt;

the terms of the subordination of any series of subordinated debt;

the place where payments will be payable;

restrictions on transfer, sale or other assignment, if any;

our right, if any, to defer payment or interest and the maximum length of any such deferral period;

the date, if any, after which and the conditions upon which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;

the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;
23


whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves;

whether we will be restricted from incurring any additional indebtedness, issuing additional securities, or entering into a merger, consolidation or sale of our business;

a discussion of any material or special United States federal income tax considerations applicable to the debt securities;

information describing any book-entry features;

any provisions for payment of additional amounts for taxes;

whether the debt securities are to be offered at a price such that they will be deemed to be offered at an “original issue discount” as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended;

the denominations in which we will issue the series of debt securities, if other than denominations of  $1,000 and any integral multiple thereof;

events of default;

whether we and/or the indenture trustee may change an indenture without the consent of any holders;

the form of debt security and how it may be exchanged and transferred;

description of the indenture trustee and paying agent, and the method of payments; and

any other specified terms, preferences, rights or limitations of, or restrictions on, the debt securities and any terms that may be required by us or advisable under applicable laws or regulations.
We summarize below the material terms of the form of indenture, if required, or indicate which material terms will be described in the applicable prospectus supplement. The indenture:

does not limit the amount of debt securities that we may issue;

allows us to issue debt securities in one or more series;

does not require us to issue all of the debt securities of a series at the same time;

allows us to reopen a series to issue additional debt securities without the consent of the holders of the debt securities of such series; and

provides that the debt securities may be secured or unsecured, as may be set forth in the applicable prospectus supplement.
24

DESCRIPTION OF THE UNITS
We may issue units comprised of shares of common stock, shares of preferred stock, debt securities, warrants, or rights in any combination and in one or more series. Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date.
We may choose to evidence each series of units by unit certificates that we would issue under separate agreements. If we choose to evidence the units by unit certificate, we will enter into unit agreements with a unit agent and will indicate the name and address of the unit agent in the applicable prospectus supplement related to the particular series of units. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement, unit certificate, as may be applicable, and any supplemental agreements that describe the terms of the units we are offering before the issuance of the units.
25

DESCRIPTION OF THE RIGHTS
The following is a general description of the terms of the rights we may issue from time to time unless we provide otherwise in the applicable prospectus supplement. Particular terms of any rights we offer will be described in the prospectus supplement relating to such rights.
General
We may issue rights to purchase common stock, preferred stock, debt securities or units. Rights may be issued independently or together with other securities and may or may not be transferable by the person purchasing or receiving the rights. In connection with any rights offering to our stockholders, we may enter into a standby underwriting, backstop or other arrangements with one or more underwriters or other persons pursuant to which such underwriters or other persons would purchase any offered securities remaining unsubscribed for after such rights offering. In connection with a rights offering to our stockholders, we would distribute certificates evidencing the rights and a prospectus supplement to our stockholders on or about the record date that we set for receiving rights in such rights offering.
The applicable prospectus supplement will describe the following terms of any rights we may issue, including some or all of the following:

the title and aggregate number of the rights;

the subscription price or a formula for the determination of the subscription price for the rights and the currency or currencies in which the subscription price may be payable;

if applicable, the designation and terms of the securities with which the rights are issued and the number of rights issued with each such security or each principal amount of such security;

the number or a formula for the determination of the number of the rights issued to each stockholder;

the extent to which the rights are transferable;

in the case of rights to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one right;

in the case of rights to purchase common stock or preferred stock, the type of stock and number of shares of stock purchasable upon exercise of one right;

in the case of rights to purchase units, the type and number of securities comprising the units, and the number of units purchasable upon exercise of one right;

the date on which the right to exercise the rights will commence, and the date on which the rights will expire (subject to any extension);

if applicable, the minimum or maximum amount of the rights that may be exercised at any one time;

the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities;

if applicable, the procedures for adjusting the subscription price and number of shares of common stock or preferred stock purchasable upon the exercise of each right upon the occurrence of certain events, including stock splits, reverse stock splits, combinations, subdivisions or reclassifications of common stock or preferred stock;

the effect on the rights of any merger, consolidation, sale or other disposition of our business;

the terms of any rights to redeem or call the rights;

information with respect to book-entry procedures, if any;

the terms of the securities issuable upon exercise of the rights;
26


if applicable, the material terms of any standby underwriting, backstop or other purchase arrangement that we may enter into in connection with the rights offering;

if applicable, a discussion of material U.S. federal income tax considerations; and

any other terms of the rights, including terms, procedures and limitations relating to the exchange and exercise of the rights.
We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of rights agreement and rights certificate that describe the terms of the rights we are offering before the issuance of rights.
Exercise of Rights
Each right will entitle the holder to purchase for cash or other consideration such shares of stock or principal amount of securities at the subscription price as shall in each case be set forth in, or be determinable as set forth in, the prospectus supplement relating to the rights offered thereby. Rights may be exercised as set forth in the applicable prospectus supplement beginning on the date specified therein and continuing until the close of business on the expiration date set forth in the prospectus supplement relating to the rights offered thereby. After the close of business on the expiration date, unexercised rights will become void.
Upon receipt of payment and a rights certificate properly completed and duly executed at the corporate trust office of the subscription agent or any other office indicated in the prospectus supplement, we will, as soon as practicable, forward the securities purchased upon such exercise. If less than all of the rights represented by such subscription certificate are exercised, a new subscription certificate will be issued for the remaining rights. If we so indicate in the applicable prospectus supplement, holders of the rights may surrender securities as all or part of the exercise price for rights.
We may determine to offer any unsubscribed offered securities directly to stockholders, to persons other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting, backstop or other arrangements, as described in the applicable prospectus supplement.
Prior to exercising their rights, holders of rights will not have any of the rights of holders of the securities purchasable upon subscription, including, in the case of rights to purchase common stock or preferred stock, the right to receive dividends, if any, or payments upon our liquidation, dissolution or winding up or to exercise any voting rights or, in the case of rights to purchase debt securities, the right to receive principal, premium, if any, or interest payments, on the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture.
27

CERTAIN PROVISIONS OF DELAWARE LAW, OUR
CERTIFICATE OF INCORPORATION AND BYLAWS
Provisions of our Certificate of Incorporation on Choice of Forum
Unless we consent to the selection of an alternative forum, our certificate of incorporation provides that the Court of Chancery of the State of Delaware, or the Court of Chancery, will be, to the fullest extent permitted by law, the sole and exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees or agent to the Company or our stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or DGCL, or our certificate of incorporation or bylaws; any action to enforce or determine the validity of our certificate of incorporation or bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Since the choice of forum provisions are only applicable to “the fullest extent permitted by law”, as provided in our certificate of incorporation, the provisions do not designate the Court of Chancery as the exclusive forum for any derivative action or other claim for which the applicable statute creates exclusive jurisdiction in another forum. As such, the choice of forum provisions do not apply to any actions arising under the Securities Act or the Exchange Act.
We believe the choice of forum provisions in our certificate of incorporation may benefit us by providing increased consistency in the application of Delaware law, where permitted, by chancellors and judges particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors and officers in other forums. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in such action.
Provisions of our Certificate of Incorporation and Bylaws, and Delaware Law that May Have an Anti-Takeover Effect
Certain provisions set forth in our certificate of incorporation and bylaws and Delaware law could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.
Certificate of Incorporation and Bylaws
In particular, our certificate of incorporation and bylaws, among other things:

provide that stockholders must provide advance notice to nominate persons for election to our Board of Directors or submit proposals for consideration at stockholder meetings;

specify that special meetings of our stockholders can be called only by the chairman of the Board of Directors, the President or such other persons designated by the Board of Directors; and

provide that vacancies on the Board of Directors may be filled by a majority of directors in office, although less than a quorum, or by the sole remaining director.
Delaware Law
We are subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, DGCL Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on which the person became an interested stockholder unless:

prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
28


the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder: (i) shares owned by persons who are directors and also officers; and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder.
Generally, a business combination includes a merger, asset or stock sale, or other transaction or series of transactions together resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to have an anti-takeover effect with respect to transactions our Board of Directors does not approve in advance. We also anticipate that DGCL Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.
Certain provisions set forth in our certificate of incorporation and bylaws and Delaware law could have the effect of discouraging potential acquisition proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable. Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.
29

LEGAL MATTERS
The validity of the securities being offered hereby will be passed upon for us by Wyrick Robbins Yates & Ponton LLP, Raleigh, North Carolina.
EXPERTS
The financial statements of Eyenovia, Inc. included in the Company’s Annual Report on Form 10-K as of and for the years ended December 31, 2017 and 2016 have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance on such report given upon the authority of said firm as experts in auditing and accounting.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
This prospectus, which constitutes a part of the registration statement on Form S-3 that we have filed with the SEC under the Securities Act, does not contain all of the information in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus, you should refer to the registration statement and the exhibits filed as part of that document. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.
We are subject to the reporting requirements of the Exchange Act and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC’s website at http://www.sec.gov. We also maintain a website at http://www.eyenoviabio.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.
30

INCORPORATION OF DOCUMENTS BY REFERENCE
The SEC allows us to “incorporate by reference” information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus and any applicable accompanying prospectus supplement, and information that we file later with the SEC will automatically update and supersede this information. We filed a registration statement on Form S-3 under the Securities Act with the SEC with respect to the securities being offered pursuant to this prospectus and any applicable accompanying prospectus supplement. This prospectus omits certain information contained in the registration statement, as permitted by the SEC. You should refer to the registration statement, including the exhibits, for further information about us and the securities being offered pursuant to this prospectus and any applicable accompanying prospectus supplement. Statements in this prospectus and any applicable accompanying prospectus supplement regarding the provisions of certain documents filed with, or incorporated by reference in, the registration statement are not necessarily complete and each statement is qualified in all respects by that reference. Copies of all or any part of the registration statement, including the documents incorporated by reference or the exhibits, may be obtained over the Internet at the SEC’s website at http://www.sec.gov. We also maintain a website at http://www.eyenoviabio.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of any offering, except as to any portion of any future report or document that is not deemed filed under such provisions:





our Current Reports on Form 8-K filed with the SEC on January 29, March 12, March 26, June 14, November 13 (only as it pertains to Item 8.01), November 26, December 3, and December 21, 2018;



Any statement contained in this prospectus and any applicable prospectus supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus and any applicable prospectus supplement will be deemed to be modified or superseded for purposes of this prospectus and any prospectus supplement to the extent that a statement contained in this prospectus and any applicable prospectus supplement or other subsequently filed document that also is or is deemed to be incorporated by reference into this prospectus and any applicable prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus and any applicable prospectus supplement.
We will furnish without charge to you, on written or oral request, a copy of any filing or report incorporated by reference, including exhibits to the document. You should direct any requests for documents to Eyenovia, Inc., 295 Madison Avenue, Suite 2400, New York, NY 10017, (917) 289-1117, Attention: Corporate Secretary.
31

You should rely only on information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement. We have not authorized anyone to provide you with information different from that contained in this prospectus and any applicable prospectus supplement or incorporated by reference in this prospectus and any applicable prospectus supplement. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.
32

Shares
[MISSING IMAGE: lg_eyenovia.jpg]
Common Stock
Prospectus Supplement
Sole Book-running Manager
Oppenheimer & Co.
Lead Manager
Ladenburg Thalmann
July  , 2019

GRAPHIC 2 lg_eyenovia.jpg GRAPHIC begin 644 lg_eyenovia.jpg M_]C_X 02D9)1@ ! @$ E@"6 #_[0 L4&AO=&]S:&]P(#,N, X0DE- ^T M ! E@ $ 0"6 0 !_^%$86AT=' Z+R]N&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z&%P+S$N,"]S5'EP M92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z7!E+U)E&UP M.DUE=&%D871A1&%T93XR,#$Y+3 W+3 X5#$X.C$X.C$T*S U.C,P/"]X;7 Z M365T861A=&%$871E/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @ M(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \&UP1TEM9SIH96EG:'0^.# \+WAM<$=);6&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%1 M4VM:2E)G04)!9T5!;&=#5T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311 M:VQ.02LP04%!04%!0D%!;&=!04%!14$F(WA!.T%10U=!04%!05%!0B\K-$%$ M:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W M9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9" M451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O M9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46=!54%%04%W15(F(WA! M.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE' M05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%& M0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A1 M5D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1 M>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q M4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S M8E&=:17DF(WA! M.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I% M9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K M=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D71R<2MV+V%!07=$05%!0T5135)!1#A!.54T<3=& M6%EQ-&M!5E!167%H8FHF(WA!.U5R5T1L>F-(:5959V9Z3V%);R]Y;5!B2D-" M3$5Z05-M8GI:8D(R4TEQ.&=::U-&5TA);%-1>%DY15)72$5S9C)T=F,R:D%7 M;S5G:% F(WA!.SAA4G-E56)C,$ML-"M++T4V8U$S24MX6# Q-#%03U9L,T(R M3U,O3$@X9FHW;4AJ+T%)+T@V5F5(>FAB1W!K85 P,4QG>6-W1DQ)5'HF(WA! M.U97255Y1E%P8C1&3S-824A$24UH;E1Q,G8P;4@R2$(V9EEC0V]Q1'5Y3=K M04%B06M#=C,T:$5J45DSE9D9% W1TAA;'%:858T*U1M,&@U>'1*1T=*34YV M.$%&8WEG>$U63'I3;6'DT9FHX M969E-%HF(WA!.S%*2C4W+V0S+TE6-E-H,W9N5&=%5FQ69C-S2SA4.$%::E=: M1E O2#8Q5#A04VU4:69X*VHK<79J2#AF9B]8.&TO=T)->4PV;'0O9$8F(WA! M.S)%:VAK;65.2DAL:DQP.6,T:FY),'E&,3E.3FQ96F)'3C4)G0TYG97A'+V=62D=53V)%,G$T175W M2S=&6%I*6%EQ-T9867$F(WA!.S=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W M1EA9<3=&6%EQ-T9867%X,U=.5U53,C9H=TDS84$Q1$1O.#E/;VM19G-E2BM2 M>5E$:#4F(WA!.V-U-"M(,RLY-35C-FY)6G!7;4(U2%5B6FU%9VI1;%$X<"\T M*U=9+V$W.%%C=D$K-3 P.'!V9CA!;G@W:#,O>G90>4-4,CEN2F9*0C8F(WA! M.W-8<4-227=A>&AJ5C=P=5HY5S,T;C=X;'!L6#0X;D9J:DUW3$A19% V5RLX M57=J,'%.;V98;2M+2S=:;75&9&MD6&EI9#58575$1W0F(WA!.U#%D*VI:,6HKCDS,B]45FIK2S5P9F0V M8E!&05-)>DA':74P36-D1F%/4D0V:DMK>FEI9TY'5#9R3#A83&EV5$UJ2%!F M.$%(-"M#1&I)2&0S92\F(WA!.VYZ4'4U:V(S45-Q-G1*8E%45'=X*VI%>3-: M0E5)9UI*1E(P8C9X9$9M3E-12W%T4'9Z3GAZ=6=F3#A514=*:EI',S%F;U!/ M6#9.:SDF(WA!.S!R>DTQ8FMY>G4W>$]$-EHQ3TEC:69316EN;D8V9$-X*VYF M45S53542VDF(WA! M.TLW2WI)9C,Q=5=H3$AI>FM-=FAM<&Y':3=$1D]V>"MK8DUX:F9M9V%H56MB M<64S,UI">E%6,E)3-T97.&MH,DMU>%8R2W5X5C)+=7@F(WA!.U8R2W5X5C)+ M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9"-G!C;44AID@V63E".3E-2&Y3,'9B=5=:6793:W)7 M84US5DM/-V-K8WAW26$F(WA!.V-:>7E(96]'6E5145!X*T]4<2]$:D]2249( M.71G,45D2E=/86%A9EEW3G=K.495;&=9EEA8V,V,T@V-S8S>5!Y=&U6=F%M4F%X9S="-E!15DMY M0FU',T9U:3=F6E!H6'=X0S=!459%.'1W*V](14-L63!19T%-87-2>3GA7 M8G(X9&4W=41($1Y55I:2FPS M:U=.0E5D469$37EG4E$U+T0Y6'9A2FU54F-T9T]F,40S.50Q;V9.:W9L=3AA M,6E9A9T]2 M:&QW:79X,VYC9G!E;S9&8T8P-&-M24$K2D@R9$15:6I$=C R9&1M,T]95'1C M4E1F1G4F(WA!.V%W2S-K;&1IE4X>6$W-6$X9S9V%)I9&II%9&-'$W1EA9<6MV;4-D-#%6;W%-=TE#>&LF(WA!.V="<$]Q>&UR M25 S<6MQ2VMI=$YS;D5/3FYL6$PX95AX95EE65!35D=73E),6GIX2&=$4TI: M8EE.54LX;D=/:E$A,;D5J,U=09G0Y4%%$ M;6MT:DU:>6]J;D9W,T5S>6E-<5!3;$E2,T5)-%(K;DE/6%!K95%.5W!M6'=6 M,%DT0F97+V@S*UA+:G8F(WA!.V98<7E0431223AC,7!1<39Q-6A"3%52*TE* M*T0P+U54.39!5573C):531(-T(T=6EX:SA:1V5G:U$F(WA!.V,R,S9$3F=: M-V9J.&9,:S8K8U%.*U(O2#9B-6IC<&QO36MK1'4U0FE#1"]396-93'!'>D1E M.'1A3W-H=5I/2V@Q1E9'-7I7-7IF-"LF(WA!.S5C2F\O9CA!.&5(6&E055!5 M=DQ$34A50E-P6#1:64,U67A&:%=QGE.0S)P*UIT2S S>E U9F=(2R]U3DE,=S-%35E( M>%-E;DHY35%8U-U+W=!3TMO1'HF(WA!.V@K8F5T3C5N M;#AL+VPW<$LV+S5K=#$U86QC5% V5FQ9*S!Z-V-N.6=F=D\R2V].-TPO;DM# M2TTS4S9J-6)U2$%R*VIH1D]T9EE3140F(WA!.V8V85EQ:3E"+T]'.79.0CAY M5U=S5TMA4C4Y.'-7D0P=3)T+THF(WA!.S)H5V%8:T-5,7983#!S;&Y&37I%E1O='-$3G%%96TK<&)8 M34U1*S(F(WA!.WE"=T]816(O04=4:7).3&XX,B]*='0K6&-0;C)A-4DP5S1I M5U-&45 S2MV84TV2U$Q4V54 M9G92,' Y:S1Q.4EX5C1:*V5V-34K62\F(WA!.TME&985&1E6&1/8F1X<%1*3DLS:G=A56-L*VM.:7)%=D]0.$%Z:TXU-CAU M,CEV;T\F(WA!.W-A3$9O=FY16'1S:#5!,TYL9%=5:%I:2EE'0DA%:'5/>%DO M=WA6.499<6MF;5)8.4)Z=3!43)V;F96;%%103W)Y>&AE4W5O M5FUK5E9*36AH85AL25=13%=T4GE#-VLU9V%J8EIZ-%1V3%Z3'HS6$QY2G!$2DMQ3W-)+V5W4S=6 M54U#6$HF(WA!.V)I2%5,>5E-5TE8:W!O,UA.:&EJ46-(265P+T@T*WAI=#=) M56=34U%M5T9+<6)I47(V:6M$:S1D-49B;54U='=695A*86QA57AY-4@F(WA! M.T-Y>6]E6#0W+W="='$S;#(R949,6FLO9$Q#4%5%D%Y-4QA6%U3E-I+TLK5T=X8TDF(WA!.TQU.7193&]T.6MW;&EX1$5B M:&533%=M4V-X6G!Y9CA!3U$Q<&\Q<&$V9EHK5FQG9VAJ:71K1%AV05)O;T-G M8B]!36]W2F1*2B]W034F(WA!.TYY>'1&2EIE53-J8T98471E14932T5(9D-H M-#%F+VPO-7 X;%)E5DQ05S5B37A8=FY',W5R2S%S2DAL:6@U3%-205A!66(P M<%5N1E@F(WA!.S$O:7)X8B]N2V]J+T%!5F]G'1,6#AM4$QR5SA9:F$U4V%E8VHY<5%Z=7!9+U%O>%9N,VU) M02M8.51"1E%B4V-%2"]J1S)+=FMN>50F(WA!.TA$96%F*U1U:S9I4%4P4S4Q M:E4S=4QD+S=T-30S:BMR:'%F-51B1$98,DYI<5=E6C=05'(S>35Q;'!Q4TQ* M<#@YGDF(WA!.W(Y1TMV;6IY=D8U<%@X:&1'.#0V14]ECAL631R,S@T9&)U=%-(<6%L<#)H-EI"<&Y-54UD<3A%9DQG4&5V6#,Y M.%5V;U!&1'=R+VY,2WHP<"],;FQQ.&U69C!N1')-160F(WA!.V\Q84XV5&=M M641X1E941EAU=4MO2%9O5V5!=6=Q44M-0W9-165$2TYY4#%D8VQ&<7EJ6C5J M-6ET1E1H8U)L67!655-7<7EY1TYQ:%4F(WA!.U-0,$PP1&DV2S!P3DIU<#9$ M33=$3' K4&PK<#%75TYB:CAC<7%89'8O17=M3S-A>G9P0F(K<6AJ9%A-:E)Z M07-Y35EO;$Q7>&%.,6$F(WA!.U1K-V)B:DYN9'@S+T%%9G!C4TUE16UR*U(Y M=RMN8FYU5U-71B]C2GAJ93EM;S-W8S)76&Q1+W5!>%IZ0G57-4TR+UI72%1. M8FYJ-4\F(WA!.UI'6C=Z.79U.&U5851R>D5*2S=U25%=*0UI70E5+<% F(WA! M.W=H86=31#1..38P*T9Q.4UR='0X5DQD4C%95%AN<#@V;V%23GA)2BM.5E(O M3=S5G5R-E8K36M,9S,F(WA!.V-,:&1M-6LQ M<44U:%HV3-Y-6HX9"]F=#EI4U-+35F95-E4C(K3$EV3'1P0UI)6FQI1#(X;U(R459L4IP M-F%*-7$X5 U378X05,S=3%-8C8O5)O M9#-95G%0,4A&56\X,2]L3G!E;&51=DPO04I,,'97648F(WA!.S@K,G0P9%HP M:S-,.%AV%A4-FIQ3VI24T),=3)V2FE43$I!1W)Z M1$AS0C=D<31Q:E0K9G0Y241$869L+S5K;3%!8F961W11;$0O;%!59T0V3593 M-G@X:&4F(WA!.V).671V3C-N>GI06G1B*UID83!Y87@P9GDY12]Q+U4T0D-9 M,5-O,F%757)Y3E!(-D%Q>D@X:3E),512+WEN.'4V8G%L4%".'II6(K5$]Q83C4U2S%#-'9O4454 M5G1(4F)Q,G5E27!Z;W K0FHQ<%@V0FDF(WA!.W%$,2]84'I:+TTK,&)Y.6]N M;#(U.&]E6&(S.3%Q=70VCEI6$I*8C4T<2ME-&9Y M9C@X3#4P:"],<#1*;B]!0W1T9%4O5'-D,E%F4TU82&M,5&XOD0K6$AN3WEK.'0K92]*2WAP-7,P,U1,87%9&3&%4-5=T=C,X,%9U-4QY,TYW>3=C:'=52#E1>%8Y5%EQ,#9H;$E. M4C=J631O25EJ-6PP851E94UE;E4X-5@F(WA!.TA)235"5C9Y55=63G942'A. M161T<3%/6#0U=49M>$AM4'@K4&,X>C%0461/:G5:2&AS2T]T>C9Q=4HT0T=A M3TM4,%133U7=10G9H M-CDT-VI8569C:S%N9')A5%%1M M>C%+44ES7DF(WA! M.S=$3E9L>%57-DUZ5S-0>CF)&5F]5,TIR535H>63=N M95-C>6A"4$ES45-24%552#%&*TIM65,Q47,P;D)I<%=I-V-C<4EA36LU16LS M>B]8.&9/='$R-DIF<5=O,T4O,6UD1UHF(WA!.TDU26YM:DUG.5=083DK0FA+ M5VY4>$$R+UAL;V%S=55M>4]66#-J-G1T+U5%=W-D2$Q#-65(9VQZ87E30TIO M;%-1:FID5S=50W)"1V$F(WA!.U9K4&9)>4YT#1V.$%F9F5Z:4]. M67=1=CFMA;6=8+U=4:W@K-T96+R]!0W$W>DXU;S%N4V1:+TUB M5G)A-F)22C%U.4\P6%(T;6AS0D]P0D5K>EA";&UL-F0F(WA!.TMJ.65+=E1S M5F1I6\S-W9M,4]V,G-Y3657=G=817E9="\W1T-A=F]C:5)U1V5/,6IA M33=.4&)W2T]+7EG'!985!V.'9T:4\X2'(S1C,Q2S=1 M;C%(.48T<79/,%9*9E%D:'AE4D=5.&)H-75*-4MV,F-W-31V>"M/5$@F(WA! M.W=P9&1V,&5F.4EN=39):4Q3<'95:E9D'5"=W%I M8S5*16MP,4AI8W X3#5*1T$S-3E",V4W-%=30VTR;6$F(WA!.U!A*W5R>'-Q M,E-&5V$T5#EZ>7,W4W)'6&Y$25DO=T(O3CEN:TYY34)X54A)>#1"93-,-6)$ MC T;$DQ M24LW9&IL0D%8F(WA!.S)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9A.&%/2TU+:G(Y,BM+0T5" M4&]6;$LF(WA!.TM69% K36)&3V=51#=(12]S:G9K>$UH9V-14U6HT&$Q8F=O:FAR27A,2D509U)I$I)=VID5FI.0WDF(WA!.W8V8D=S-#EA M=G%S.&"MT9FHW=F=Y1VXV9FIZ,S4O1DYR6'DS0D154%10W$P.4]-8C%61E W3F%%-SDF(WA!.SAQ;&QT=4=)0DY93&5/1D92 M3W&EF.E!I>&5L641I;65N&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED M.CEB9&,X-F(Y+3 R8F8M8CDT-"UB-V,U+6,U.64W,&0P-6$T-3PO>&UP34TZ M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN&UP+FEI M9#HY8F1C.#9B.2TP,F)F+6(Y-#0M8C=C-2UC-3EE-S!D,#5A-#4\+WAM<$U- M.DEN&UP+F1I9#HV-3(W9C@R-BTQ8C-C+64T-# M83EE,2UE.&0X.&(R,&(X M8S$\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U- M.DAI7!E/2)297-O=7)C92(^"B @(" @(" @ M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@ M87!P;&EC871I;VXO<&]S='-C&UP M34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.DUA;FEF97-T/@H@(" @(" @ M(" @(" \7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$UF7!E M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(#QS=%)E9CIF:6QE M4&%T:#Y<7&YY9'8M87!X<' P,2YT=FYY+F)I>EQ84% M:F]B&UP34TZ26YG65N;W9I82!P86=E&UP+FEI9#HV M-3(W9C@R-BTQ8C-C+64T-# M83EE,2UE.&0X.&(R,&(X8S$\+W-T4F5F.FEN M&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"CP_>'!A8VME="!E;F0](G'Q0C,D=A'@'7^C]^HZ4JI3=WX?AO\ SZ@#UI5#!N.V_L'? M\NFJJ50VX=!'??W]-MMO;I2JB?I[0'^&E*H4!$ '?;;?;]_@/X;AI2K2FZB/ MC[-]P#P\0_/2E>@:48E(]$'"0DCQ.#\P*IF^3%-$'!P< !MTC%0$#;#L/:(# MX#JK8UP!U/3^=J\^['9C<63ZM>FE]?AI_K6GM+$UE"I.(U,7D6LV77),I+MC M, ,D*8>2/]N"XG/W".X$$H=H[B'3>61HV*OHP]*\8LI9[-"-T!!.\$;=/3K? M7XVMIUK1D\CUIVY;,8=PK/NGL:YD8X\*@K(13\C9)PH*"5@;D/ I.%1;&*4J MCD@]P@ ^(:JEAEA4LZD6].A_D=:\5Y/$ED[,#=R4IN&T$J>NF\>R^G0M7K&R M94VYG::LFBX?1SMA'RT1$ >?EH&0D6)'Z#*<9PA9!6.5,@?N R@%3$NP@80$ M!&DQ3+'W9%*I:^OPZ:?'7X5YMR^"K,A<&56565/>R,PW .%OMT-[FP^=:X-H MCT#N$I4R,,LBI(*(M7SUD#M]'1P$.K*M6Z+E58S,4S@8=P Y _K%#<-4 ,06 ML=H/7T^7\ZN?O8UW?<6C92U@S+=E7JX )-K:ZZCU KW6%DBI)9-!BL=P*C$) M%-9-! G\J*OGIB'E]_F ;[;==0"-VWUJN/+@F<)$=UTW @' M:1>WU=+W]+W^5:P!@'<=_'<-M^@;ZFKBK@W 1-X@(>_^;]GAI2AMQV#H #X> MW@Z53<>@;;"/XZ@C2HO3;<-]_[WA^WVZI MM<:FHOK>J (;CN/3;H'7??\ 9[-4KM(*[C>A)Z^E5#Q !$/<'CT_?J%"H;;B M34ZU7LV_Q@_:.BPE7W;B1\*%A:U"D-W (^'CXZI6*42[RUT^%S3<+6JP@G[Q M$=^T _@'LT3OF5@UNWZ4:P4?&O(10IAV /#Q]P;:](Y5D)"WT-J@J17EUZU3 M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E- M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E6_$(^';[QZ#O[M*58'Q?# MX=H#^>^E*"7J!=^FP"/L_/?WZ4JX0+M[ ]P_R\=*54-A#W]-A$0TI5@%W_+] MW\@U'Z4JNPE$-MNHC^[IMO[>FII0P=0[MAZ^&W38.H^.E*]):1;)KIL^XIG1 MP Y4 ,'?Y8;]RFVX?"0H"/X[=-5!&*[O[:\S*H<1]7/I6.G=P"PR;V!K3L31 MK:,6=2=Y@)6NRB%?E64@@"E?=QIUG;@LBX:%.8>]$2$3[@W ^VLBF&,:)RPNKJ74@^\, !M!MZW)MZ5CVSAE3'&Q"3&%NTJ,C!&5A=2+D[B+^F@OZ MU'RV5PY<4[!>7=!O-&@:_@?#U MC=2E1S+,9D;M:9E6S3=98R]9A)&#>2BD8E/R;AG#(*E$Q'"H!N7;<-@M>8\0 MQ>'&5QV4[\ESJJDD'VA[L"(^USOV!BH4L5Z@?.JN,YK+Y&?&Y7B$AX[@IV>/ M+;)7MY,K1!HD9"Q7;5DT[J M">,J[.NT(69E#HO5*W#S0J)0ZB@B"2_E"&Y@#O#>WY/P]N-A7)\EGAP\3-QN M_"D9$FXA=P0[=Y7JHUM>^G2J..YB/( 3QJ&;EN5X_(&+/)D;HR$8JDC6;MH^ MBDW4$'H*S!8&MKX_E9(QI,+$ECQ=AP,?,AY7E(1-A2I(T.(H>6.)^VJQR1 ,VKL3=5Z'0Z5EB"RS]7 M=SC.B8NRA;&Z=9B,N5.;>R+B"A[>]LK%*;95J/=V!Y'HQSE DL)%&KLR2*0D M[3$#M P&5QO8 6:6,3"1D90;[=I*W.V]P;7%KWK/8W*=P2GC\/,R (UR8R6 M*=UG&\1J7*A2-UBK$ ="*DK&R]C75['-95CFWT=@[34@UOTU MZUO BPG*4IT^P_:4?$HAW"4!. =HCML;IJBK]=Q&HM7G$#" "/;TZ_L_;TTJ M:M !Z;==P]WX^'AJ#4K\Z;"&V_[/#2U2.M6?L]NO(*2#K2]7 7?<>G0-]4JA M+?*JB1:J=1#;;^?7AV)"U[^M :H(&WV\=NFHF$^_VWV^E5#;ZT$QB ;^[^? MV:JEEDC4 :GU-4A0>M5!4"E+W /4!_CU#;7KWUC0-+H3Z5 0L;"KP*4Y0$H M7T #?< \!]H_GJ57:+=:BKM54II2FE M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I MI2FE*:4II2FE*:4II2FE*:4II2FE*:4JP!'N'\O>.P>&^W32E #XAZ CN.X M;_E[?$=*4'[]@>/CI2J]@>[K^T?\.E*H! ]OC^'0/Z-*4W'IL / M@/MVV\-Q#2E6@.QQ#H)A#?;?V:4O_.L;3^0&,>G).8Y6,F2PR2Z;MHVFXYL[ M^M 80:0QQ7< 1NX=)IK& #A_]F.KJ+&9BHDNNXZ&QM;X_.U8?)Y>"*.23&:. M8Q @J'4'N>B$DV!-CU^%1NR1EY6BTF 2D+%)47*F>9E]'8V:VN 4M2%1L4B6 M-8-:\Y7JD:5-.+8.'J*A57!Q[O.-W*" ?#GN/X]0_XGC8ON)7QNO4;XRRUDNT_)3EHH.*^(:4JXSI7) MF@QIX;-#5NJ<9N05BVM111.ZEF]9<_,)J%%8WS GL.^M@"'B.*226**?E.7 MV_:R+,V_&_V+N[EP$+C:18"VM:PGDD?/ M*YN(VZ&YW>NE8L<9>AN1TS:,JOK[CMSP]@DY"O5/ -T9Q=-5?9!A(?ZQ"P<. MHJ2OS#APM-*-7@BV5 BB9A1W$P&+K(XV+)XSC+Q@AR%\WE8.^6C&3;"QVLS6 M++].Y?<+CKTUK6HO,L#S/(E\G7/Q'_'RAH8,*=5@+92#>B*7[;L2VUAM-B-. MN@Q.RRC5C3=(Y.\N&%TP#.5WY:I8EQ+&1MA<8QN4+"IH1\>X?5F0:33YW -& M<(R!I&E;TN=JS1GZHY889*F*UQ"XZK62!LV.9CY$7W&C-%7.4W(+S%(R:O 5Y MI*MC/V[A5.#.V:D@$TB+I"D07C8$A,*W<4)EQHY7Y# 4QNYB4J$=?< MSH O4BX&X7UM5<:YYP7]*P?%J0"?*,^%!AMBQ*&3>M[7-V'O-[W.O3 M2PZ5Z\)Y%XU"G&XYY?/SVRLMWAD$9(:ZK[)"D*@*-NE['W:G4"I:4O-%(/&* M2<5$YT73:9IE8%=-W2+:X"=5=X[!%:RL+:@:==3KT&M;9QO.8+(988N4TY-T]T4A.X=VYUCTA]ILQL MOTZZB\F8+(T.JK.%67N)RQU\=4\WUBJ2C!,TFX=IM&Z,2J:*:$D:^BK_ ))\ MF*B!BB)A5$.H8X'[/X_P =37J!\:M_9X:H<&VE!UIUV\/9X:\@&-R/A55Q5/=T MZ]>GXC[_ '[:\%W=RRDVJ2!5!WZ#O^P/#?VAJF2697T-M>E2+>M7"?PW*4?S M#7I+D!;*P!-4JM]?2K3=A@*)P_E^S;7JW9F0-*!;YU W#I04SCL*8[%#;V_R M]FHDAD?;VVL@]*D,!U&M>P4! H /CJZKSJ[2E-*4TI32E-*4TI32E-*4TI32 ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4 MTI32E-*4TI32E>+<=]_>.VWMZ:4JHCL/<("'3IN.X>'NVTI5=A$ [A]N_P"S M;P_/2E"[[![MOY_#]W32E5V,(^.P?AX_X=0#>E>%10$MMQ -Q H>'Q"/AN([ M>W4TO6$K3DUM!T6X7-Z,^TC6)Q8,/E*K+J3C)=X=O'-7!(KRE74D1!\Y!7N3 M3[.P.O0!'5]'C%LE( 4+&U_<+?&U^@OTUK5L_GHL7B,GE)1.L*':NV&0R*6( M4,$ )8!B"2!:PUTO45[6XX?3Q*9?X1IY#1Q!RX M5.+E8:;<'^FS:@G(HBH4IC%[@W$-9B(_:=[*B+PNMT0;=ZDZW&X@@:BM!S)) M^2Y+C/'67%S\9T^XRF,H@R(Q93&_85D=KK(201H;7ZUA2#SA'WS/^::PTM[46%;5R(D9>:2%-PO&*I M.@^6<+*+J"N('W'56/)C/RN7Y#R^ 1QL*[0JN6V%+[BH'2_MU L+"U4\WS?) MI@<1^)_$O)0?,I?=/*\" 3++L5$9G7:2I5_:Q+D$[B36PLBRU9R#E>LX0SI1 M QAB+#KPTI*Y%HK)U%F-.-8160(\L"KSZC%/$966<$:%%%-)83*$ JG0 U[< M7E3\?Q\G.<3.)N4R5*+%*0QV,UK+:S#:/=K<6!TK"^30^9P^+>;<<_'> M(\/*LK9L5XT[J1[]TA8&,AW8)[0&N0 U;<#)YYBT?ZPN2QVF8^(]9D9*IXEB M73A('K92.>"RJ)6B< +2?:*H0<4H58SDRJ8'V\T!/VB&06-(,7[/Q_?B^72( M'E8 V(87D!+W75B"+"_H-*QO_*XIN9E\F_)#P7 M8'CLW_-?/,H\IXOR37P(62Y1E%P]@"4V;D;:P&[;;J36EL[#"XMEXS)'+^'- MG+$^58*7E\,T0\NJR^C+-IH&D=8?-B%2N8Y*ND9+L?DE"D(L4_?V^&LW$V7R M.*W%^&DX',XSK]Q* #O!7W+9@0=]P^X7((M4GFL?QC*'D'Y8E/+^+\HK2<=B M6V]NS@QREH[,O:4-%L(]P-S7OB[DKC.#5>9N33L./V1*FA>L24ZO2L&E*"T< MH+N\<@P10;NE*U&K L4O^>HG$2AX_ ;61QIH>/C7+\+Q=WE&+*8\B1U8K?03 MENF\Z?VD#Y:UGL;)DY?EIL/\M\A"?"N203\?CAT5]K$MCD!;-&-1;>"3\?:; M[DQ_9N07(;%LKQZQQ U+C5$X192%EJ]X4AE(NRVFHQ\@I*/89S89^0,[D7C5 M%VXE# U42!1%/M G;OJ[S8O%_'.:C\GYB6;EY,]PDD(?=&DI7:KA$6R@D+'[ M@;'UK.\)G^9>9<+D>+\1#'XWB\6Q;&R&CL\D"D,RLTC$N;%GNI (].IKT"Y> MX>4V#<"B M(.0$?9K*IPOGG*SKXG+]KPOBTTLF3CR"S2J0VD5]U@UI#H5O<:54OEG@>+') MYIQ@S.?\NQ(8*#*_P 5!R?W3%T^J\ +D%0)0=Q&PZDVN=#4CF4] MRUQQB]E&SXYDHF-A9"&91DI J$GE+2I),H?YN1;0D4U._8- M6,C(K(J"J*G:1L901 H@(89F5+G4K\M3-T57 M3W]WFM9;9R;&1!86+E!T#=95LN*"J:GE.$3BFJBIVF- MVJ$.40$!Z@.@(/2L]%-#,#L8-M)!L;V(Z@_.O?$1V #8/XZH8D5Z"K>NVW\ MO?JDL=NE3:YUJF^PA^0]?R_NZ\E;8=W\ZD@6M00WV$0 0Z#J@Y%VO86_K0*# M0>S<.FP[;>/3;5R7P#\@U=1EBHW=:\SUTJ[7I44 MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32 ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5X]A[_?\ T>/\-*501$P= 'IX M^[^^.E*J!AVV .H >_]_NTI0!V'MVZ[>_;W;_AX;:4JTZA4Q)WF#N.82$ 1 MVW-L([ 'M'8!U(%^E02!U-83R/:9:(C;V_9P5REOTM6%7C&.K)"K.K,Z>MG: MHLX=#Z6]54EV)F8%)V@I\:H;D'H&KR")28R6C!9O[C:UOB;]#?Y=*U;G>2GQ M,7-G2#+D7&QBRK"-SRDJQVQKL8F0;;* #J0+&H;YUN#6"KW'3';JTY?J\M:K M:Q>?.EBFTG./DRR*\@:)MAOHR3;RP!N*8]J* I)"41WVZY?"@D=Y\P)$X12+ M7L!I:ZZ_._4URWS+E,7!PN!X";+Y?&RB!C_'SJ(C,O*,0U3*&-'CW4RBVGXENX-()/VS1R9-(I M54A.4I3"!A'K=8S12^<3>3^/>+\-RG M&\CC0XO?>!C$#(Q0R+OB!+@D-[;,NA#:^N%)FU*7S(.93IH+?K>_6M"R>?R.:Y7G_*OR-PXX.1,9H(,N.&7=!.XD$2V9[.V\]4V M:C0:BVWF\!.T+CXS8O&KG+M0Y 6)NJA)QQ'*5HN9*M' M%L "L ;#8#>Y8 '0DWZ5N)X9PF/B9?XQQXHLG-[\F^6"5D!D^Y9= M@C,3.RJ&51MW;M16W9!6OA99"QWA:NV;A;4I:PP%+AHXOU9O!R;B);H0Q(Z* M8.D94RS:8>,U5RJ.5!*D!1$0#5[BS2]D18QE3RN10SOT+"Y+78BUMNZU@-2: MQ\F3A0Y\_.\XV#E?A#&G:''BC_>$3E$6,*J'<&65HRVYVL #IK7H0M(B*U"S MEFSA-T:Z5^]5B27XNTB<<&<%;R);4R2CI-=E'RK%]!HQ\4@[; FN94#+G+W" M)C:RAY*6:5,;@UGAS(BHRY5]5V^Y;D$,2;&XMI^E93#XDX:29GG6=QV;QF= MS\+CS$>T]Q3&UE9&01Q[H[-NNUKG6U8XR-0Y>VTZP63.[89CDAC!6JU>F8H8 M2#=I*K4B$/)$=%L=73:FEE(2MD2(':C\L82JJ *@#L)=FX+F8L#,CQ.#.3Q8JYOB?!1IER1QM(DSLIUQ>IB*BA M33\T>[?IJKD4XC-\8AE\KY%LGFL"06A61;O*MP8E50'-V'0&]Q6_2\=Y MI/B^&<-#A^(1AYGA')1>8>4M((,M2!CCN,H M:1 -(C>S$6&EQJ234GZWE/A3%92X\9.-<^1%W>7*@I5]SN[-',FK^K1J5*7< MA&#"N5G+<1C3"5,52F,8Q3B<=AWYSR_C?G;_'G_ "/A^=7(Y7(FSL,PI]00B$"%FV[.OMN+G4ZW/KF* MCV[A'4*=/P9;IR;@8#B=F1K:'DD_>_4Y.U3%CE$0:1DDBG7V78Q!2E[)I;F% M/SC;B;<-W9-D( MS)<+"Y-A&RSF!Q\Q28,92!;-&E=@X;F8I9I8N"Y]9.0SG3)6+)4'MXZA%=516C<;A& MY#,Q +$V(&VN0>J9 F'7FO)>I)DA)6S-8FI3-0?IVMO-L'ZCTR-DE2QK9((* M+(W;IG656,H5,5@ 3>_7Y3V2+JVI TN3KZD>@OU^&E=4P.5R);R3P#[628)$ M\1$H<-NM(VT>Q; 7)N!?K67VKQN^2(Y9JIKH'#X%$S '\M]>$:QLQ9NHJHW'2K-@$VP#UU2\(DD]C:&BD@:U00,7X0W#IN'3 M;K^[29I8@$2]K=:* =35Y5 *4H' !'8>OCKW&0L<:F;1B*IV%F(7I7G*(& ! M#P'5PK!A<=*H-7:JI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI5!#?VB' MY=-_STI5"B ] WZ>_P##2E6@.PCT'J #L'L]FE*J/78P[E[1_:/A^7CI2MER M0'=X^D M"?&=Q!>RV!FW5L9$)<_=7G!:\F0B@F53$B^PJ '<'9UV'!5I<9)A\9Y_(GX[-!;*,?_P9]V1*@[NV1?VCVCZD6:Q(UTUQCG[) M3"KYAXG,7F9KIC-M(0T*(8_?03>5?R(OI&:CD'1YVRTFL!6@&!#P*4= MNNVKGCL62?&R@D*2D,??<@"P!-NHZ:]:U?S_ ,DP.)\R\4@RN=RN,$L26PVC M#M+N[JJ9'+*5+M9 0NK ?&HBUJT4%/(O/R%K>-+_ &ZP+Q61W+R,GYCZG798 MK:W>7+M@8(0K51F9>0Z, KHRZ:'KJ+" MY/QKCO#\KXNOD7Y!PN)XKD\_D2F4TD4[]R&9EF/<15$2]N[M9%):Z"XZ5#^W M6.7;\7\9QH<982/CQR;:702[VC;@YW^'R4@:.:'N'4Z$KW-?777U^&M;#F8W@1_-,# M9B\CQ_*_8QDJHO%'(<%=MO:/:$.HN/<+7%6X\KUB-Q;R@MC11MGYO:LAUEL] MJ]CJCM5U7'$>M+@VF21[:;4<"M,"\.8IS* 4@H^!M^GGFRPCDL<98;%9(V]R M-;<"!IY;<6L+ M VJ0S"F5]KR0QE1*[-ER.Z#>9 \W%2=8NCVPRMA/$Q3*(A7KIS&2%=:)=H*B"0*]HB/CJN3(W3 M8W$Y<\?V<85PZ"Q#*!:Y)^#'T]*Q'!\;D1<#Y#^0/%_'0Q1K'&QLT2#9.AXY@CS$+5&4UC*!P;4(N)M')O&EXETUSQ- MH6?.1=(K-$E(Y1QYC6,;%:G,*(D7+N(' -M74F:^QLBV1)RA.W&D46NHZVO? MXFXUTK)<'X_Q<6>G!X,W#X_@6# LW-X,SAC%.Q)NP&V]U1=K$+8B]C:U;>M\ M7^MGC][=3X1E'1F,HWX<,6S\Y(=U&1=E13:-SHB[4.K$,XUHZ!?R3[A()E#N M\0UD./R3C@?:_>JI8',(ZW(U-[=22+7_ +?YU;Y&)_F7<\Y_Q^?,82_\<56. MUX4D&T$$DE54-N*:;U%M*]-*O7:2N]9RW3J*SR_R7?3LW7\[M:9*&FXG'Q9) M>-*R?OX5!BH]@;"]>'D1%9PX42*9K_DA[3 .6AGQEP9.*R9VQ?'0H?',@VM+ M:]P&O9E'MZ"YO65P\?E'\@Q/+.,PH.5_(;2G&Y48LF^+%W%/>R!2TG%=J04M).H1&/M)W<] M+L"++)+'*+0A$1/N3KOGS(+RCA=ZW6XN1QA2*ZX4:P4+!Q4$Q;0 BO.__ )2UDFIR=@*) MK"@"0%'S!W$=GXK*GQ^ Y+C^ Q4G&/*[K/*XU9F8E_H]Q&M]1>]Q7IF0;/,_ M'.9\NY*3#RLW&B3[&*([$"1QAHR3)^VKG;H0=NW;*^-S2\"ID.@14B)*B[+[VU8:Z5F]#(O-:O8QXP5NNXVQGCB9B7\H%:AU(%]%7([= MW-RZR;DD:[?.5"0R[-43'/U PF*8! !VUB)>)_'&7S/-9>5F9F9 Z+O<.&AN M$4$%@ -X;0#J-1:MZQ^;_+">-<)#Q^!QN#E(SAHI$=)%7>X78EVLNVQ:Y(.A MN*Y!X')W.A_G3.=3?XSPK=*U TJV2\E482-5+)&HD<@;4.W?:XT4 W&GQKI<.?^ M3!Y/R>)DX?&Y7"KBRN(DW%I)E#&,,?BQ%B-?2MT5[D%;D*_0+'R5X+N4LFY- MEGN+U)NJ14K7SP5&6))@+CY19I*&+\H9%4QT_,*'D_VHF /AUI',\)QXRYL7 M@^2[O'P1"3W%3NOQ%J8GEF9%Q>'R/F'C#IS&?*V*YA5@8H;N S#: M2%!6YZ"Q#$VJ;^$Y7"TO)3$9QURM-0+3 Z$MBUS0)UVS"G*VR4=D1C'D@T[R MNGZO?4G/EB59$3D5.( 'LYKG8F;"XFGT:0;@3?\ 6X_G[NMS87%;WXOD>+9$ M\L?A7(O&G$J^*<=F7L=UR-F]?J)'9:UF71FTJ:]5L,Q$(LXF\-DVL@VA8M1[ M/1[11E4GDM*2KEBC&Q1E5' @\#9(3)^8<=E2]>NK4.0/?:NFX.5DP*F/R:A) M1$MW4$1%V8J%2_KT]?45E8NP@ C[0 ?Y!MJ@VW7-9_7TJ@@&_0 #7G(1< "I M'QIL'O >G4 'KJED55)O[B*7JG;W#W!T[>H?PV_;KRCB8-W/0?UH2+6]:IW# MOUZ_AJ$R)&DL>E^E"H JTW880Z]?#;KUU[S1P3N Y]PTHK.HTKVB%[2@'NU< M(@0;1T%>5[ZU=JNE-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E6E'J;QZ# M[1W]_A[M*4$.H#[M]03:E7:FE:5*NA:1KQT43E,V:+K=Q$@7,44DC' 2HBHD M"IOAZ%[@W\-]5(-SA?B:\IW[4#R7L54GI?H/AZ_SJ.DE87+C+&,ER1N1G;.9 MA)%LM(QJJ3&BLU2+OU>ZRQ1E%CGD5/(V2,"@[$,7IK(]OMXTJ?M@@C0ZMZ?2 M;=/C6ES9K2^1X#A,]HY86!9/;CJ;MK*ER=QM[3$ MXQ&T.K>)3\Y>D2J7!R+MM"F)"=C)P404%+Y@P "H%[A\=9[%9EEPY(G M69V7;M.@7Z="=?YV]+VKY[\EB:/@O-<3-P\C@L6.:2=,K'<2S90M.QD$1$=K MZ'9O-]UMU1ZRCD&QV?$O%S+./XFN3-?ILDRA)7(>7H0R-H92+>QR2RGF.4G3 MH$8[Y1\D!! QQ*8XAM[=93'PX8?>*1+5O84HF7A43M?(;_+E3C5Q*FJ!S;EW$2^.U[B08C\:LL6 M)(\D#^HU-K@F_P"OI;^-:SRN1YBOY-Y3B<_RG!Q<7FL']@)(Q"&3MR1$1Z:[ M";-OL0;VJ),-$2">'L@0"?)N+CC4&U-Y)[7&3]TZA)="4=,6K.1A'QE$3N'I M'$<<03,B0.XA0[NNX;&S(^?BSG!8K(MKD6)(ZWZZ6(N:Y7Q>!E-X+F<4/+HH M'XS.$DJ*Q>)EE9%C[;EE)8/&VU;:L0.IO4S64S;%;_@/(D/DO$\Q1+92W$$T ME[T+AA*6EU$Q$A!O8N3:$*_3>*MIV+,W2W6ZI)!OVCT# S8D2)F84\$ZYJL& M"IJ%!((-]+74WTKNOWG,CRC@N8XGDN&R/&G6?.G)'A9QB!A,D+3BDP92Y:(ZS&XT'H?7KK6(R?'NS^(X7U%Q6)4Z36+%B'B\QDB99R;7',Y<+"[RO+ M+I4I&E-R2[90YK5!@I83F8BH[^ P.=^Q 1VZ[:]C.T>;DD&&![!0@&[=H1[3 MIK\:T_&X7"Y/Q/Q3%RO\SR^"\\N2>0D(Q_M_<&'W,5W.SWV4;C8+6[_H,VTQ M45Z^3XJ/;UF:?=S=Y=QR#U9"\X9KQ(U^N_CS&9%5?34O74 M]Y6R@/\ Y0QH$LHTNLIN%OKTN5Z:]:S./@NM;(BJ:UM#FKP%3E\3'>V!E*+<7USU!=2.I[:'E5V]O M36?!(%&&(L_:R8B"2:GGF/WCV]P@%ZN7) LCS+/86^X]]B]P-OH=;;3K\-*M M\3C\7/?'Q.$FXK[F5'/",(+QXRQMLR 2'&V[B8>W0[A<>E:M?:05O!9'H%(I MSRD1]GH+;)V1>3^)O(D"W&WU)C+R4Q486 \R*5=DD'#PP%2,_P"X 7*'MWU? M\?F=R7'R\R1"X+"DPH8P=A.1D0AW>!(KJS%B; &37>!<7K';7'(3T8CEAZ:#K> ;=B=\RR/(JQ00 M_(BTFAW\K',79XX'B[9ZLG.Q;7<3.0W9I=G3M[ASL/)2XT@XL%Y.:BRE,2WW M8R!@K$7L#T)UMH3\Z\L3CI^1'_(V7'Q_!\SBW7+:1-G*3-&7C4FS6^M$ZL3M MTTM6)*#%5J+_ /=LC<%X(:9'Q8YDK3)I9CS%!(*VRJ2)I",/.R)2DL)XSC<7C#QR#PCAOO\ Q8O.ZYN8 \KSF96FRNWU:*T8$C5T0;E*93=5,WAKJ M/ 08V'Y)C?\ '.'6*6/&WRF;]H%2'"A#MD)-P2=.AK1^5S,KD/Q[R$WEGD9R M<:?D@D)Q1WC=7A)#>^( "X%@=.MS>QQC%4'&6\QC M]XB'8/SWY6O_ /*/03CMO.NZ2\:H&D%C:UMVAUN>E2[NEU& C,E3G,OC9(5*@QF>H <>RF M+H4@3-MF3*W0[.Q2R:Q&Q)*/!NCYAUN\IA%62\VV9UVK8>M[_ -PUO7)+ MCJQV:N.)-LG=F.7HA]9Y"5G57RZD*YQ%6&]?B7+"'69E&=^H"DHBJKU,V !5 M'8.G74Y3-'+8A>V=3K;:-?36Y/\ #TKLG%Y^7BR/$N0O(8[3LSD^PXL0C0A2 M/?N((8W]O7Y5*F"EHN@=/#5:LC MC>MBM;MC319,*S0/OA;4'XCY=*UC]OO_ )M1L4U<;B*M_E_#5O* 2152]*N* M(@&P;=>H@/Y^.F]HHP#J330F_I0-AW$=@';^6P>T=50E&)-@&%&! UJA2;^ MAL'MW_N:I7&_A;2U>SJ]KSII2FE*:4II2FE*:4II2FE*:4II2FE*:4 MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F ME*:4II2O&8# .X?S>/[?VZ4JNW< "/\ +^6VH M^E*KT+XCX^'X;:FE;6DG) MEC2D=NNAW1@F2<-5BE="HH1R0X-4^\ABK(E*40-N ;B&O90 VAUJSF,.[++AJT$<;H&N!?H%T706)]?3KK7SYY/ MR;8G%<5Y*V%SF5DXG)/%V^ZJM9C,O=F D8-$ ;H+WL4-@=!A')IX?&O-9>.J M6.+%*R_(&J&C7EXL%A(O3X!S<50*[74AQ0)5D.Y4GG)B4H !>X!Z7V) M$^3PS&651%CO<(!=FL/CIU TZUIO/S8OC/YG[7#\7ERY_/8@1\N2:^-$9">L M1W*0AD)< J;$ ;ATX^K>=JO1\HX'Y'YB6L]NQU-O[+C6F5=T^F 0?+-V*Z\> M@J["/!HS^D'56.BFF)$NXR@;FZ:VJ")XYX>3XC'V0N KR-8#K:]A>^OQ/RK@ MW*)CY?C?+> _DWF5S>?P,M\C%QH'=W7V(P07$=AL+,5 LMRP%1Z7DL;VO%T5 MEJ&PK:SV;&L_3ZA861[&YDH.?:J0TJ1L\,M]((LU.5& #O)Y"A0%40$_0 '9 M8\3.QN5&"^6@AR8Y'#;0&4[AI:__ *M-=;5IOW?BO+>+XGY PN RSSW%SXV+ M*IF9HI$$3(KD]O6RPZ@IH6MNZ7D1'P$FC/PTG <9*3 8VSG0&[Z8);GD3+Q< M;:%?K!(E%C++1J:T2+1^=N<42MS;B(;B'=OK'[(>U-%+FS/F84]HP@8%DTUM M?6^OKZ5UGC."G_R49P/%>/@\8YK 66?OF-T6>SF- Q4%-K;= C"Y'QK),5CZ MSW'#KNH7'"U&N6:<(6I)7'>,Z4Z:0*L5C.667EY":F69(P[.2:+RLRFJ4?, M3>>140 0[=4Y4F-!R$?)8F3/%Q>5%MFFD&X&4"P5=;CVK;IZ$?.MF_XQGAZUMW#^,O!C^08W%8V5PD?)XRY+Y\,XG=IPLS2 M) EXV_;+"P# >X ;36)+96G^5[XT",S"M8X,+#!,U$J,8[;TZ=^AQK!],,H[]2S"I7P$3.7X7 F' M<=QU"_NN-J@PJ;;D-BS$;AVD(VPW5[A"7QPT:.*[1XR4^B_ M(2V18A;Z6NNY(1JV.J1,BIA\E0-_??\ W\^0)%$I,;A.Z')W.1>X0ZZ:GK6. MA\:XC@!C-]G$LD,^0.39M:="4-_:I8*#>Q%87?4Z9N\ICS/5V>P[ MI1+&-P@9GDD1^]A:Y2W[RRW:NL&"U!&-6._57([0;_,"Z1,07 "!3=@ ;/P9 M<6-!-Q6.'"MD(ZXQ +N-L9)$EQ;H3;::UY.+DY?+PO,^5?'D9>.GB;E [1I" MQFGC51BE6O;<%W=U=3T-81DJSCB!LD&@_:7W.N=^.V,%LHUIXW41KF*\BQ\D MA 2$)$$>.W[L3F5:K(E,55O_ &WQ&$"[;:V[$R,Z?&>,/C87!\AD""2X+SPD M;@S: =-;6;3IK6MY6)PF%RL(ECS>9\ZX+C3DPN"(,7*5PA1+M(REB ![UM>Y MK$!TYUA(8TIE1XY8 IE-L4,.3LTT[)$3#VIW5G;19\ZF9IT\-!E,SC(N+@4W M*8(IJG%1$_0NX#K;(9<=URLO-Y3DILZ)_M\62!F3N+H%4#=J6+E=2.HUJU@A MS(VXWC>.X3A<#AYHSE\CBSA':&0 LS&R #:(U8, URIT%KU@^PY>SC&5'(>8 MF<[QQ*BS(>691L3RD]O#8-; M]QO!>-Y.;A\$T7+C%6+O9D9?]M6*[B\JABK,68&X!U-8Z;R#RQ.)S_)XYN#; M-?(,/&R!3=HP2JHA*AM%0BUP/;U %8CR)%\BZG$4;!C7CYAAS9<@M(B6R-%5 MBH5X\_-RPBD6/C[&NDFF=E+0[Q=S_:=SD$CK&$!]^8@?Q3DCE>0'E.1&'BLZ M8[22/M1/[FC!.JN-O^V]A6O\YC>8XN/A\'C<'Q4N;FJ'SD2.,EWTL'/]I5B_ MN_WQR*RG.*M^SO4JA>L/63 %3P+4T$5KM"39W+5&8:%=V,CF?B6D9'-V MZIK=+ DBH5=8Q_[(@]H")B\OYG#\DP>)DR3\?,KKD1R6C5A>3WQJ% M*^ERUS:]JY \'Y+Y2 M5C'-\S5AJ[*\QH7)N5&[.L4^3F%EG50@V[BR_/NABY@72$>HB)T$U$VYE2E- ML &$ #7&?(,\UYGQO"9GF'BV2WE M6-R7)#M0&0*N-&#+O*AMP&T[5(7U %3XQ<;$>4+K?B8&MI\3Y5AKA7+%G!NQ MA"N?U&9%Q#N'%=!R+V''Y"31:F:B8>\Q?-,/ECML/-LJ#(5QW"%/S ((OZ?^ M==3X%O'>>Y/-/B4_^/Y^/*BDSMJ7[A';)C.J7WJ E_2_0Z"IOT6TO)5R*5AC M'54L[U:>.E4WYJG4/ ?QU0;JM_C4C4T -Q#?H/O]VO(_N-9A55K#2@@'LZ] MZ_WM1+'M2R=?7XU"FYUHF/;XAM^'AJ('[2DR7VGI4GW:>M>P4>X 'WZO58,- MPZ5Y5755*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I MI2FE*:4II2FE*:4II2FE*:4JTP;@'YA_/TTI73EX1^N[RWSKZTF4N#N0(FB. ML$M;O=Z)4(^+AFL78JXM5I].(;S3NP(M#/)T7*3)8QFZGE%**_\ 6'L#NCTO M4_W$>@%Z[C8!L ![@ -34572E-*4TI32E-*5:)@ =A'2E.WVE';?\-_\&E*\ M9C;$W'GCT]GXZ#K:AZ7J/E\M+>K6S']J=EJ,/!R3Y[7;!,V([M"Q&7D! M:L:M'U\C**D"N!=RC\Y%2JK-RE X" CN(!?PQEXY(079AJH7IIJQ-R.@MT!Z M5IO,9IP>4P.2(Q(\-W:*624L)KO98$B"HX8L[$,&9;7'7I4#;956KJ\\@..# MU7*T;7-MNS;KJ3J?;:^OSO7&.5XZ#*Y;G/QY,>6CP>0A&1]X9SM#*(V[6 M.&F# ':1M4*+[M/6H'V"54S]Q6G*TVL.2,3I<5FAG#@)\ZSB7R%'@Q7!-PV9 M'E"JDD(PE<$01 3HIF<[%5VZCM&+&.-YB+(D6&2YFRU13=E7N7+KVKVO:[V#6)-11LF4(R06JO( MKCCB*:7O,1)N:U?9BW-$+/#2CDL'\F].%?=?/,6K1S"/$DSJCL!3"81W -]; M?A\4(=_"<[DJ,1UWH$.T@%O;KH;A@3:N?Y_D&)F/C?D_\7\1/-Y N1]OER9" M"0-:,*Y[1+J R%5+@]=3<"MV0]WM.);A'YFM^8(NL8FR UC6=HQ]BY585(N4 MFV*;V0C/TF@2(@&ZK-TBNGY@+%W$H]NX".O=.+AY;"?A,+#>7DHF9DEE%@RJ M=#N-VUN#:U;AQG(\CXGS?_.>=Y:/%\/SHXTDP\4L3'/*FYU[0"1@JZN-P-_@ M"#6ANL4T2%E6.#K4KE+-$+DV'-E"@V5HJ[KD V;G30'G%<,8_Q=/NH MS]&Y:&SWM.7?.,1Q30D$TFF*+.(D#QYO.C(LAEF_U80 0^+6E\DN=R*3Q\E),.4CC*9BB%"(C' M<(MQ);KO!(^%;+PWBW%^.Y6'DQV _RU30K MMN(]FP4) +OEU)^,KB1D6RC5ZW;AU+L7;?:P5S"VQ@JFQ! U-U('7TOJ=#_& MLAD<<<^%F:3(FB[PD260@1=N7<__ &RQ[B1 JA5U7TL#63G54-+3T:LUD5)% M$8PK-VRCV9JS'_2G17#=9:6=-?[:0!)(ZAF*!DSE2GS/PK/28/>RTD1RPV6(4&-=IN"7(U:UR4!! ;X7O7NF@7K9Z,DFXM\> M8THV;UR./,KK,4ABX96-*1Y%$>'8KQCM-N9<"&'8R@D.8H&\*-P(VG:1;707 MU-^MK_+]*J^T=9>^&R%.\=M2YVC:FT J"05-MUCU-B=:PK)4%2(._M2D0L[O M3UG-6IK/5]%@SCXVSQ*17J9+='MW9%GZKUXN'8D5)P0.Q0#B7[&%"K*@!'>4-=BQ.@ 8:&]M+X)'GBC 1 M]T\$L4+K,]L=@(DD)610PN;@'4Z5&NR5O$5S34JLLRRA<,79FB4YAPP=V!K4 M(/#J5+;)Q,4R")"Q*'B(EXTL*GDD10(FFFV " )0Z;?A97)XH3*Q_MX^2Q)! MM.W>\YDNQ-]FMBHO<^OI6M\AQ?C?+J_%Y4?(9/C_ "D(9P91%#AB%0BJ%,H, M0=9"1L0#V?(5'9\E%.T*7?%^$D6ODVZR-DQ;9H%_F&.=N(O#KF+0CULAH+&1 M5*L:19SLFF94=CH_)=QC =-[Q%:":7 3G73B\<)/&ZX[ -DWN(2-.A1+#H= MUA6H2.\S8G.3^)Q?\@RI9,.=7RXRT>"19L@-KN#*\H(Z^WW$5$'(D!@$\9>* MY9N'EF@,>\?V*UDJECJ>4E)AY;9EU/LCJU]^NV!L*[8ZDXX6(JBHZ42(V*GY M>VXEZKP&5Y0DF+EX'/0ORG*L8Y8Y<>PB0(;2"][:1J+$*#NN#TK6.'G9/D)7<@98P]F'. M*%UCZ7C\8(21]+>V9NV\F1>WT!V;*?R:7 M!7Q3,Q<'/X'C#$99P_NE"$Z"'9L#V4[@7M%D($3RVO(T@;>$#.EB%N #H36_HFQ9^X^XJM&/YYK3N1LOE^?8-K-!_4% M+G-,:XLWB9%H@Y<2$4Y7;F7?QB*Q/*[P1%8#F$IP, O6UJ]$S_/?"/&LCB.1BQ_),C/R562(R&5UB94MN+(3 MJR@]"!?<2+5-C#U'P7DK)&%*U@3)MAPUE7$M11NMLP;?XM<)\8SY.)YKBL;[B?C(]$:0A.Y&[@K]+DW)&I)/K4O:98G=J=5*G\ MH8<>.G(*R9+-9:A%T-96, M/+^0QH5E"8;;X1K>VE_AUT^ ]=:WSCN2EY8XW#>>0_X3RS)SFE@CQI"IR%AV M2(97C"W#F,A@;^V]ZY+,?6F6GW7Z1R4SA:KETC.Q.8]A O9.6>?H6.L9&;&2 M/.+Q,:B!GK<[,ZR/F"?S%1W >T1UCHY;N(I1MG() U)VWM>]K5V/B,Z?+;_' M\X(8/(PLA41L[GL+)9&WE$^I=A9;Z,3UM>I)I"8$R]X )@* " #N&^WB B&X M^&KG6WPK<_2QZU=X]=NNVWX?S:\B2WMJJVEZ;;!OOOT\/V:; @ZZU ))L>E4 M 0W#I[.O\MM6BJX<&J]/3K53&*;8/#^G7NYBR/9?6HLRZUYB!L4 _#^__3JX M1=BA?0"J#5VJZBFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I MI2FE*:4II2FE*:4II2FE*:4II2FE*M,7?;;Q#2EH9# MY5N,_/VZ:G;-#8T>Q!6<75['8WK>2E)']2)V!TYFT%'H.#$;JLTB$*N /\ M9AO'R]*DG4D=37/P'0 #W &IJ*KI2FE*:4II2FE*MV NX@'LTI5!'UU0;3M^;"W4$ M@W-ZYIY'A9F;][PV(L$6;(O?PY\IEG7[G4WCBD+L!"R1.%5 !>XUZ0"S)+PN M?,-'RBUM-XO^2N+4RVC;1 42+E*['VFR-GXLG**"!?H8@S0"4$PJ-T3*&32[ M>T2B.MEP8\CCLP8KK%'AY8)5G*MM!%[^IOI;7U-<5\IY'CO-/%3Y/C3Y^?Y! MXO.%EBQ5EA6>=3L90O[09!W"?:#<+;47J%V9KT\?.*QSFLTB_13-+Q$7:^-9 M9(KLQB^85Y(-9^(.Z\Q*K3&QT7!7*9513*/>EN&VMOXC C+[1J MNE1O?V+(["6FN1]>FE<0\9[F9R2;Q]29IE&+,(V98_I64C7-!9O6B3E\[4,8 MZ:RB7E_VI!\P!*/;N6)A8;JOCTD8R?(DU65P2I*G<")+&UAZ?+I6JP2^08_( MR_DS$R%XG\69",SXD+=MD65>PZOC)93(7NRMTU!W7%:55:W2L>,:M:L(XJF. M1.),M31T./>.^P3MF\ MAW,3G\M>.YK#C7:(B3W0RAKWT:QL/9;UZ:5=>,<3Q'"8V/E>#<7)Y!XIS.2S MR2Y2I;&:)F1?8=PW+O<-)<'VWN2=;C!4:AVK"< M9)K)X5&/DX]1^:25F$:DX@X19*92*X;H"9IY"2G0W<8!\I>+FGR%YKBL*# Y M#CH'GD3+90X,9*DV:Y&HT-=3P,G*QN//CGDW*S\K@J$''W\B3XS1J\13,[9[-CM0(!RE -6N#R6-R<<"";.ER'+ MSY6# OVS0@*ZK(DKM#<7*,=C'<&OJ:V[-XS(XA\K(:'"QXX(X<7%S\ACDC(# M&(NDD2+*0;AENRZ,O4+4XJ S1ES6ZB2\8,@>%GG^+,6RJ^*<:1%:K&Q]:Z/QT44@EX[9[8V./CG[>%4Q"OL9H@X7MI+34Y#M:G)*JO8QZ\=OD3%6;@X* M\%3=,$@*H.A0J,76P90%.AV[;:WTK<\#&>$+$H MW1Q26A.V.-+% 791&VJDEAJ+[KZ6UJ0#:MH.B$-(*&DS 601,FN8XQXMI%P1 MP=N+(?[!T5J9,I$C'+N! Z;;CK ,Y!(73I^NG^GSK-KBHXO)[_J%C]-F-[6Z M&UA8_"MUH-"(@4.IP*D5( ,8Q@ "[]0 VX (@;81]H:\B;U=*@7ITJY1L0X% MZ !B#N0?841_QBA[#;#MOJ+FJB%)K9LI5D0%1S$_*PS06@_FUHYO*/%4E%G#01(5%R8 MAC=#%UD,>1MP8L-VZYT!NMK$ZZ&PZ ^HK4\O!PA&R&%RBQ[!,88]6C[I5&.+#E\ABSY/ M"X;O8>.;RW_ "\Z MC&XOF>3SL%9BZE V.JB-&0^T6/K\;^E1#G^'FS_ "?R:#"YN#'F0X./%M$D:LS6+!5W MJ%&TD &P!]OQP%B!)GA]$N9L3Y8>TWE9<2O/TKAJ5@'+=6-&:FUXQ5$[J8:! M$@!X@RIFQ':A1V%,Q >S6K>5\A-R4IXKE<9)/&H2 TZL&W;4TM;6^ZURHT] MUR:Y5PRXOCK/Y3XUGR8OY.Y2(M#@3HP*;I2K &0%=45B@D87&RP&E3 AOISE MY'X1RO&3N$/4"RQ--2NLJP35FR9?3+,8RT6WGWE:=&%FZG_G6[IRX:(KK&40 M$5![]M^,\DNGWG'R-/X[$=$=B0+?[0QZ#4#I:M^AR(I3'XCY,/\ $?F?E0 V M7#&H(63Z0\D8]KR7#$J"25]QN%OR7XEL[Z1G93B]GS^+ZBK4:IR^G3QP MS0J5;S-@,!0$!US/.[NS\%GG[U_ _)X95RL'$$47,2]L-(\H==\4A8,'N;:;2"0+6M4U,=1- MCK#@F++6\GUF5<:QD=1LW6*Q12EDRHL^8HR[Z.;[SSJ86$CD5"]@_"S>_M," >C:?P ];_P"M='X3&S./<<)GO*T6.J+!FRR*9FM3'BW2[QBU7PAMM>3*:J%=.'EC]T M1F7(5P?8S],[C?+9#[5TH]I?K3%*O9F1> [,55]7:TS2GF!H9=$H%(>33:J M;O$2E*4IAK]I3:VFE0!K[1>L,N>0'W:W(FJ-Y*E8@E:37Y7>2C)$T!QNK2Q/ MEC&0%HD8DLVLQA.[TJDLPN +'YZ_^=89N?JA?=*< M)"L)CE%@Y>ST^-01749J8UPQ)%=QK8XE5%[-XM9V&:)YQ2[&4.)52A\6K@[? M32J 7N21<5RY>FA]U'QPY3V:)PYRPJBO&/,THZ/&QSQ]!9A*S#1+SEV$+'KJAY+ F_:.,L"8/3IYJ;:X2$D),\Y"0\B]%:1 M2B5%O+7?PS]8A0^>/MVG#V:CT)^%3< J+=37;DJDJO+5.LS+T2 YE:[#2;L2 M[$3!=[&-G2X@&P%*3S%1]P &IJ*Z\7JJ?/HYQR"Y%LC_ "KJ MG5=0B]9K+\[9)PFUL\XBY0$7/]N0ID67S*J2@&(H4ARB4&OI0E5^J_Z>M<"- M0]7/[F_G"\=S'$'CL%/K+XRJC1B3'6)S-6S)0IW! ;3&86$&]7*FUZ H!SF' MV")M3I?K>H)>UPMA^M:ZOE3[P_ T=*VU_1Y*SUWRQG;%\W7>--K^GE4532,S M;-7G3?0;;5%Y"?0UJW'G[LGE-@F\L,=>I+Q>EFC$7B M3>5N%>@ J]N;$!4J3I=O75VM9K+MND41/W)*'$>FW00TMIIK4[P#9Q:N[!Q0 MYA<>^:V*H;,7'+(D/D&ERR8@+AB9=O(Q;M(2E<1\Q$OD6LE'/&YQ !*JD4# M(&*(E,41BJK>OI762]?[UP>6_IJ\HL0XCP.G3QJUTKSB4FSV"&B)%P"R1ZEL M*:TC#R*B1 +-+;]IRAX>X- +U#$);2Y-;R]2C[I#"7%63+A7B]4?_>4S^G'- M6DVX8_,%Q]7[&Y(BBK&IR# XR$W)ME1.3G'[#SRKX]FTS')Y./,%5Y9BT4O?FN6GW<'$>(2F,FXQD+?C^+7<+.%7%*X]VYV_ M H$.J09"$5F[@5,J2(]I?+V#N'M#?32WPI[[] :G]Z='W7%$RED"$P)SZQ<^ MX[Y*D7Y(%O=&S%_^E%)=PH0K%.RL7:;67A%GJIO* 4F'RY1,0QC%()C!'_VU M(8,;=&KN*Q$O&ST:PF89\TDXF59-I&,DF#A)VR?L'B)'#5XT5/(6\2&-_3(XG3TTP1D!18WN MRP)9ZRN"(D\HXK0::-CJ;%BZ6/YB9W"J2H$[.X"B82ZFUNIM4!K_ $B];0<9 M*^\5S>R;3Z%$D*I")=\I!(1\!QFJZKI%V!%TVBH1THTD7?E$3( ](7;N'WF MT]M0#)<]!_6MM7#U9?N?.$:S29Y;\>AMM9:&0=KLSXXQ"9NO&)""!DG,IB!A M/2"!5/(,8RIC%5#?<1 -AU!M?K:I4N!UO_P I*AZG=1X!\!FM5GC&LM-Q?;,VR M+/6A:+FE6JKJ(F / PD,\9NCK$-L!04^'IU >M+@-MM<_P"E8?\ 3B]:3U+\ MU^L"?A1GS+=.GL9PEOLU2L%>AL68\A5#/ZY(_2W96EDBJVPGA0*[24[#"J4Q MB["(!H.@H?K8>@%=V_(&0Z5BBG3E^R+98FH4ZL1SF4GK#-NTVP%S4:&.?\ M[OKE#76DW5,=/*;09=0LO$/&E4XX5)Z!VI1*FT,Y,[C;>5)4KH1%-=$B9A*' M=U -3I;XU3>0-Z#^M:%9_4<^ZMX;HM)?D7@]U:Z;#-R/%FA\=8.EE'T8W5/Y MPN9?&Z$_83"L!! 3"'GE#J'LTT_2@W];7 KF%]+K[GS O+ZZPV ^4507XS9Z M?E3C6BLQYB%!G)U)0J"D:$C(*EDH23=;^9VO&S5L02*%[P'L T6(_2J@5;0: M'X5#W"?K1<_+Q]P-EG@7,Y6J[_C!6.0.6:) 5%OC/'Z$FC5:K+*-H)H:Y-8( MED=*(-R@ KG&W3^C M2E:3+M2R$>X9G44(#A,4P%!RX9*]_P#6(!734Z;A$1.4 $2& =M2ILUZ\9XQ M-$T1)]P]"5UZC46(_@:A_E=C,W.JHVREL,>RG(+$BYBI'DGOUA=^9LG9B M@L9JH\5$8QM\/>F8>XOLUF,8Q13=F8R#CY?A:[6Z>H'7IK7,O(XLSE>.7E.( MBX^7SGBR0ID:3M0E]HFLVQFU1?\ :;VL:@%>,JQ]8D6_+3%.074OC?'KDE:S M%B+%E5?11;!D)VP6C)=19FYA(9E($0DG!U@>.%0,/EE INH .UX/%R9)'!YL M*+E3#=%+(_TH#N'1C:XTM;UKC7+<_C8,P_*GC.?)/X_Q]XL[ PH;=[*/[3^U MHTW;7+-O)!-@0;5!_)Q8G$LPRY>XDJ\OFN0SJ2>E)_$.08MM9$*9]<.UD5FM MCK+,TLX57-(7;I3XY8@[\.AE=_>%39)"!LVQN1*-I8K;=U%9 QW=K+#K,,RP%G9TS'/TB3< M*<)&$Q;$9*THQ[ELVD8AM5C)BU?(V9P NVZRBP/'*9P4W$3''66R.*Q)XVX3 M(C:?D2Z@3['QEL1P. 3Z075KJ[ @GJU9SQ13X*>0PI"83F8;C.[M+V;:3#B.&QQS!9BS^9D&0HN2B9/L-\>K'E\J7"_R.3ST4G,)CJD6/ MG1;.S UR$,JH5#;"P=MJ-==#<:5OOC?$0#%XC%\->+@H#7(8[>8QITW5&.)L92F2[^=_A;*58?9$L&5+"V7O M4C&RU3FI:,M[*KJ(D; (JJ2$:43)F,41 VYM.\JDDY(9>?#.4N3W"C0 MJ<<5QY8,EWR @!2E[-@Z<8YR22.23&C*-!&B('C0('V[@K$%5)O:][:^M;OP MRX^48'D,D.?/+).\4[M-VOH:2,.IEA7:3;9O '0"PJ:6+VSEK$U5.7:)*E^E MR:<>EQ4>H#4TW%6CTEHNM_3]?A6Z\6LJ11"8#Z6L-J@AM[:_MWC'M^!N?47)J0R12$33*0 *0I"E* M&W@4 #8.O7PU)ZZ]:V =-.E>32III2O$J4#E[1W#??J B A[-PVTI:XK"U_! MHR82[SZW)-3&4B72;4KB<,0L@M+L8QHY%&"(YG$H]94")*D33^5 .XYPV$QM M7F/8L P!&M^G2Q)M?2_J+ZU@.4:*&%Y7D<"Z&UW^HNJ*;("X4FP( VVN6TN: MAGF)YDV"BK^^CK$_GHVFVJI71^M6&=?R)*K+IQT\K/4V&K4F$HM$H_/._+14 M5;M5^QN&Q@W-K<^%CP,G(BA9%26:)XQO+1!=5VR,XV@FPO:Y&M:=SK\M%%/+ MB3N\6+-',W:$4SN K[X0C[BH)86-E;VZ$5!',\U5IXF;*5><*U_(#V2RE09I MU6L-%<5V]1T.[L-80:2=\78*UI54WS;)44RF76,DHB83@4@[CU7QS$S<=\#/ MP<]L15Q)E$N3M>)F$2XV')DDSL>0QX9[> M1MWQ!99R#&;JR'^YKJEA?I4>,@P[.[VC,LOBB_Q_(N2H%,J+2 XTY*;.B,,7 M.6#&I1QW[8;4Q;5I67@S=S$ZK5TNJL9P=01.(G-K=>-R).+P./AYG%;B8LJ> M4OR&.1NR 6E;:>V3($?1@&46V@::"MX-*H7<-;E6;ZC;UJ)BS$U&R'9I+'\C:*YSBR/%BK+XZ?1]>4QM ?J?YYO M;H-DZ>KK-/FRKK"BU%9,&B/;N"A $1'WY3.ES./Q\7D.T_@>,_LG4L)I-NTQ MLU@#J!=K'<;F]ZY=EXS<5RV1+P[;N'0FXU-]=!6K>X^#\ MBP9'_P#J?96TL6S[=9=S" .(WVEOHU13&#;<18VF#5)VQUIQ=,<\]W(U?D7D M5!I#X3RDWB8.7M]%.Y(NFYF'%FK:+YXF1L=PP4:&3567:D3$J92;B \PY*7& MCL>&1FXM;&16)V7/Q5CK?W7L+5O&!R'-8)DX/\QRQ8WF_)_M\=E1Q1-D0G4, MW=C0[;;HV0@DK8BPZ5+ZATU%E-P'"OD/ WC)<=6EEKY4\[W&;L$/3D+0V:_4 MX&/&R+2#!9S&/)6 :D31,0RQEW AV?$&^BYP[RM,I5=U[+T TZ#X#];5T?C> M+PURL;\4>8P9O)Q8P7)3D)W=8>ZI+QJ9=RECOB3VZF["XL:Y',2OI"S,TL9Y M0-05LTXX6[6* MQY!(!CR;?NEU&E]HO8&]K=/@;VKL7"?<\A&.)Y\87_),)S)C[%,@CC!*Q.&= M!9NTX!MK[B+D5,.N//FF %.L+ETU,+1^N9HLS*J^0 @+J)I+H("=,PCT,4O8 M/L'604[EO_U_UK70L.3N1V+%I%.UC8B["U^H'\P+'TK75%"HIF55,5-,A#** M*',!"$(0!,LMZBD/Z6W=GV*'>(#29!U%0X M94-^OP!U/P&MM:[A/ 'TS>-/I^8PK]/Q328)Y=&K(OZFRG)Q+-Q=K%)*H$1= MJ?6%R+OX^.%( 3(U05(WV 3=@&4/OY]O=K4DZW%QI7(@40+T$H#[N@;_ ([] M-2) -#Z5.TG6O$^CV4FS\16_FSQ%HD3CS,^.QC[%>JC2&8043;RF/++,NU'LU8:,+9\T M?D'\-15=5TI32E?-C^[&_P!J#@O_ $6JO_-JYJ/0_I0]4_6NQ-]P+ZH\_P"G MSP*Q[3<2RPQ^<^0%3BJ?6)!DJ 2E3A?H,5]7GTNTX+,UG<89V@T7(43D<$ 2 M"0Q0,$@7TH3M%SU]*@#]O5Z$5-L=(KWJ(YM7-=V&*AXR#8-( MF(CF,7%,&Y&K&-CFJ+-BR;I=$D&K1NFF@W13+T I"@ >[45-:EVE]P?N#2E< M>_/CTSN*7J(XRG*#GO'%?>3K^.<-:[DZ/B6J%_J#\6BS5C(1=@;@UDUT&!E0 M4^357^55,0H'*(%#9\Z=18]*^=YPQSAR/^WW]6-[QMO,W*2&))N_1%+N];"1 M76J=GKMQ!BQ@[FQ9K*MT&SR*>/6QEW)"I+&!B9,1.F':,]1?UJGZ'V_VGI4A M/O"YF-LO,+CE/P#Q*2B)[$KZ7AI!J83I/V$E&X[=L'38268J6ET]<+['614.U%LBJD42 /@ !^.P?W-* M5TW?NI_2ZQ#8"8L4?7V9I0K%)LU?2 M\4[G?.%VK_G)DD$TP.)2$* :'Y5##:V&Y6>-B%F M:"QBF%9=! JBI2E Q9Z"_K5)][6_L%?0AX4^G_Q>X#XQ@\:\=\7UFID80Z$? M.6Y**;'NEP=_V:[^2LED7(O,R!GKXHJ@BHX.BW#M33 I"$ (JLF^GI4U.TO_ M -$/W!I45Z,E%Q\NQ=1DFQ9R,<_;K-7S!^V1=LWC9<@IK-W39_ M)IX%OSIC.DOHJ&GK,X%5U)H&8%5QC;).1.HI(N9B%OS(ZJP]I^U!JGOW &VH M(L;45@RW/Z&N*_[=WEO=?3(]2?*7IW9\<.ZY2\HW29I7DS!DVC*,R%7G0_I6 MS.'#\[8L?"RM69.E"& 2@H+Q,1((CTDZZBJ4)4F,_P *^E40=RE$/ 2@(?M M-1557:4KCU]43FI7> W"O,?(J;<-23$! 2$30HUV50Z<_?G\1*/(&"+V=O:H M\3BUS )C%+_9^(:5/S/0"NFW]J3PGL?)'DIE[U+\X-'M@+5IZ8B*#,SY$Y T MQD&:BE$)]VY*^,=94&%=LS8[=P & %D@[3 8NX#_ +1T%4)K=S]1J+7I?_\ MS,>1OPSUF'^:ZR _T:>@_6JK>]A_Z:E)]RAS]S3S!YET3TH.+4S*I0[>SQM+ MO[:#>.V2=PR79+*6L?IFQJ-5?,"(JKN._M>XI43)O3^9W%\)'Q/2H8F^Q>I' M]*[1GI)>C;QQ]-G#5'/'4:MV/D0ZA"O[[EN6CT9*RA-RY06=QT&_>I*JP;&- M:&(R[6?DD5!,QS (J'$T?.IT4;5Z5S0@4H 'PEW_ "#QTI7B6;HKI*(*HI*I M+)G2524(4Z:J2@"51-0A@$IR'((@(" @(#I2NI;Z_7H)8SY%XRM?+;BG4XG& MW)?'+96U2412(\(%MDQ! Q >&,RB$$F9+*F<4W(N1(F=0J2IC*]YA X:?I0@ M,-=&'K74(^W[M=MO/K.83M]\FI6Q7*Q3MKE;-.SCMP^F)69=)IG>O9)X[.HY MVC D'Y W'\Q4-LHV*7I3LV5HJ/GSL:VV?*7W"E/@:M-6V^ M!-I SB9E^BQ8/951$CE-4PF45(!@3, ;[#K-X<,,X^T=E#M;;*Q8*ENHZVUT M^- $=@JL^A!/47UO>U0SS3&O,48D_C;C\@^.NH\3@A$ MF5Q./!$TLLDH ]Z(A]ZLX9BY# K_ #X['TS+XN4?\P\%/G]GO>27\LBVXWV) MVA+2E0BK$H5XY?IXYC3GE%XB&,J4C!0B"K=(H& P@ E >D86-#RQ'BO, 0X& M-MOEHM@[)>P[S#:"UM1<$Z6O7&WR>1\8&1^6?%&R MVQ+B.6=/J^Z%9)"054, K%!(O=V!KJ,:39\3<=R42R^$1-5MXU9QZ5+E9N$A4Q0\^.KA2$ M=(,FYA36$X*D X 1BX7(GQ_/R/$YHLCP6-KM#)O,T@)/=5&8>KWL687%M;5 MTG!?BHO*N(3SK$EB_*LZ$)/$5^VC9$41%E1BA(BT8(K*K7W6-JROC['V3G". M/['%N<:\LLAV&[S>+IG-]?L[YI8,(TZ<;PT0P4B4_JT,F6:BU+ ]0F')&#'F3*79MQVM[&V*K ,"1U]+[I MP_&>1LN'G*>/\AYJ3*EQY,Z)UC?#QW"J EF%Y$WNPT.O3J:D[BO)LKC!K7$+ M+(Y"#&F"\B6"I767Y&8ZDKM>K[8+&G9G$9R=R9'5:]%)6ZJC;W4>+!Y;T+)8UWLRG9!A'?>S3^8*F5JYL?VBX&TBPJ;%$>HLXR!56?SZ;^-%TPF8X#U\QFL>^>NG4,1]&5X@Q*2 M2IWJ!TEFB8*BF<@*GV[PUK98;PX8W&AZ?PT__"];O@2*D4;,TG<6X9?9HI8E M;JGMMJ""NMK;CUJ1[[8-]^WX1'?W=/=JY'2MC%["_6 MU>?2III2O5<*'+V F4HF$X 8#;[ 3?X]A#8.[;PT%O6H;<-%J.-OMC1ZQ2?M MW+"7B;$^7,U^Q5BB76(KE*962,L%DG51>P,W:ZX]>2C958SI5X8 M143'Q,.^X\8L2R[.0$<4<>,X:9TDD1VZ-YHR7!(8N=1I4);=D&GY8J\O W23G%9K-><&-)5 MSMQ9A74+*U**J3JIS929"M(1Z(%BVJKY8SQPLH;RVQU#'.!>H=7XOBN3X+.C MRL..$15SN.YS!;$Y2209/(\DL( MS.+5@T:PF-U7(F"FP#;@S%MNUC>US46L_P!:-7&]S;9+G*GAO$:MJK$!C[/6 M%IR/L%SR?.U^$)#-HRW2M->3[TZN6:*BR0F _5A00Q3XDSY*B M?N28*FZ1LQ71;%Y8'1F!Y=%F_9G MKRKYXD208,C+&(LY261>3]Q+&$PIEJ275N$/CB9L9#K1;I[)/_ *E)SC5[\XW5 M[2@[31*V$OP@( .B\AF+F2MDXX[>&652G2Y L;@: 7^0ZC2];5Q4,GB_()^* M?+P?^765,0H+]I#@MP!J+GU-B#_2NQ^,QQ<[C3?B_S7.GY'S;CV$Y:,2PJ2 'C3> @ M*WCZ[K:VO>XJ;>,IFVNJW#3MH:UW'62,6RB<;>J%0E*E=K=8Z1'?,0M3G"'!YOCYML^- 8)Y9(%W)$LAO+(O<3M2_4K=-;7J>Z7:8H'#?XR%Z#N' M3;?PZ;#[]90=*ZP#K?UK%6>I1>"P;F2::*&1D%ZM>$^"7+',G([D+CJ_9$G[FRG(*NR MM3)'G,FK:)LLI8'<@]F!$IU%G#! Q3IGW,/<(B/CJ E@+?#I4%T>X<:WN-+Z MUVJR_=H<+C$*<,&YP HE W5>I@ )0'?_EP:IW-\*JVK\:Q.\^\HX,-'CEH; MC]G@PM7"SU0.XR"ADC&#^V'H82[^(Z=JYO:J>Y&-+Z_I7C#[S/@L'_\ M7W/0_P#IU4_X_7K8_"J-\?\ N_I6T<@?>$\#;S1KE3'?'K.9FULJU@K:X.7- M361\N;B7<:8RB9E3 8I0<[B&WLTL?A0/'?K_ $KKQ_;:Y(:1/K-JR.-$G,52 M;W4LK0L=#O (GY-2L%CK0-$'#9O_ )J#UJP,4I3%+L01'MV#51T ^-ZI2Q=K M=+5*W[3/_:BC?]>M?2R#P#\@_AJ*KJNE*:4KYL?W8 MW^U!P7_HM5?^;5S4>A_2AZI^M8B^YTS2A)>I#Q2@+LA(.<8XGPG@Q>P5]F=, MXRK%I;9B6L;MHBX,=#Z@_@W)FQ>\ (/87N#;?52:@U1(;,OPZUS8XZ^[[]/O M&5!I..:WQXSTC7J%4J[3()$7=13%*'K,2TAHU,2I*E3*)&;(@;% "A[ U%C\ M*J+H3?=_2MY__&:<%?\ P^9Z_P#7JK_Q^IL?A4;D_P!W]*?_ !FG!7_P^9Z_ M]>JO_'Z6/PIN3_=_2G_QF?!0?'CWGD?_ $ZJ_P#'Z6/PIN3_ '?TKJ?>NYZG MG'CU,^1V+.0F <=6['$[3J/$U6P?JH-2/7]#759]'BYS>._MV?5=N]<7%M.5RFC(1JX'43%-Q]5NJ(&[TC$4 M+\"H^ @.I.K6JE&VQ!AU%ZE_]EUC*N%QSRMS.=FW4M\[:8>F.'QTB'62C(=% M.81(BH8HG3[W$ZL B @)@'8=5-UM41_1?YFN\]JFJJ:4II2MMV^'C[!69V$E M6+.3CI2(D6+QA(-T7;)V@X:J)G1"BH9!P1L[5[T^[N IO#8=3U4&J; MA9&45-/[L[T^G^,KSC3U-<(Q[J'E#V&$K66%ZZ1P@\1GF,O15O:)95,1VV'8#D#4?VC]:#69O_;6_P#T M,*L/)S[A7-V9\E,D+"\A+7FZ].D7I@@JD"TCL/2OI6!X!^0?PTJ:KI2FE*TR9CB2\5)1:G;Y4C'O6"G> B7L M>-E&Y]P#KMVJ#OI2OE]>GCB6+P/]S9<<-PA6I(G&G(3,E/CBLB'(U!I"RJC1 M(&Y#D(8_H?]*^HMV]0'PV'PVU%35-Q-N =-NGY_ MS=-*5X5P[4S"7?N[1V[3 43& .@ )N@"8>FI'6H-[&W6HQ7QA--W:N1L?NX" M"M$8E$JY38/C/K+,O*=7GJ\FK QS"'?_ !5H&7J(9O&5ZF7F2K57JKZ1>GF'+12LM+%'12$@8'<80 C@56 @ M&*4Z6P@ ]-P(N5XK"P_&/)(!-P^0Q=Y(@\D@4!0=^PL5T8V:P^1KG,G_ !OR MKF^5_)_@67/!Y/B1_;Q09)2''>0ERH19DCW>Y -FXVZ$"YJ#^0IAK1;(A;.8 M>-;RIR;R6JK-Q-JBWT? L?HK^//6*]:Y&*CVZ")92-EH\QBD9E0*=NW2,"8F M,)S=3X7$EY2%L/PO*@_XIBKM:-@6]ZGN/&"26VLI'U$ZL1<=*YO+E8OCO,0\ MA^5.-F/Y(Y(W6:)@!VW4PQS.JD1F1'4Z1@>Q5(2]S6MTZ$RS0*Y8&6'P$ EXU[F9 MRZFZLW0EZNS>'^;!-0%2(IG'H ''?E')"& ", ;3=KAMP"FQ"VN=;:&M]QN3 MY?(&5,<:1T#)BONQEC9I5+JV42Z 20@G<-"+7MU-2QAK%9VTQ/-;%/UJ'DFD M7#D8UT5(*6D;E4TSL5%\@L(BH@%H0DU)4',2FFH/RP S 2H]WQ#K,FY6$L;B MY&JFQOKU&VQ)]/46].M;;!EY29DT.3+%'.D:6CNC-+%<7G5(_P!T,6W0@'V^ MS1;ZG-5;N:3AJZ<,_KTA%QJZ"CF7E03CWC9@^!98S9:'7;M7I1B?+!$2'1^8 M';<1$=QUZ12Z$ ,5'KH#K\0==*V#&SED5I$[C0H02S:$*=;;; ^WIJ+_ !K) M3:PQQTA7.Z300*JBV*+PQ6BBBZYDTT.TJ_E=P.%#@0FP;F/T#5R70"Y-A>U9 M)G7X]!7G=SK% BQC.$""U422<@*R9CMU%BE.1-5$AA5!0Y# M (%VW$!W#IIN6]B:K:5%!U%P0#\K_$5C2V6]N@=^BNH2.-!D^N$5=&>HKS,3 M'"=Q/(P\<@HF\?KL6Q2;J%(HD J%Z;#KS:=8F(?06/7U'K8>MJQ>9FHI8,0O M;]^M[LJZOM (+$#X C7UJ+%YL\@<6,S5'23:6FT)"FW&#@8YS;VU(KD:Q>7J M1C)DE-2>&A)2PP9.YN*PIK&6?IE+\9BAK'0[E4F5@(T8E MS]*FQ()M8'J :UO*S]Q#XK7E>\ MI-F.7\5V-##\)?H]'%V%)2?QGE"RY!K,S+MT5+"%CC99E+%^CR,E!I*)BX: M8")E IMA'?J7"8L'(2MQ',8[9V5B,9\M5R((H)$0VCV,"GN56(N&(U)MTK2N M;EEQ%7F.(D&$V0@QL-WQ\B2:-W%Y.XI#>PE%MN46MJU84N/C\9\'%A_'#*\V9][*'GQ MW(9E]K2;P=['0@W74];U@BXI8SKSM"J(N&PG8-T45T"H=O803%WT:?E)6=^0XJ(8T-(Y/(QX%61)!,C&[ G07 U-M!8Z? D?&L=QTGEG/9.9X#SL6- MP.-V0F!ERIV7%Y!(BQ3.R/*TBA@0I+ L1H!:I(8'AD,LU*T<1:I? +RIQ1.6 M2PESC+0JLH"M?K,>5SR$D)D]D3LKQJ[JS>UF2S= MS^T;3:]Y34"_Q5ZQ#C[+U/RO.DL''.TL8S.5F@,9J+67+9$Y6/!9J=1&HJS; MM%=!Z*"@;B*:?Q35Y (I;JH-6 -H!J8BI5D04 Y Z@.LN@42"= @2102 M2"&)TM\AIUTOZ5]!8W9/)XW/8*00X?)PIW-Z.N0\C(#&/3;:,6(87!'I4DHV M.0BV+5@U Y6S9!-N@55=9RH"9 #L[UW!E%U3 =1,8QA]HZO !8=*W&*)(8 MEACN(U%AEZ]5^H?K70-^W$PCQYLW,3/_&G/>*:5?96,K4LO 1MX@VT MFK&N*%-!"S2:*#Q/RTW9UY9(%-R]_<7\]>(]S GI:O4D1@BXW;J[M >FKP0! ML#8.+6' 1,F9/M_2,<(]B@"!@\SRA4#H;Q[MP]^J]BD51O;XUMQ7TJO3P6'< M_$7"IC#ON;](LP,(B.XB)@ZF,(^(CN(ZC4-;TJJ_J:I_Y47IV?\ A$PM_P!T MVFO6U4;C6B6/TQ?31J,'*V:R<5\%0T#!L'4I+RTA6X]HQCX]DD9=T[=.5S)I M(HHI$$1$1 .FHM2['I6$>&1?1\R#?Y^9X.17'B:R=3(-Z=]*XQ;1CB5AH]T' M>)Q=,SJ@BDX69 )1W#N%/46@;_KUKZ69?ZH?D'\-15=5TI32E?-!^ZUL\1)>K!BBLM72:DO7*A07$ MJU*8!4:I3+&"7CS*%#J4%TVYQ+[]M1Z']*,063]:TS[E;&[+&_J><)\KV9@: M7QS;,6\>)NRA*I$-#KA$WV3&P5]00(0JC16 C@,J4PF-V*CN.VVJE( /Z52X M.Y3Z7M7>"Q+Z<7IM97Q?CG)L1Q&PD>+R)1:G>(XR54:&2,QM4$PG&ADC")A, MF*#\NP[CN'MU3:O0D@UD/_RHO3L_\(F%O^Z;3^YI:FXT_P#*B].S_P (F%O^ MZ;3^YI:FXT_\J+T[/_")A;_NFT_N:6IN-0LS'C7T&\ Y0B,+9;I7$^F91G#Q M*4;2I1M"$G5EYQ_],BFQV!5Q71=/7NQ$TSE*S;@ @V:,44TR$V^$I0#58 MZ5Y2_P!OZG_6OI,TK_L;4O\ 1F!_ZJ:ZIJNMS:4II2N$C[BC_9!\L?\ HV@? M^TJIZ@]14CU_0UU>?1.QA.YG^WZ]4?%M9:NGT]=*L,1&-&12G=+N!D;PY[$2 MF Q1/V-Q'P'4MH;U$8#1 'UO6;_LQ\Q35=44I&6 M*](YC7R#0AU 3Y7O5:QECFZ7^X2[2 K%2KDM-34P^4!)I'LF;10ZCA90P@4I2CMX^T=* M=>E?.(^VXBIOE!ZX&3^5#>+=OXZE-LD6>9E^Q4$XPF0:?=*-N/\ EOQYR7Q_R7$I2M5R)7%HMTD8J/GH M.T5D)".;._E$!T =H]-I.FE4+K>0]3I_"OHBA_5+_ M +W^(:BJJ^8SZ;K)22^Y(R_')" *O\RYS9IB([ !W-IED2B(CT#XCAJ/[1^M M2#:8_I6\O1_L9N$'W&N8,+97??06T_D+,V,01HJF4Q7"4 MK-2 $343W(81\=M5>@-4B^]@.AKZ6I?ZH?D'\-14U72E-*5M6[66.IM3L%KE MWS.-C:]#R$J[>R#A)HS039ME%@%=PN=-),ISE H;B&XB >.E*^7/Z7&^MDB 8")HV%^9Z0I>[X@ 4]O74F^T7ZU2EN\;=+'_2 MOJ?=P_%[PW]GLZ>[W:BJJN+MMO[1ZC^\=*5XQ+W";P]OCUZ]=ATI6#+W'SC% MXK/U%5Z@O7V,G/6:O,8M(P9" 4#GCX-"0=M7*:;LRS54H F/<47!1, @(:R$ M#QR 03V*N0JL3]'Q-@1\1UTT-:MRD$\,IS./,BO"K22HB _<:$J@9E87N#H- M?<+]:@OD&GQV2YYYDO$KT*+S%C*.Y&L8:L-KC2Q\6V6G&L<\?SE?,:/0W=P[ MA10AE2D3$5BF$IC==;3@Y(PXUPN23N^.-*-\R(=Q(!("MJ="!H#Z&N4\SQF+ MSN?)SOB\BXOY/BPCV<.68;40R*K-)""M@RDV8J/J'4UQEYZAL?9"MF*N-O*: MK3^*%A:@ 3(1"LL]FD$(9^U>&9*L#J ]26(T0*8QB@4IMM M=9\9R.4XS'R?)/&Y(\K"F811037=S8-M"Z@B]P-MMQZ:VO7&O,L+B/)^3XWP M'S^#(X_F\;&^ZR,K$*Q8P9MG<+D(5.QE+!]UE%R"+U'23CLZR$_>.3?S-#Y* MX;Q49" HS&7E861=R;M-JTCX]HE#PTBQLB3J"=RA9!1%4QP.F3O$O8;70<1_ M'_M\;Q0]_B>=RKO,R*RJHN23O8,EG V*1;4VO5B&\SFY7D/,XVP>?\2P45,1 M \4C,Z@* -CB161FWL&9B1T O4/FUFI%5Q_EO-64L/Y)J^1LSR4A5:Q(TY\X MJ=0BR3\B_D+#-P82,:^>@^82,<@3R?FS$_M3=I .L+A\ER/*8'CG"Y^'/ MQ7'HLLBR@22L4551'LP!#*S:[;Z"YU)K0<;/X_AN%Y#S7R/B,["YWEY#C[H& M:)$[K.7DB#AG4AE!-W.INJVL*D1CZUUZKN\'X.J/(S*5?4J#^?SC?)&9A965 M1?((1L<_D*=',4XM)^()L:68J8KJN&PG=?Y/^N!M$\BP,W/3D/),SB\-C.J8 MD*QLJE?<1W6.XKJ9=; -[>O2M]PLC&XK/XOPWB>9=O$)F_)]HA,@9 A<759A#X_18.\>3ICLI1. M?.\4J2K9QY\9 N$S)MR(F 7>QQ$Q3;\9Y[Q_%Q1GXW+S4Q(5AQ"),:0;2SW:!MP.Q[D* M "]CK4X"PN?YJU9$C6L!=S6R QI 86@)#,$ZG5,89H*[93,+*6I@V:I5!^E9 MY@[9!7_-7Y#)&7#X0Z:XUG0\>Z@Q[!"Q9ML8NT5[64EMUP+GJ/3K71!C^4Y> M5G8\299SH<%,6)LQQ'C9A971I0(^RW<8JI;8ZD;A8"LOP$_C0[8R;)\\S)53 M/HO&CNF5E9TF7%%@JY([(#AP2R1W?<9B*1EA\TR)Y%0J@K&)N)?AUJ^1C2Q* M=Z64+<7%O4_'6UO3Y:5G,:3A98S'$YY'$#ICO%$__P"UDBVY!_<0]YEWV8H9 M#?=8Z&U2 KMN=VZLKWZ;25L-,C(?*L$Z4J-3M\+.WFIM?]*V/$Y-\W!;E M\E6EXZ),I#VH9EF(290JI Q+R$ &[!6W$74@'7(R&3"H2-GD[!-1D(,5+N:U M#QEPK$S3F]B>H,FBE>9Q+ZQ.&[:95)+/R "S3H3(Q"K0S MU&QUSYR8GG,JA"5N+EW]V=-&"[R%GOT]#.W\HZFY%G/]Q!4!NNW(U*H()AL4 MQ?!V&W).V7I:)RA )R4\2!CI%.J5YG)9)B ;%E%[:Y79KQE#V1B"%GG M MR$>D< \(4QT-DTP[@/5--MG!+60A1[Q_NT]O3W'UO?TT'K3G\J,3F8A/,L M,+F*-6R%L':4[=D!.W]PD ,#OU*V4>L5 L\1(N['BNZ7":1B+TG)1Z,+8:S( M4C)F24DAF4;B)1< M LNIN#K8BPZ]>FFEC6C0\C#]Q)P/)Y4GVV5O14FB:#*R)1 MDO(,7:ZP@X6\TXH'WZ@.NG\?S;'&ASB<<' 8!HAN#SJVK;_?S.0\=9$*JFU,P MRMMN;1*KA=Q+_!?AH:VCE.JU*H6R)M;G!>7(B5 RXJ%(R,06'NPSX\4V&>V %L9%&ER"3< MZ Z#7K6M^2X?'\7R,>6_"*,M)I9GD@E4M(;@ ,=;&W2^OM_E6&B'E\0S?"LG"XW [,;#BN MZP5R=K"/M&5[RDE8[GW6(%_C6WF5+4R3B*Q6K.F5Y6ZYJP#+1ZM2>)3\GYYR,O(><<%.LD>)C/$TIA5TLI"*0Q#NQ+;=P46! M%32C[M9TH# O+6LNHSC/C8)]*D9&;24''R-AM!V2K5)!XNJZ;#)RB,TE$.7! MOE2 (B<.\1,)=8"7(DABCRDO'&K;">OT_(];B_3]*ZA#S/*R8/"_DV&5/&O' M1D=G+CEB0S3V( )8C<>YVV?VW)!N:Y"&*L;5^0[2*;YB10Q_R$I[\E%QS6,9 MLB1[:3&,FO-GW$^SA3L2*M3$(LF5R8=U&X ;N =M9#=_\WW2_M3H=JA/4#4W M ].HO7:X>SQ'FZQCD@.%YO&*XV+%BKL615D9I6E5-HTV[0^ET'6]3,PC"NRX M\;U^2D[D^>UFQV!FC/7"&:1TXY!K-R3=JY:-S0L>S+'E:E[6JB+R%=G8JQ^H6.C$? :>@(]*Z;XSCO\ X@8DKY+2PS2 23(%D-I& 8 H MHVVT4A=4MKZU(KP*0 ZB4 #^;;\-7E;90Y2J@9,Y"F(8IBF*< .0Y#!L8IB" M E,4P#L(#TTI7STO6'X7YQ])7U&:SZI7&9"6=8AM>3BWJXM5$G#RO1%K>RS> MVV."M(L%6YF59LLBFZ.1+=$/(;[ ?X1'5'R('RJ"A=22;?IZ? B]Z[7_ )] M97A;SHIU98GK3VXY-NE8H-3C2"H_L=NFX^ A69" (F.XD9)=NV1 #?XC!I2Q/2NBQZ M]'W!]1Y!TZ7X">GK(R&09G(TS$UR^9/KB+MRW?LRO#/CU2D%3:>7(KN7S1IY MKU%5=$6XK)=H#N8)%K7/2J68@[5^NN:O[<[TJI3T]>(SRQ93AAB\^Y_;0EAO M+%Z@F1]685NT>NH"MKIF!1RPDH\+ X2>IB)!,=,O<0!#47).M2%"@*/XUU*H M2;LOH ^N[*3N4(*0#!=AM3XQ9U-B^9M++C:Z1TI"HVF,(0BOFMX6>?N5SI[' M$WRA@#81W">H^8J/HW2E MI5QD].W$,_D?.&0("+GV\:9:HX]"21/;[C)KG.W8M8B";^=*.FXKIF,JJ1$Q M2))'$1 "B(*D::GI7R0.3W*7(7-CFY,\HL@,7C!7*63%'\ U7\Y1K%5]*>4< M1==8NU1,#A& :/B(!L8>TH%U)^@CUKRONE4_.OH\^O5Z64KZBO 2D3N+XQ-Y MGK!%/B[K1FJ'ED=V:-2@(I6>KX"=5$73H(9%V=BW((J*.U *0IC& HP#;45Z M, PL>M<1?H'>OY3,$4J-]/KU#95?$]GQ$Z=TVD9'NB3R)29I1TR\8C2KV9VB M1M"GKJ!T6;==8S8J2+,2J GS1Y[YW(U:RGFENC(MH#$ M5)G6TQ,GFFJ"H(MK(K$ED?TXV%Z!$S'=%3#J8=P[1TZZ"I-E%VKJ4>BUPSY" M>L1ZC4_ZFO+*(D'.)JY<%K8#Z09'8PUNM$1%MV%:@*V0023^4KRQV3LZB "D M=5NH _%OH=/:*A?<>XW\*]/[P4H%Y\<;2E "E+3'( 4H;% /CD #P -5# MUJB7^S]37T=Z5_V-J7^C,#_U4UU35=;FTI32E<)'W%'^R#Y8_P#1M _]I53U M!ZBI'K^AKB,^SDCVTKP>Y!1SU)-=H]OL$UH["<]>+,5,.>/%GMZEA348L#.JY#QTK(GBK#C M&SJ@15)DA)0LH5LV7X9ZBU#=3O'3UKN'>G-ZZ_!KGY1*^O&Y M4JF,LQGCVB5IQ/>9QK7YA":[2).PK@S/TX]ACE''Q$.V*H!"G*4QC& 1&#H; M&JK!M5U%1<-R++'$O:0A1$QS" &XZ=.M38FNASZY/KXN>B91U,Y#%X@6.+3J5'E:%6^CN'KY4%72(+F[,4QMR[!%R34@!1M%<_VP>X.GAT\-*5T;?NT?3MFODL>> MI=@]B\C;MCAW'UO*3^$!(KU)NR=-W](L[1LB4%4U(18DBL\="10 W()Q#IO( MZV]#4,+CK[D3U4>.' /AI1UY%>YNF4(AFME','29'M^0L]HIL) M%+><0_U)D2H-XB7552,)"KF/N8.T0 !;4U!;?[5ZD_\ 7]:^B-Z7'"NO\".% MN%^/D6Q3;S\)58R5R"Y_S54[[(,LP:.;:L5RV( +- F16\@!,?L(;8##OOJ- M?7K59M_;TKD,'P_:'\0TJ*^9;Z8'_P S)D;_ /GO,/\ ^]G^@^D?K0_]QO\ MVUR2_ESEBK92JOJJ\1H63+9J O&2F6FU5:J/):&EZW,&L4/D4C!-15PJW M(X7=K22WE'01(@05.P#!O(/H>E0P.A7ZA_7Y5R;>CK]Q;QBYD8RJF,N1EYJ> M#>3-<8H5V3B[9+$@:[?C1B;=LWFJ_*3)T&995\B8@+,2KK+&6354*!2"!"0; MCK50(87%=FIG),Y%JV?,'"#QD\03'3N MWW$/?I2Q/2NB-ZYOW B_*XSWT]?3=5E+\WR'+)U"]9$JD>]D7UQ[% .:M49- M%J8[A@J_(147K05@4(T[BG!,^PS86N>E06L=J:N?Z5PP>AMAR\<>O7-QO@_) M; L7D#%ETN]*N$<19%P5E/P?EM)%L"Z"BJ2OE+D$.XIC /OU+&ZC]:IB%I"/ MD?\ 2OK0@(!OU#J(CXZIJNJ#N([%V#;; ]0VTI3H3;Q'?Q_NZ4K95LK3. MPMDB*H)#)LQ6=P3YP#M1M&RR0$59/'"#1RT^8(@X1(<2&-L?M[?;KWAD:(W! M]G]P^(]0/YFL;R6!#GH P'W"7,;&Y"OU4D*1>Q -B;'I7'WG6G1QV-YC\BNG M.-[*XH:!I_EG$,U82#:LOUK!_(5D4I(SQ@@NH7R$MQ=>882;^ [:VKB.(<=QZ.P#($,"87^\H# ."(/!GFA7Z+= M&89(B=90B!B)&.'0 VUN'$8W%Y0!$9_[4?N']I(/M/2YZ>M: MIR&1Y5QF#E0<]B8O*_C:/@BOW"'_ .5DGMD=5!7;(HN2H-B>E<1V0*;Q*MM) MX^UJCW^_<7GE]L:=A?TVRQ;VZH/ >33VO)3#B=8#46;?S/IY$ 4.V,F4J( ( M".XCWC@^1\QP\SDT-MVGN$VN20&!UO7"-_\ "H>_ MQ7(0\YRC^SMI*7,LA9K*]OF;"W2MEQT\EC_(0LM3N8\"+V2>LL94<:W:6GJ(G82&1D&P6Z"A7 M*7RL8#1I S21E2JM5C^6X'X@W 0\N=\?\('-XO#8.!R:P1PM)D1".;8;J>T[ M@W:Y=3:S#515OQ_DGG\'C6?RV3R?"-R,^0L>).TL.X L!+%W!M6RQL"!M)]Y M!-K5(N"SWDVL9OQK3K-G['\57H['SF?R;1J9#U>49R\G+5M=[&N6/E*.E)FP MKED4'HF;]@D)YFQ *4=,9V5Y!PW#9.!%R7D.$>6=FR' M#0'&V/&=SJ(P"IUO< 633K4GX9[4:TQ@?]8=O9\B9J4SG(*TNPX>;>1"XZFS MU=FS8,;N-?7E4I L49$#.DECMS^6<#B8I>FM Y*"620-&C)&J#VM_=\2+BYM MU 'PZUNN'+AXJPOSN1'S68_+M]O)@QL(\9^T%49';9]VP [R^W0CH*S-1Y*U MYXNI"F6H.1']$M=XQMF:U523=4YU1ZO.6,RK%.'B!FY)"4EW#2K#V*=NX"B; MVSE,LYG#-$SR1(PC(5;.&&I;<;W!(-]/6G)\W_D"^#@SYN7AQ2QX3G% M@VSQ3JHD:9I-DB[&V$-^VHW.!N'2O4R->GT)G:33R8QA;+)I*O<=M1:UTL6HDF]*9RH59YW@Y0V[>WXJ)I]F:VXF)VE0 R:JX4 MFY7I:WK\B*HYGF9<;RF1)+\>[^/*5)7!^U6T=FLXNP:2Y9/A8Q^R M/DP]4R+:I6#R?/T=U!YB@G,Q/98K31W%2,3(5VML'L+2E3-H$S594KLR@@59 MP)6XG/M_C!X33[,B5HW=65P;M:UC8::#XGUZ:BM.\@YZ7C.9RLC&Y&3"['+1 M&23.@O$8WBA5HL5OVK%MU[AI+7:X^&$N0-/B5'O(%L3$&:$:&]599Z:Y%I=J M=MT;O--D)-XR:Q+E6OR3-G7YE*TK+" "KY %3*8QAZCM_"YY3DG5"I@F@^MQ M[0!MZ:]3?3745J/F_%0SY7.8Z<3RW^#VIR7W6-.R'*F56*QQDQR (XF8V%P+ M =;5L_*V0Z],7/!>8Y_(^0,10V6J _H!<:+5D)V1C%9AC+P;*RN)]-I',99) MNXF0/_:,>\3-Q JA1V$N=P^0$7&D+"7.-)N+;K$J""1^A'H/B?UJV\D\GQY> M0X#R[E>1S>%PN4Q6QAA]GN.))59$D:3:H)0N#[H[$H-14:8 ^/WV.P7ZDBX/QZ7^(%_4US[#7@\CA^=_'P\ERCR"SME+.T+!50': M8_J&I+B^QUN;V4#2L=3KS";^HXNR\;(F1;Y;<:_I2L6JJBU5B!6CHM1N,>XB MI]\WDRQ!G!P<=HJI.1/L&PCL.^FIFB3!R.,=3WA(S$7&BMT :UM+'TZUHV=D M^#Y'!<;YL.0Y'D>3X5<>":*QCOM(V$,ZN4W$-J=UP+5/S"\-7Z3R:Q_;\(XO;A&RY M'R()8E=U92MB!=>ON!MZ6^%OXUW3QG#P>(_(^#R_A_ YS<=SF$3)D2;V2$V= M&(';"WNE[,3>^[2]9PQE2Z]]1Y?\;'V38_+>0&1I"^U:(O\ 5W%?HE4D:^XG M&IGR[Y*79HF4:K3J8&.15%(0[A[ #;;PQX\=3E8#L'FMN&X$+=;@DDFWJ/\ MZ5M/!<9!)F^4^!2\JG*\^I;)@BRH"F-C$&0*2RNFX@O8D,HT.FMBACG\\;R%B(O'2+A)=9X1P5R)D@%4R;TQC";;<.FLWN8G7IZ5U'%Q^Q++92%9@02U[Z:Z?VZG^-;J#81'X? M?';W?C[]35[5##L(;>P/YA$ VTI6QWTRSL',9.UZ:; MY8R#%TB=NNBH "55(QTEC% Z9B*% 1V,&E*ZL?(7[3;C)8[C+WWB?F.Y\;IR M9=JNC03Q)6W4R% P@=)&N,V;JO6%DF543"(K2*YA[N@AMJD@D_*@ON)/TV_K M7'=D/[=/U@:A*)1F$>;(2L"7S4G$D:7&O@Y(U4\A@J,=-W&1=$,=J'=L"GP^ M [CUT7YBJR3;VM;3X5X*E]IKSBS1(A*M2 H% ME&E3P]0OEZXX(\5,DPQ3FW*((Z5"D,-?IKB"N MGVO/J5\5;6M,< >:B\Q!G5<*Q<2^<(T9_"H>:!T&KMQ,VIU"2+DP"(G519(% M$0'X0WU)(M3O4;Y53U_*E( M?.RF-ZP N'K_ ,I+M1(M;W<]8XM)J97HH1!DD8Q!$ ,41WTOI8:"FT7N3P0$!TI7"[ZD?V_G!KU&W3VZVFO26)LSKG,X')^-U&K!]+. ;IMDR6.+?, MW\<_:]J1#'\A-LNH<@&%01$VZY^-"%(L1771MWVG_/;"K@SWBSZ@:TNS.IYC M>!=0TQ5%6(-% ,S(=V_R&XC%S['$!%-LF =O4!#8 FX]14!2/I8C^M;?9?;6 M^LGE,0@LO<[?TW7E%"@HZ)('L(@3Q$_RL'=XEV.W<+)HDV\WMW'M\SRM]MQVWTI6J:4II2H1>HMP^/SRX@Y8XM M$NB>/C9-;0#?]6*Q*DVG%A"66)L F-&)/8\[GSPC/+Z+$[>_?KMMJ#K4BPZU M$ST9_2B4])O"U\Q&?+J&7_UI8HZ>"80K"U7!C\@O8EOEQ:K2\N*WF?7MNX#E MV\OPZ])ZZGK4: ;1T%1$[7YYH5TR?Q[]$S M=T@(@)%VYSIG'91(Y%4S !B&*8 $%*ZD'+G[0#CGD>UREZXCYXM_&B9E5W+X MT#(1YKC5(QRLL944(-&-?5:=9M-M@ JSYDB2O++GX_58@HD5[7(R EIQX\;@9-17R),;X[AVRFZAR ME[F9]A#?P';2]AH+524N;L2?Z5V9/3J]#_A!Z;:"4QB6EN+?E!1HU0?95R"L MVF+0)T3^>H$.\:]:J%AH.E&HMI;TJ=-Q;U(KLM2T/'3D:[B)9BSDHR0;*LY!@^;I MNF;UJNF*:[=RW5*9)9%4AA Q3 (" ZFHKJZ<^/M4^&G*:UOLH8$M$]Q7R5)+ M_,O@K"0S=$=.S%5%62/ KJMYM"174.7N%&222 I=@('CI[U$R/#N'54_L$S;("#*PWR87)WE,/P@< +MM[M2=OPJ M &']UA6NTS[3/G+FV2;2G+'GTLP8&*126KK.(EK4Y>E,JM3H!9=!43L;?;W M*X_]6R_^IZ/(QI(IW?+>0,G_ .JD*(Y;K, O#]1Z$4-D&Q*HK"P[^T5/E"@? M;H4NFMK46RDMZD5V7AV]O\-]*5:!?;OUZ>'0.GAO[]*5;\1OP'KL/L_PZ4KT MY!@VD6XM'B!%T#"4QB&[@*8Q1[BC\ E'<#![]2K%3=>M4211S)VY1=*P5=8> M8.U2K4Q6&>0L>6"0<'N9)R2*U/6JY$QKN0;C'PP,USS8FEXUL4J8*H#NIW=P M]NPY3&>(-WHW,68H&RP^IF(&IN+:$ZV-:CR>)FE5P5BQI6[8_GLJ<;,PR5#REDBEKT['>.[^Z9Q46BTBF9 MT% C:\N)%R T/)MBHJ"8X(_XP'WUN?'\F<2./B^?Q1-QF//W))$%VU-]6_\ MRD_SKD^3P>)R67D<_P"#\I)C<_FXAAQ\:#(D5LJ905 [A$P"3K]$<> M/+I.6X?A\;E>.?$@Q^\3V3N;M"-!IWK-NW$[A:WP-ZX-E9?A&/PO/>29WC_+ M8^7F91QR#+;68R.Y5OM[QG9)9"ZOXB]S-C/ M:&L-)E&]2+&O.H>&9*TU^F_8QZ-?!1%<.PRJBYB[!V[ZV%QYAF2L;)!X-%C\'XN>.Y67#SI8\@2]P1NOW++ M$5%X&W*O;!T"G4ZU,/'EYGI#*6:;%C7BU7J7D/%&/F[:C7&W%D2F@6\0M6JH MVGK8JJD@DN^E*LN?8Q0;I]SD-B[:XEY+Q6+#QF#C\ARDN5AYF=4;FN\H66IF'H$)ZNR5:B%ZDJHO-/$IU (^;E&ZI@< M=Y3EW#H4-AWYYR7CZ-/R.+Q^))):,!6G;;("V\:"PN 1II7DWE>5CX7C'+^3 M1(NXY&23<,50=^:B9/RC@)1*8$Q[N:YL!>9/ MLYAE9;Q%&!UV6W=+=.EAH?ZUFL; R>-XKE&Y['/BOBV+GQY*9,(N805.X M ,'!ON4J0WMM9=1IMA"F98SKDF!:MFS2 M/=G*Y&/'EX#P3"',SLJ-5LA!60.6[C$[5)#&UC6^"W)QCB-CLF75EF M3$F:.4!@QM"0_DA+15"<@1%BULB44I%QRR"::MD$Q4C*%,)D-_-V$ #6YU19 M&>+WN)B/]*2;#&NTJ92? M<0#MZUKE!FI]SD9:0N,9F>U6KBQ1Y.5&RMC-X&%S6YF7K5J1NZB@@GHMI1FS MLYC)@#IP2$,?UNU@"+::&^OH*N.(R.0DY_=RB M.83/W541P\BTFVX*]MO>HE-@KD^PGH+5BG%_R_E6K>/Y>5D\SP^/P[8T+Y.>^?G8/)3B3,BC9XW+XZA8R0I+;+I:X M4?ICFV9%[#QY&2'W(" "BL"+LPNMKVO6"W-JN4AQ=I MDEC_ "!7\H3M-S-)OI:9N<42+E::S51IQ8!*"!.2<$,U=RJ1_-.8O;Y9C; MAN.7@DPTQ,L.7C9 2 -"">G4FZWO6G+R?DF3^-(LGQGDL3F,O$Y=M\V4@C:! M"(-BQ!6(U;ZB?[6/K6]EX3/A^4U5;IX.H#YEE6B09)9_#0'$87")!>2.61&1%L)B0TKG:0FWVN M% 0DG:1I6_[*0TMAKAQ?LO\ (!_-3<1D-I563C"XQC]5"9L"[1M(3$<]8 MI(.C(+^6<_EB0&^Q>S?XALLHB;%AR)I#GI62SC'-XCXC MS7F?/22YT?(+$KX($\4KAY@JLZD "Q(8[; :6OK7*HBF97FW9HHN$/-3#TLD559)0'IA,7R2;^:/Q:S=R_+O&778T6J>O0:F MUO\ 2OI%+Q_E:6 \AB?:9/%,PPS%:4[>T#*TG4)'W]H8PI"H!3$'82W6+"3A M(MPJ]1V^G7T^1Z&ML\8QMWB.)"KPV#H0V +16$@/L!:7]LVL_N)V[A<=:EF0 M@EV-T#N H"(;[CTUDJWS3^->42@4-P\?8/O_ &#I2J@)=O8'O]G7VZ4JW?J/ M9L._L\-MOVAXZ4JH^' MP Z>S;]VII5=*5AKD+A:I\C,)90P5>DE5J?E>DV&BV1- 4BN!B+%'+1SWY=^6=L"R,2ZV.(@1P"AF@$^'?<)T;7^ZJ=4)]8S_2NZ#QA^Y/]*KD1 M!1;V=S_7L"SR\:BXEH7-LK!4IO'R/P)NX]I)R$J3Z@5)P)@24%%+S4P _:7? M8%C\*JNMK@C_ ,:FA,^L1Z6\!%#,R7/'B\BP%$ZZ"@9)C>5Y"Y<72.SA'C06K''[) M98AR!)_7XUQ-'E/E3;&!N4B J>Q0-NLVJ"RKK>Y^5<._H7^F_P I/46YX&]4 MSFI 3L?1H&Z(95J[N?AWT:VO-[_4'ZFKZ-62E@6!:I0"S_7T%?1@3*4B9"$ "E(0I2E*&P%*4H 'L #45-7Z4JFP>X/ MW!I2G:7W!^X-*572E-*4TI32E-*4TI32E-*4TI5! !\0 ?STI3M#W!^X-*4 M #P _(-*572E-*4TI32E-*4TI32E-*4TI32E4V#W!^X-*4 #P _(-*572 ME-*5X]@$PAX> _E_AWTI5QQV#VAX!T#<>NE*M#&DUVJ3(DVQ-Y4@@T*^;/%&Z2H@8H).#( M=I@$!W*80]NO:*7ML-P#(#>QZ="*L,S!3*5BC-%DE0O<4V8+N#$ _,BQ^5ZA M_FFBF&2/<+7ATM\D&4JQIE F<>IBK>Z["V=51&;L2QSM@28#%$CVBG>7O #? MEUV'C,PB,XV/D")&4O(LG_;8H#M7K_=UNAKCLDJO6J4QKUG M4UC7(4#S/LC+DA6F_(# MG0E5POU&KKVRNUG,%C]X+UY$S:+?Z>!( /I\RSV M !7W*J'Q=.NW<-F> 8\O%Y^Y5K]-03:IS4_).7! MSZ1\EQ4S,PEPT+L=D!5BK,+#8?U'-DKJB5>CTU M0.FV)$R:J1C"/F[(LAZ>T-HS3F\EX]PHX7B6Q9-X6-IE]L0".-Y-M=P!^&K5 MSR3 Q,/R#R,^4\T,_ > F6+'>\S*9([*%'T[#M6XN=HO:O9H-_&%X[5*5P#Q M_CKXYIEY?RMWLN4(8+JUK#MXI'+UDL,LBK"ECPD5&3P50$RG?Y!-OZHZY[S_ M I'D.3B>2YPC6:$+$D)V;P-P;>/=?JMOXU8\?R#X?@&'/\ CCAQG'$S7>5L MP=XQ-=&0KK';=[C=3_:-*D!/V:H4O/D@ADVVO,Q3&=Z2P(UH;R&&5I$;9I%E M]$K;*03B!-A1K#C8LA!:]G8=2>FG MM)_7X5LO)0,V8'N<'7\88KQ[9SPZE:KQVLW]9?VR)<0LLNK 1J\''(M$T MC)B5)7J;?6F9^'%DY*+B,T>',"6=Q<,01;7U)UOTO7D1D>.\&OD/G>%CY_E7 M Y"1X>+@R&,Q1,K[VF4HY$:]N-5 &@/K>]:G.9.E*>Z1OCUW>;JKS$A30SRG MD>%16P\YEB.H@QTGOE2/ZA>MBR15"I"C&["F'Q?%N739\!9H'D4A)(6-CZ/K M?P<\?/Y#7HL)QK@-QK.O;9E:S]QEW@[2L>JZ'K;;(&1(1PPFHC($AEIZW2/%@^E:L\M3:NNH0LB3R&R2_ 7F1:S&4LTY)K%6QYX ##ICM*_W$0+1QI[38W!Z$^ON/]+:U M[8_-RX^?R_F/DV)B<;S.%C''X_.R'"QS,H?MEF !5U0),JL2^&5=).6BBGF>8D ) 4!# MX=QLCCVP29P-DDE]"-Q70'^((/KZ6^=:)Y+F)#B\)XW^0N.:;ELO.3)&3@LT M2%79HUWDHQD((N;E?;KI;7*CJQ97?Y7SD\HL_2,TXXQCBZ6@VU!7D32YQID& M>,CHR"EF/D)IGGVD?'I(NCE/V@N!@ NPZS^/&8N4@AQR8XPJ^YQ<[+#W>FEM M?_&MR/)^5R^6\U+PV3@\SXQQG&O&,02;W"IM58G6UNX%3:QOHUQMJ(4L\I$M MQ:@T;Y5)7&4N;*LPI6;!3:_YL;8"KMJK]982TSI.'S/Q-$OD>)+PTK6KL8>WKXZQ/;A;CH<<$K$222-&N221;Y$Z?*NF97COA>%YIXIA0< MKRBN,7I7\9Z/CV=LG/IS396]Y3D%(2RI!1+;!E M@64TX?-[+?-Y/,D$F_&R(NS&[,)QM23=('W&ZWV +\#>LJU>!E MZ/QMXV57SB\69^:S&JY=5I>/"?N\7/U=*V;CL*;BO ?'^.C*>,3REMM0!.MXW6;/ZZ:KG4M+5Q+)0JS63&<+*%*I$B M5F<3MO( 3=Y [P[.NPF2^:1N3VITM[M;:W^'RKO3(Q\TEG7)QPL&"5>(PWE! M?ME7[F_Z %-TV:W&HMK(FE5\8:J0\2Y/%NCM$ %5:(BAA8U505U%P4:Q8N7@ MM"!W!\/FGW-N._75W&C(@5B"1\!8?P'I6W<;C+CX$>.VPE1_:NQ;WO<+'0.G4?=TVZ=->E9"@!OU-O[MAW_#KI2J=I0VW'W]?9TVZ:4JX=@V$ M \>F_P##4$7I5H"HB)1_=X:4KR:4II2FP#XAOI2L-YKX_ M8:Y&4J3QWF[&]2R72YA,B4A 6N*0DF:Y$U2+I?Y0OFD%)=,IR]I@^(-*F]DR:I62)C_"F*HB M !MW: D52P5NH%1LJOV@/\ZY(^-/V[7I8<7YEK8ZQ@%OD.PQQ2#%367W4;<)" M*Q;) ME2;LV3=)LV1(4 *!4T4B$3(4"@ = ]FE*U+2E-*4TI32E-*4TI32E-*4TI32 ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI5FVXB( M>("(=? ?9^SII2K=]MMOQ 2_CO\ TZ4J\3%_/Q]GA[_'2E4*(=OY>/[1'2E6 M[$$-C@'7KML(]/9[]*5LZ6AI8#M5HB?/' >=9/I!-VV&4(\CTUCG=Q+0AW#< ML?\ .D-V@J'?Y>V_:/AKW62.Q$BW]MA;2Q^)ZWM_6L;D8N3=3BSF/]X,VX;] MRWNR+J-NX:7UMZ"HG9.JKFUQ-FW[ #IL7XQUL?&9;XLSY/'9LF-/%%92UP6+&Q70Z"Q)_\*T7 MFL!\_"CP>>XG'SH,C*NPBLZJL8$B2-N4:[T MKJ!K7'1EJ'X51/^LO)MYP-G M"NKWV4-QLDVE>CH])(T,W5<,&\G78U%V"<>T(E241!?S-R@J 4>[ITS@LOS M:7[;B>.SL%TQ@ZUQ;6U[UR/G(_QIA19W.\GPW)03\A/_C) M-B#<4]P5U"M98RL (:]P"-+FU1-R9CS@#4T+O3XO$7(BQS'$N:C)MJ094C9I M:)9^Z0#R5)$B3E9U&MPADS''RC"!3&^$=]=+X+FOR;FO!E'-XN&#FXW1KIJB M@&YL2-K'>;:_#]*U+.X[\4B+)X>/C^5DE\4=)E-[=QF&EF!/< $8W;@?T-ZQ M8Q<4NNY1Q%E+!W!=T\BN0%7G6LTQR&^92,.V=MGCZ'6.T9N*^",M_D7_ -7=KQT B1ZW$4P6'^W.H/:'=OK ^2<5A8_+9"^33]I,F(&*..1M MA.@M;;8M=6UTT%:3Q^3RI\0P;S MO&^!09RN)FS,_(Y7R+%C5'V;?MFD:2 M-#O$C[W#,"=$LH%B:T^WO)W"47-<5KU)A-QT=)M8 MV+;K(@:71<(2":CQ(Z[4$G('+\?8!C8&;#^Z@/)J55+V"'0GJ"6/IZZ?I6/\ MADY#PO"?\7^2S9?)ORSI)]XC,S8ZNJD)&A_[FZX9QO0!BPUMKNV^-H:FW*K\ M.,@1TO8L-XSO#^7ELG-W'RKU&-EW[!E9+4D+49)%M$E9P!%R(?,CV AW>W6 ML3<"T&,!$V[(G<^W;8@O:X'6_P#2_P C5SR\'%\9R.%^&>:QY\WQ3$G[LN=W M-C*K,%EF]N_:BB/=MWZ=-0*W!25LA1EION=*5;"Y4XW899OZ^%;;S3\Q@B9Z M&2@DHN.BE6BC1LL66LI7)S%$0()C+!W&#M'S_P 4!D8_&Q 1M'FM7_!MS^-Y+G^:\'GKR7XUXE'C$"2NQ"F$($6/;L!$LF\ZGJ7UZ5CZKPF& M(? E\S.2W9!Q#?\ )4Q+4^K5U%$\C'A$2+J36?LUY920B%)%F5PP:>?1Y.=PW. M\K)+C1J265-[N6U+)N&Y%).P;0-+W)J7#W&F7U8_BSQUA+[B;.(JS$??).KV M-!U,N8Z,A^\JGP> FIBPCC\=)/,)>],[E#>R6L M$N?3XZ#0UU&;QOREN+\>\(Q,[C.7?[E,B9,D,[&,,A)52#?;VRP)]0;]+U,6 M*"3F.9EAM8VS +[&.$,?Q["88QL8Y/8<=NV-;@HE^@T3&**@U,VGU1*B*1]R MMA .F^L7D('?'VILD5=Q)U! N+II?1NGI72L=^0R/R7-FMD\'+XSQ&&%940_ M<8L@CC##IM47)M:Q"VK<6&(*ZR?$3.=NF'41R+#+[R2CXYICAXK6I^78R3-T M+A!28D6YE$Y,J4D0")%*H5,Y]RF-OTL,6/N#)>:SB1C< ZG747TL?D+VJX\; MQ^4S_P :\MR/)/%S:S "QL";@F]2ZQ3C9A6I3 >(Z MU*OJS"XSICF\2^.[9#DLK]TUFWD^P\HUM4>-?E95E,RX&[0:G$4D?'XNGO%B MB Q10EE@0$[2 ;ZM_=IT)^'I70O'>#@P/\1XU@,V/B9.ZQ$AD4#O% MAM=7:YLK$@?.]3/KT<_5EK++/'#[Y6070:,(U\S3;'CR18KMEW#54CEP#AK* M"O2^0-W"Y/7H/T];_.NE8D4IGGGE+['8*JLMMH6XN#M9&KRB.^W0=OS#;V;>&E*IU 0]HCO[?V^[II2@ ME$/$1'I^[P\-_'2E5[0V =QZ==P_(/P_#2E4+[/_ *V_[P]O[=*4Z] VW[1 M1V_?X:4KR:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2O'OV[[=0,( MB'7]X>W2E5Z .X_XVVWX=.N_NTI03%WV$ 'Q >GA_-I2KNFWAN&W0/X:4JT# M%VVW]G7^G\]*5XS%$X#L ; .P!_>VZ^.E*V/)T:&M875Q]=&TG3%H;-CI.&@"6**E(NP12TTK,"AWL]P5 9; -<'TM4:%<9\NR-, M/ ?D)C(TG'Y$5/E=W\BT:C;JI\Q "2L1XD*<7LH5 KLHE5[! 7)/?K;DY3Q$ M/EWX_),;8W[ W']N2S_N'I[?IM_[3\*U:3A_R!)#QH/+X/>BRS]V>V )H_V_ MVE&X@-8->Y/U"H19FP-5<9@1&2QD@WE2L:@!+6#64[@ 1YMQ*G"38[MGX@VAD9F>/<_:%F+>P@FW4? 5C7'U>CJK8+)QOXE5.:MF(.2D/"$+ MR/FE7#)6LJ"RW5E&:#D'81JM-7FU6BYBNTA7-L<.@=+7EL.62%/(_+YXX>;P M92!A*H;H= 3IN[@4,/:;=*U3B>#Q>$EE\0_&^#D/X]SL*WY0R$F([3MD0,Q* MF(R$$AEN=?2X]$:O5>-L'%8(F*_6N2UYRN^<1-=S-"HJRS'$#N<\B$CW$1(N MXU9Z$I$OE/FE@_S9-(O:03;L&+'4'[=SM,P6YU -K-: MPZGTM7E)QN!X!Q6-XKR2MS_+M]#7M353 M?\1JPOAFV,&&>;;GI-)2)R)4G!YM[B-,\DD@J5D^^64>-I]P9#9TW\QN0"++ M#YA@*'=K)XO_ #DTG*L!BKC,-L4BV[EA>^MA;4@$ ]!I7@V)/^,^./CO)?<< M[R/,.=N3%[_LP?:0#0I\ JFFP^28EFR V(ZE2NGI'2J!P,A\L41[NFV(EPH<[+//$^%-C\_P YDR2#+QV"JT<3Z%0K M^WW!G#$'3:.M>*0Q!3Y+(E9X9<7[!=<)Y6C9&/MV8@L$A(FJ4TL>NHS:&9S%)==SQ]P79@$ .S:$)6UZD[-0: MV%/%\/'CY$.7'SF4;QJ&]KKU2P4Z^TCKZFNE9>&?)N>Q.%AD MX?D?!.(5%SUDC&])E4*[G4K8F>@3PNVT@PB@7A8:..B*8/GY0^9,F901. =GP!O:\]B1HV/P.#)) MD(IW.A6S C4BY/H!>W\;U?>/<#Q^;S^;^1N?XN'CIN/1H\&?O7AD#*0&9$7: M-6M>Q/RTUWG1:%88"B2+UY'XHQER.Y/V5TC6YAE6UK#7;A6)"0>3Z9I!)"O( M-6*$K#1B2_>H BL?8QP QAUJV;&DV3++&)#!&MK%K%;6!]3?6LMQ?#Y7'<1+ M,R\?@^9\Y.5C=8C+%*C,S@N!&OUQ*&-QJ:GF[PW"OT\3XF&F5@M3IIVEOL;N MF21J>2M6NO\ R#FM*L:U%1WRKF/EGS-0IB&42 A$=MC!T#"#'C1450;@WT M_7^-=+?@,:5<'QXXT X_'"RRF%NT(Y8]ICM&B@%693I<6 M4F:A#*-#34FLM M-=T\^([+&3+HS@(9-HS:Q9&<M[G2MSP82 MBO,QD!E:^UC?8 H U-@;;M/4DUO4""4I2E /A\!#QZ>'CMJ:OJNWWVV#N_P"[ M?\]32@%W'NV_OZ]?STI0.@".W@.WY]=M_P .FE*N -A'V[]?RV_PZ4J[ M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-* M4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*501 -@]_[M*5: (CT\. M@ /\_P#/I2J 7?QZE#?MZ_C^&E*NV !#V"(;?NVTI0P!L/0 _=I2@;"'LZ]1 M#IU_';\]*59T#<=@$!\/P\>G4-*5H,G78>5!F+Z(C'JL9(DF(T7K5%4&4LD5 M4B4BW$Z9C(/$R.#@50FQP X]>HZ]%E=3<,PN+&Q]/A^E6D^%BSA>[%&[(^]= MP!VN+^X::-J=1KK6";#@NE+)Q3@N-ZR^<0.1FMM@T&BAVI6CMX]A0D+*J!44 M0"4;H1B:G8'<4PH$#<=QUEL?ELN,N!/(%DA*-?6X -E_0W/\ZUO)\\!;V&F@J/MMXW0:==ML17>+F,+"G/9886Z0C[&\(+*7 M<"S<>?=BG^2='2FVIEQ1*3M+N0YNNWCL&'Y)F)DQSR\GEQF/%,:E.H%Q^WUM MM-K]>M:K)X7AIBY>/!P?'O'/GB9EDL5D-C>8^UO>.@L*V;D#!?)>42S6G3;+ MAG!DQ*6J&=XNO5;CF;.QJX_B'4\>58VUT2N-'(JBR>M.H*.2)F\SXR[[FS7& M>1>+8\F"W)1YO(8L<+B>%R2@E8(%:,%R!J&Z!>HT->7(\%Y?E)R6/B38'$SO M,IQ9X@#(T*%RPE!C76Q6]BP&IO\ &/EMP%QC)FZQV?(]_LV>KIR!QBY=,<9I MM91]1K,YHT.[.8S23:NEH1,[B5I2OEIJ@CY;HH'Z&V'6TX'EOE8\;@PN(QH> M.P>.S+'(NJS()6 ]R[0YLLHN1?VW&HK79O'?#HN=FR.6RYN5Y#EL33';?)CR M&%6/MN6B4EHCUV^X ]16T86N9[O]#P"PI<93.(O&E.8MM,RCANWR32/G+%&! M*HH-0A'2"#P[J2D&T+H1<,U$79>S<" )2".1Y:7$EY%N7_ ";E)'F/@H^&N,VY2ZESMD"6UOMT M8%?G6)\?XD\7BMP7XPPBV O(L,ULK]H2X:_MO8JRV]+=:R#6\;4OB1 M(73!/&R:>VSE1G!%2]T^QV6&"=QO6[*F\;*3+/ZFX^N1*CE)D+E,C@Z11Z"! MA*<1+K!SR9OF<,?E/E"+%XA@.(I$1ML[IM.PA;JUB;$@']+U?XOCW'^ 29OC MOA!:3RWE6;(C:8,^.DI(#^\AU&E_07U^=:,;'K3$,Q5[$I49.R3S:R8WR M9F3#\PA(Q^(KA:"1\9-V23B6C^/95Z0&6L"RYO)0*7_-1 #;%U.+#%SKSY+S M)#XAP^V>#'R0RG)B75ENHC)>1GT3^W7I6;D,=6;CK48; ->O$/<>=.6HQZZJ&<+S2#V-N$ M621?O)&*M%N<0DXZ72-789VBFFZ[A*HW!X*14C#X"H%=Q'8;K<#5EKSS00BYRM?5F\\Q=.9)[7 M9 M3;,1;OW2SPY?DU4E$@,4 *7PTDYB-)F\IY-\V'$C$AXEMRR6,9 42#N%@ M0+7W @F_6O3!\:QXX&\:X_&XZ;E\GM?YGV-&)-ZL696$0#W8M8 @J";VZ&3: M>)Z9),ZEQEQTVKC' V)E B\FX[O56--,+"T$Y'5<9PLQ8XMPD]<-)P/,%1-8 M#?U>HB &E3Y.:JOY'RF]^6S03%)&X!'HY=4:X]OH16W?\>XQ\&'Q#BHX$\8 MQ+)-CRH&21=-JJS _P!WKZZ"I,T"D&0>JV([":@8I@B6 J^/)9O$F951I7@3 M@8R2@BQTC(,FR$A'L071*42'*BX[3E(;N+K4\B0DB,LC_P!Q8=23J0;@&X.E M_B-*V?B^+[,ARP)(H%41QP,%VQJED5DVL0 0+@:&QL0.E9:B:VTC'+Z4528N M9>3301D)4D'AUZAI2JFZ@ ;;B/L#^[L(:4H._38 V /' MQV_+\M*538#?LVZ^_&7;)))!&T:[Y)']C@!MP M9CO)"C5KGKKK6R$L+/J['Q$3CR)QQ0F=/L11ISQC MGSYI47JA7\VQ.>1B'' MTN2D).0D _S4WE^4L ]P&,8-7K"Q +@64D BX "]==*QJ M>.3X21X_$1X6)C8\_P"ULC!(B;5P=R':[.TGT:6(UN36/K%QKQ7+N]\LRMGR MT22RPSLM1CYM>5>(4VQKGGW+%@Q!BJJFTAD$GITA\X$VX F0#?XNLGB>5\KA MJ%X<1XC#%,5MM) M"JH)&XV %@3K7N6"O9#L4:D8K6-PY0.Z\-5QO* MR*$BD7SOC161>? 78!$"AKQQLWCL60R2;\O/';,#L3MB=7O9@Q (/6UBM4Y< M/+Y.,)F5..X_]W[F,*K22Q=OJAC#MN&O0AM!:MDUW LM5J?_ *NL%-GV/F,0 MU&=I^9+FLCE>2GDLS_* MU#8 :WO<^M6&'X_G8W'/Q'CS2X<*KOARY=LSD2'N M,MINXX'N*V918"PM85DFL8MK&)Y6_.L 5.!1O5[G(FXWF2L+N=3KL[]7=R+E M](-7K,CI$KLAC*'*D@!4BBH&X &VL7G M:^[*RRHD211J%2-55)=LF[]T* #I?4@G05[X?!+B&2'%9Y'EE8RR2-(TD6Z* MW[#,20 2" &"BY]:RS XZ1JD#%P\2+>1DS,X6&M-LE#KMK-8(N-8'9C(.IAD M4[YY- '5,RRH@ G-\0:QT_(ME9#RRW6$,SQQBQ1&8WL%.@7XV'\*SN-QJ8F* MF/&=\FU5>1B1(P MNG"#CXBJ**&.40#8>@:M)LN:?)?+:RROUV (-18@*H MZ 6JZB MPX8L=,47:%/]Y+DV-Q=F))(/J=>E;H A>FQ0 O: = -MOPVU;5=#2K^T/X_ MCL([?OVVTI51 1#8!Z^T1_GTI5"B AL'L_EN&E*H':)M]NO7\MPVZ_SZ4H(A MML&VWB(!^8>&W3?2E4'8.S8 #J'A_=TI5P (!MT_#^_I2J"4=@ -@#V[;[^W MI^772E5#KN&VP!TW]_L]WCI2A0Z;CMN(?S;!XZ4J[2E-*4TI32E-*4TI32E- M*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI M32E-*4TI32E-*4TI32E-*53VA^0_Q#2E5TI32E-*4TI32E-*4TI5!\!_(?X: M4KQ$_K!^W^ Z4J\_A_+WAI4'J*]1U_D2_P"Z3_X1=5#K7FWTG]1_K6V('_ED M[_T@'_"6UZ3=$_2O/&ZR?_J524__ %^N?[F6_P"8'U0O_E_K5&3_ /NXO_S_ M /VUK[G_ )&X_P#P[C_[@^J5]*N)?I;]#_XUMJI_]CX7_H)K_P U#7I)_P!P M_P#N/^M6N%__ %\7_P"B/]*WDG_5)^1?X!KR]:O?3^%>R'C^S4U ZU74555O M^/\ [W^G2E7:4II2O /B/YC_ !TI5QO OY?T!I2J!X!_O_\ @AI2JD\?V?TA MI2O+I2FE*M+_ (W^Z'2E5#P#\@_AI2JZ4II2FE*:4II2FE*:4II2FE*:4II2 MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*: ,4II2FE*:4II2O__9 end GRAPHIC 3 tv524860_img-optejet1.jpg GRAPHIC begin 644 tv524860_img-optejet1.jpg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end GRAPHIC 4 tv524860_img-optejet2.jpg GRAPHIC begin 644 tv524860_img-optejet2.jpg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�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end GRAPHIC 5 tv524860_img-retinal.jpg GRAPHIC begin 644 tv524860_img-retinal.jpg M_]C_X 02D9)1@ ! @$ E@"6 #_[0 L4&AO=&]S:&]P(#,N, X0DE- ^T M ! E@ $ 0"6 0 !_^%\>6AT=' Z+R]N&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB061O8F4@6$U0($-O&UL;G,Z M>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V&UL;G,Z>&UP34T](FAT=' Z+R]N&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O M;G,N861O8F4N8V]M+WAA<"\Q+C O7!E+U)E7!E+TUA;FEF M97-T271E;2,B"B @(" @(" @(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P M.B\O;G,N861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B"B @(" @(" @(" @ M('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @ M(" @(" @(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@(" @ M(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @ M(" @(" @(" \&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM M<#I-;V1I9GE$871E/C(P,3DM,#&UP.D-R M96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(S+C @*%=I;F1O=W,I M/"]X;7 Z0W)E871O&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM M9SIF;W)M870^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y M:B\T04%14VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241- M=4U!0311:VQ.02LP04%!04%!0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%! M0B\K-$%$:T9K8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM' M0E%92D-W9T="9V=,1$%O2T-W;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/ M1$)-5$9"451%>'=B1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E' M:%521E)O9DAX.&8F(WA!.TAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9( M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9B\X04%%46="04%%04%W M15(F(WA!.T%!25)!44U2068O14%A24%!04%(05%%0D%114%!04%!04%!04%! M449!=TE'05%!2$-!:TM#=T5!06=)1$%114)!445!04%!04%!04$F(WA!.T%1 M04-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%! M1DE227A15D5'13)%:6-9155-<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2 M>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=: M:$I21E)Q4S!6=$Y62T)R>30O4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR M:'!A;71S8E&=: M17DF(WA!.V]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S M4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D71R<2MV+V%!07=$05%!0T5135)!1#A! M.54T<3=&6%EQ-T9867$W1EA9<36931T5A M:BMF*V=23U4P-G39/=WAD M9U(F(WA!.S9L3$QJ.#)F4# U0W)E4G=G+S78F(WA!.RM5 M8W0X+W-$8B])3VU!*VXW6F9R46DO;4(U*U)V:#%M9'99.$0K=&-S+U U3R\W M;4@X:#9F*V(Y<"]7:F]0>EHX+U41P>5!P*S)8-C V#AX26\K#=4:5!Q1')S;G,W;"]G,RMB371,.#@K5W145E1B6'E";2]W0C%Y M9G4R*S5Q6FLT=&0F(WA!.VEN>4QR32]:;69(.553;F]K56=%1V]043EJ;5#928FY56LF(WA!.W524W%14#=-:6A:=T9D+W=W,FPP M<7%53D)V5$=*,U%285=X=U-25FIR-&M(,GI+36=D,FMW258W4TAK+WAF5&QE M4U=Y>'AN=E1'=$LF(WA!.V-D:&U/>DEV;6Y/:&5C+TU7:R\W>3-J;4MU,$UN M-WA+97=B<&U21%9:26936$$Q6%I71$QZ:G8S=E%D1"].-C!M2W@V=D%B9'1G M6C0F(WA!.R]I46YX2SE2;3)W.7-!-U-$>D=R.6TU>#-G8CAN;T=M-FY986AA M$XP9$18-S@R=4Q,1UES1S-N.'5'5T]81$E555=#1&PF(WA!.W)6 M5'%J1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$T.4U65VQS5EED-74O M36Y33D0U,C!(*VUA:4(O8V]F:%5N*V1H,"M7643A4=&Q: M-')4-%%P9D1D2DE5:07A)-7-A<&8K>G1K54\U9'4K2S!H-3%"<%0W M43,F(WA!.UA,26QL5%AQ1#!U86)C975.8C=S:$954V-I345M=%)59E1G360R M=70Q84YW0T(W6D%H0D-O6%!823!X<%9S3F,Q&1A5F-V07DHP*UEW3FAX3EAO50T2$XY<#EE2C!*.#-J93 F(WA!.V5W-31R;$1E065I M2S1906IC2&]C,DED069.8TU+=#1Q-T9867$W1EA9<3=&6%EQ-T9867%T3%5* M-EE&5U14<$9%.&IS15)"5FU9,$$F(WA!.TAI8T)K04Q02DU14V%(3C5,-3@O M3F%74DI.3SAV:FMM-GI8:$I5:U5P*S9O9GAZ5&%V=$%3.4UE5#%(6F996FME M3$DX=VIU4DEX3&LF(WA!.RMQ9#)$.69X-C5P<$%V6GAX:4EO2W5X1U%:1%IQ M:4XY;UEP43AW6C)A3TEK040T,DA193)74C(S3$E+4#%F,#)+2V=)9C1L2C-/ M,U4F(WA!.UI0:G9D0E(V5W%/:7)X1%8YF)!>7!%3G!I>$I8:%-V=&MF M14IA>&QS;V-7>%5K=#%06$IC5&)X<55L='=B,4ET;3=J6Y%>%-9<7!1D-W>'-T4W1# M<$DAA;EEG;C8T-T8W<%EA M:&$S,7-L,6%3<$YB>4%'3U)$545(3C%$24II-'9(6DUC;U-Q5WE)3&ME1DUL M-VU#-T-R5HW2W=:;W1+4345G;'=G2VHT2$DX061X:GA8>EI7,T9B6$TF(WA!.S1Q M6$-Q5%1952]8:5I!26Q-0D9X,E%294-!=64Y4$A)1U),56-I2F7)K-V94-6)#4W5T5'9L M9V,T1EI,6D-7;GA586Q623=9634F(WA!.TM336Q+8V-.,DMX:#93%-$:$M0,F9(-5I%;71W>&MA,T-Q66%P=4M%1VU2 M-'0R2$9U:%AH.44I(,&AL M:VHF(WA!.UEB-# Q0E0R07%-1BMH4DA:;3-K9GIZ<4AL=3=!3EIT3VM0-RLR M*V8W4V4K5# R<$]+5CE(4CEQ9&MX>G@R*W W-W!/<3)/<3)%5C6EQ=#1E>#A#33901FQ'46-56'HW3F=L:6QW>51$3%=P,DMU>%8R2W5X M5C)+=4]+<6-K<6]P9'E&5E%3>DAO2V(W-&MG2FDF(WA!.T-44690;C5L9FU6 M4#5K=G!.3C!I67AA4EIY;%=D9CA!:C1D9'%N+TE"-D1V;6PQ,F\T:G&5Z945$265B1&]:8C9V4EI".7@F(WA!.WI64VI(,U!6>$YQ>&AV-41S:7!8 M>$YC9TI10VUN3%IA:'9744PW2W8Y8U1K:C-)1WDO-G!D4A(>GI:4F)W>$E65&E"6#A-3'%P M>4I2.7)B>%!-=W!25G)V:WA&>#5Z24-A=S(X5' X4#)W4&A99%)L,%,T8W!K M2VDF(WA!.W=H3&1O,T9';V9K9F9#64UE3WIB1DYC,#E45FAM2FMI-V93-6U) M,U-24DUW6F=004A)4G-U-&A+,$MB>4=*:'5$=G1L;FAK=&A#;'$F(WA!.U=O M5FDU4F)3<6%Q9F9*-'-7*R]*;$-&2TUC+S$R2W)S430S56IQ1&MZ2&=,6&1& M<4\O=31M06UJ4'!N675.-C!X3TM*-49NE1%$HYFQX;FM(:6UH=WI'-FQ4:59J-6-L0D9.:FUO>FM5.6AH1RLS2FTF(WA!.T9J M<&9X0V\V.4UW1&-M*U4V5'1.1V)B-$]24&AH1TYX5'%553)G8U9(3E%L96YI M8TUO3DDQ92MY0V9416@K26=C97AW1$DYB3D=$5%-T9W5V*UIB94FYQ=C@F(WA!.W9H;#1X041:>E)/:7%&,%I.>%=O-FI)57E*=&9" M>F%G3$1B<#0T2E5X:DDY-U0R$M!=S-+:G5U430V.4I: M>&QA2U5P3$=*22MN8V5'5DA9,%=827%)5#1M2%=H>5),349R,"LF(WA!.S5X M=&QX24\O:4-Q:SE0-W!G5%1W3S)866HP-S(W1V(R8F@K2UIM2%-G05 T-$IC M;&QS155P3R]H;&)3471#16(P,W)H=$5Q<&XO-58F(WA!.RMF261,=G!.13%+ M67)A5$U0<6)U9FA34FE!5C,V0G,R+UHR;S1D:C%E5S=E-TM--"M,04(W8D=X M4%553DTS5-$9516 M:7,T*S5K238O2F5U62MO>CA%6$TP3VQ/85E$-35T3$]E-'548U-S,#@X-4QY M4TAC;&U.5%@W.#4F(WA!.VY*:TUI*VA9&MH>$UU=D5:56YT:F]K4WAK>4-O:DY#8W-%2V-(2G%I5'-O6#AQ M44XF(WA!.U=+6%2;4XX,&@Q1%1"870V&)"1$&=-465Q9D-#=DAC6'!B845Q8V=9>#C1"4S8F(WA!.S5&-TY'03!'=S-&3W1F<'=135%E8DM%66155'!. M-'AB-F\U2VHY;79593)6-31F>$Y--&-*5&0W1&A34T$X5R]A6'-F;FU+36PW M1G(F(WA!.T=3.6EP>&-76G%J:3ED,4]'5$UR6%0T:FE#:T93;654X.2\T:3AV:7=V2DLV=G F(WA!.W%H2BM2,V50.6E4 M*T)Z8C983GA#:C!E0C=6,&AX6DQ(,&PV4FU7-G0R2W5X5EEX07%A-'$K6&9Z M8C@R>65:4$TP=C%:,DYH6D4R.6\F(WA!.V=Q47A5,&0O.6MC,'5O>3A5>C-0 M6CEL-DTT.&1N-FEI+TE&-&I3:7EU5G!C<5%Y,3=J-F,Q,&AV4=/.6HKC!S:D1D:3$Y6E)1:%5,.&DF(WA!.T(Q M4%AB2WIS-V9&:THS4T3=N M-3563%E.4T]2>7A#1#9F8DM3154F(WA!.S%D85=B:$9K:%!P>G!U1S=(-319 M6G5(63AK0V1C,6)3=%)D:3%T8VIH8U(Y:C-'47I99TYX>5E:364Q:$93,F=M M53A4>&Q1:V%9-4$QH9%(O>E$F(WA!.U!1 M3U!M0G5-;FIY1TIT=TYD<%!(>#A06&\K=#=/-F=U&1IF%.-51U M-4E(.4\V=78Y1W0R-VAP3FU).3%7<'I%,6U89V@W,UED;6%F>&,X63E.;GIT M<&)7-C-K24MI:6UR:RM/8R]/-G0F(WA!.SE"-%%.:#!29#EE=$1R360Q8B]U M>710:4$V-SES:D1C34I1,C-E3!&,2M81F$K.#%21F%R4'5E=$U":WAX64-G1S$W9U-&6550 M6'(F(WA!.VQF1E1K:E-7;$XQ$=7-6-I1U!G635C-FAD4VMJ:U-4,GI*:&DF(WA!.VE' M,%-+;D1'5D%R=51U5#DMQ;'%/24)B<60S60O86U24$II0U%M15AX2E=V5'=Z2&PF(WA!.W-76DYH9%IQ5SE3 M:D5563%"-C0U1'EA-%AU:C158FHX0DE(8VY-95):1D9)6D8V4&Q:<'%+1W9, M3C5:5G5&*T=69'%J8DQ)6DM&9$7),0W9C,#5S64F)N:$IZ0F]:4&A/83982C9/079D M1S-L;$IC>&=R3'AC1#9-<7@U04,F(WA!.WAY>#):0C58,4C T;4XP,'9F3E5K;T1%.513;41X3%A(;U%%0DYR5G)+2T9F M:EA)>4QK=S X9W,F(WA!.VHQ67%.:C Y.&=*1FMD4&%'=F14851D5V]X=VDR M,TAG<$MZ95!5:VLQ2%-U5#1(2SA-2EAQ171Z2S5Q>#1F4$UN14%!-"M32C9) M4F\F(WA!.T-O,T973WDO4$Q22FQ#0C9U3G5Q0VDY935W.%9O;4MA2DMT,#=9 M$8Q*S%S3GE$;$UP57I'-G0F(WA!.T=5 M4'=-4E5';$(P<&M484I25C0Q-#%59EE0,E7(Y M1DUQ;61M4$I-;%55;TUX,G-L559!34),16Q8:E(F(WA!.U=5:"ML36=3=TI3 M,C5T<#%N85=)56M3;D9X*S!0035F1UEQ:35%2D%I:7I(>79O.35Q,7%K=U1I M1DI$;'1T.'G!/,$Y62$0F(WA!.TMK.6XX;E=L=DM*0WAF,79H661+ M4"]B:T-3038W2#)P2V4S8VI5,#0R1G(V2E%"<$)S0C(K94%Y360R;CAX-&MR M64I:,CAQ6%8W1%,F(WA!.V]H;%!%*WI#;R]8;#)5:EEV47IM3T=*-W=H-VY4 M,E1K-5AO2VLP=WAY5S)W>D%P6CE8:VAI0C0Q:VLS02MF5$UJ:7-U55IG;%)' M;7HF(WA!.TMZ,$Y#9G1V-RM!>5)Y0FXT=U0O05!,3SDO46YN0S-C>6XP8CAF M5EHQ2C(K33%2<65Z1$YJ;TY567I!-D]L-V8P+VI95$E$94PV1T@F(WA!.U%: M,#4Q5,6(R3U)O1G57;5=O<#,Y.%!#,D%+6F,P24I/1VU8 M0S!05C1%14%6-D4F(WA!.S=N1'1B06="46Q754E&1$)I0TMI;E1F2GAP06Y% M;V%C6%AQ0E9+:757>'%N2'E683).2E1,*SA8;G@W,7=K:71M=EI7=4I*4VDX M22LF(WA!.TEQ1#A8=&M99UAU;U8T+VEC0UIJ>$DK>E%G5GE"-6)-:64U1VDS M=#)79U5D3FE-<#1I9U1A:F=J66-15$=W2&)P6$5Y23@P,V%T87HF(WA!.U-P M27%M:D]H26]D:E)S:$])254P;7E34%%65$U5:'))0W!(2WI%9W%D$U5 M4VA"1F-G5V]O,U1,3C=U44EQ5D1(9DLX:W%A8RLF(WA!.U%11C)Z4%-,,SE% M>FDR;$)%3'(P.$0T-$)/-'5H,5=(>'A9-7!X2WDS,&9"1S-69WE/4#5H,'I$ M-'E44F1D2$=C4G-O-E-#2S533U(F(WA!.VAV5#1J;5A/26M,8UE:1$4P1T@V M3F(R.7ID,V)X449L;75$4FHP;V]O4#%:1UHU0C,R;WI%46IV>4-V$IC=%)15TDS0B]96'14 M,WI--4\Q3V-!2F1Q3G%905548TM4:&EB3&Q96CA83DHT=55.=VQX57$P8D(Q M*UDF(WA!.TY2;59#9$A:>7-K4D]":C!,-E0P4%5X<4]K,E8X:'%T>$-J;C)9 MF9,14MG4F=,46XX8S!P M9E%O>')K=E='4FE35'-D%),9&Q/;5=%9'=N-SEF:G P3U52:&),2FQ) M-4EY9E%967=:46XP,#=96E%943$F(WA!.U)*<$DW=4-/3W4T;V-R9&AJ;5-L M16AA<$-F4&QL-#@S2D)82D=O87!&5%1Q8T)+.&%,:71G>6,V,7(R>7-Y87!Y M=%1A>&Q6.3 K,F0F(WA!.W$QF1' M<64V05=/471X<4M(8VEN:&QP25E!:TYY<59K4E='>%!566IK>45R4D%D0S-W M:T0F(WA!.V)V;&1&;C!29'-L1S1L:%)T=U)L57EX0TEE3VDX=U%E4#)Q9'AL M65!2:T5->6QP,6M&5#)!-F)$3$%D<5I*=D%);D%.865)2GI%;%DF(WA!.UE' M4T]T8D].-4-&4&9S8W%L33 P>GE%0D\W8E165TUL;"M+:#1K-6EY>3=U1%!. M6E144W!R6D])6E%'<#E'5EI,8U!01U)#65A(;U0F(WA!.V](4D%%6G5$4#,V M,'%-1U!+63=/2D%M1WE984EI,G0P.7,U<6%C;VXX4FAI451B:6%U4FQ',#E0 M.7EW<#%"1S-V;5IJ1F@Q6DM6:7'@RGAC:VQU=E1M=7I(-#E-=7AH M>F-D>&IA3%U5F9Y*TQ9347DV8V$F(WA!.S=45WEN5V-1>5)R M>%AP2C)O4FLTC)6630T=7 S635%:V]216%1,$)R=EAX M-E4F(WA!.WES:W-W:45K57%W:D971S%185I74C-S<3=M42M38DLP3W)2>#-K M9G%)5T9!4EAC;D%*07E&=78W4GE'3TTX37%,,GE4>5 U8G5)9U0F(WA!.UI2 M.4]W;V9W>F1('I5+TIM:#)433%V17E.5&%M-$)Z M;CE89S1$5',Y4#)R;&YT27!28U%Y4E)K2GE91&(F(WA!.W!M<6U"8G-95$5I M9TQ#2U=716]A0VQ145)V:'E%0752;$E"5GA08S)S4&]42692<4]-9S95DAO:FAD3#944T$Q5F$X=F\V:DUQ1UDP-'!H=E1(=%DQ>39M0F=G47A2='-Z M3G-X0CA-=$UN838F(WA!.V)2>$5=#2&Y0841'8FA-*V8V1TDF(WA!.R]W M1$]3='=Z>#9(84)U27)02V9O0W%0,6Y-:E=M<$)(6)$#-W0U-N141U;4)C;3%.0G5444A)>6$V.5-2,VM94G%(-3572%!X1S!- M;&I027=D4E)F2$PF(WA!.T)*;DM96G8U2C T3&5E<'A-:$]X,C)'5'AH,%AA M96(P,'IJ>DPU93!U.'-(16MN1C%!3D-.:&PK5$5+968P5W-N1V16665B,R]K M,U,F(WA!.T%L46\Y459P-S536D5C:3E(:C%"2C5*1D9984A:5$TQ=W9WE-$5WE1-FYQ3FQ,8T57:UE3269:.7AM5&IX:V,P>$(F(WA!.U=7 M1VYA:'%&=W%7-F)-4E)Y9'-K6E)#6D=H6EIX<"\U42M98FTS179R;T)11V=Q M46$W-%)!:U=!-GI*,GII9V%+96%"*U1%=C%L1'$F(WA!.V0V63!Q0TDP1S=F M9FI(1'A':30R<#EO04DQ0TXO1C9P;VYK-U$Y2E%F5C1!6D(Q;&)D:69(9DYP M:#=/>%(S<3-L9%0R:FQY;C%(6E F(WA!.U%G06].:&UF5S%"=T5Q,6$S6#!8 M63EG5%@U6F]U,'1-3V)L-F5:-&='0GIS-$QF75):&1Y4FLF(WA!.SA3>#)"22]$2W-K5%9U6D]*-&):5&(V8D$Y<'AM M6&YZ1SEC=RM),UED2FPQ16A),&I9;U-K87%M=U5!1'942D1(275*2U8W<69P M:&XF(WA!.VM1354S<7='>"ME4C-"<'-J2VAD268V5E%B9')%:W(P=C155#DU.%EHF(WA!.V-1,4I75S%9+U1' M-B]W0F,S9EI*-%HQ,W5K.7!S6#=M2C=I9R]W1&Y)-78Y>75J2C$O8U-N+V@Q M>D\Q,TU/<3=!+VDY-&565V=$8U8F(WA!.T]X3V$R8C%S2FQK,FA78TQZ03A0 M:G)48G0X.'=S:VE45%I-,$Q:+V(V8S9W<4%!>3!Q=WEW0C X.'=*63=Q-WIW M5575TQ7>31X,U!,E!';T9B=3=H;$)#<&]M M;F$O66%L1U-H5D]1<5%A<5%$;$\F(WA!.UA,:DDX,4I":5%8=EAL=E8W:#E* M:D,P0E%$:W9F65ID1$EE2%HT,U@V4TIY1DXT-S5*5$F(WA!.U9138P<3 Y M5C%J63EAO5G K3U5Y:G-86EI),45V4V10:VM-84DF(WA!.U5) M;T]H24\S,%IR2695.&QQ0C9I53 T+W5I44M.;3-J14-&:'=I9UI&3%0X=41+ M4TM&>%1.5FQ&;3-+:DMH5&%%;%%+1F9!2')42TLF(WA!.UEL:6YM=5)**U5+ M8DEJ3'EF>$DS-&I-=E12'AH-D1$1DI:,TI. M5%=M6E51-7-1:#-99$LP>7="=$$F(WA!.UIP*U1T13@V3%$O871P4BMO-7-/ M>FHK.41Z=G1-3# O>%AF.#5):FIQ96E/96AH;4@O1$MC,E=U-6@P2%E**W(T M9G!E5#)S<3AK8T@F(WA!.V5G,GI7>40Q54-Y>GDS9%)I8U(X=C-J-S$X37$YS-4=W>FU85S1B5WAF,4A#;%)T-S5,:3)D6C1&>71G,3$U:&EV;%IO-G@K M9W@F(WA!.S5&=6A*-T1);D=25G5W9T%%;C!O5V-U;T\X=$]4;C1F8C9-='E7 M26=--&,R9&%J8EF5P4&1'49A15EY:T,U;6PP.&]$9$QR>GI/6II3V=433)-46-D=E-98TDT84Q- M=DQ51C5Q45(U:U$F(WA!.U%Q44,T5VAZ0TU.,U55C5F=(9&Q92#9-3&A$ M5TI65G%J>%!56FY91%%D4"]E;V%Y=F(K-#%,,3!9&MT4V5/;D5K+T-4.'-V>51&3V\P,D=1:V1T M:6M.-W$W,T8U06PR4D%O,E)K+V%(=6,Q=5-E-W-S5VM%66MJ9%(F(WA!.VQU M,%=:,'188C Q3SE4=&U,3$LR47=$:#E144YW.$XQ959+;5)L*S!Z1W597-C5$-08VI,6%-E8V]K.4QG3VE51DUO36DT*U0F(WA!.U4P2W1L:T534GAQ M=U=J56]C:D-)1S=O8VMR3%8Q<45C0V=33E-V541R5#9-49"02\F(WA!.T1-<4QN45%S9VDO83(Y.'-&=&]*6G(K5&-83'IO M4I64T9I0U1U92M6-4%+,UI#5$U*8E@V>F)):S@F(WA!.W8R M44-D.39J34%3;S=.=VIA5'9P<%)J2%-I4T=O4%=P3UA$3#%2=W%.=%EI,G9X M>4)A;E$U2V54:6EY:DAD4#=M-79U16A2:E1J*S6E*8F5%9$5O M,'$O=E1F2SAZ1FLU0D0T5E!F3'-K23%S:WDR97!X5S=V6DQ'2E%#9#EJ-#5# M=&Y2>FM/2S949E),9$)B=D5D-44F(WA!.TDV9#AN:D=Z:&%Q6G4P0C5S=4QQ M,&=J1G1Y1F5R2#(W6E9K2D1F;TEX;695>#GDY M85A&;3!B6$DY5F=!;U4Q,DAT:UEW3'%-97-L1U9G8DU$,7IY=DQP3CAS<6M8 M5%0F(WA!.T1K1U1S4$-M6E%*<6YF85A7:DQ(=51F5$QZ5C%#=U=-6$9%2#&1U'!12F-A5T-23F\W M4C591%!Z8EED471E=2M5-4%1,&$F(WA!.VE*<6UA5TTT;4E65BMY2SAZ,'EH M-3=.17@U=#,P34P=W=117I35C(K<7A8-6ML0T)E M0C1G2'%A9#AJ:W@F(WA!.VU,;E,P,'-E>E@Q.45M4E95;55S3TI(8D%)1VU5 M41Y0D]X*VI*441I6&@T85!.3$Y:=GI-6&AD45AJ M-FHF(WA!.W=*>3!$93-.,'5%4C-91G%P;%IZ5#=V1$YH:7 V4$)34W-32#,V M-6Q/84]3;DI&1DU#<"LQ-$1*0U)#9'=Z-SAK8DU,-6=V2FA7:T8F(WA!.W-% M-64X:B\X,C5T*WEW6E1*95C@P-%A0:U9R9T-R5TYX M1DU$-$)I67HO04U4>EIA,DYX=#4W6Y*16QT9T4P=%IB,C5F9T%2-S!Z2&Q'26)I0VIR M>C%)23!76G9S:6])2&9+-&EY>%,F(WA!.S97+VI2=S=!=# V-U9Y,%EY47ET M9F5E6D9D1VEJ:C1G9W)86TU57AN;#19=E4F(WA!.W1&,'E+4S,Y54U1>3%51'0X.$EI-DA5-F=G,')A M8W0Q6C-Z975#5EDP0DA3;4ES3F59:6-D;&9Z17-.,4,P5$UE163AI=TMB:%$U.5=7*U%D66QV3#9/,W4U<5-O5'AC.7@F(WA!.S!P M:#110S9R=$1(54-11V4V61I5#0U6&MH2TI$;5EU,#AC.%IJ,T)8.#$V;$IO M,$%T1G5I>7I+86MM<'(P-C0U<$@F(WA!.VM'$5-145H62MR2V54 M2#=*C!-64%B0DY,0E!805!P0FQ!<'0Q3U54,F-F2V5(<7(S4'!X M2E92.%$V02M/46HF(WA!.UI947-Q=6Y3E!U43=$545%:$4R:T8Q2DE,;G%O3E90 M8DE324%P<7DU26=5;E=P-C)B9$DQ5#=:1E-29VEE24]S=V%0:4\F(WA!.S=% M.5)V-VHQ;G96;U9P4U)#3W9V;51I:4]29#=H=WAR:%-#-C%+,&UC;&Q-5&YF M8S=(-5IL4GA%3W=X-%I!2EAE2TFLK8EAK>45$R;6\S;$XU-5512#)J0B\U<7IF9&M1;T5V M2&4P;5EY;$=(.#!8."\W1U1E9DXF(WA!.TUB52]**W(R86ER>3)S;D%F-5-J M:U!X1V)054,X6F1(;S4X3V%*.#-Y2'E$97I(=&UL<#&-U463=$:T%!1%1):SE1=W=Y=FUX2%9.3W0O5D%2;DQJ63=B6F9J>49U M354F(WA!.V]U8E=A2F524G5.9&UP=#E/6D5:9W)W5GIE:V9L-6]S>C)9;&Y) M4TU(:W$P,TE0635J>49Y#(P6#=O8FMF6D3='*W124U-/4E=L4C))<%A*46M:14]&,G)Q M5$A%864V36QV6C)7-4%24E=P<# F(WA!.WI96F5'34AZ.#A5-6)*9G!7;S)B M>4=/3G=9-FLW;6Q$6'=Z0S R54-4:S9J0DE20DDV27I7;&EL,'5D1D%Q5DI4 M-6IF8DTW551":G,F(WA!.S V559-93DU2G%C358P9E1N479*5VMA$9J:W R9FM'+VMF,45K0S=6-#!Q=$1L9FEK-U5J3#)P0TMB,V5J M6$8F(WA!.VA#:5=Y1'!6,D9E=$UP;C5U4&DQ56-H,TM43'!D>$TU;$MS.4LX M<3%Y4$A18S=X-&=51F4S4C1:2TY'4E1+-6)S2FUX>E)Y,FLX#%/>61K M#-'-'DR07!Z64-I9T9):V=D5RMW86=J3'528GIS M5TUZ>%)24V5N2W1568X04-N*VU7>$A&-S(R231Q-S!80T]536)H=FA0435(50F(WA!.S=G8S!M559):GIE-S!'9FIX4E!K179S3&UE0V5.;WEA0F@X27I( M>5)"1&YI5D8V4' K;GA8;F]U>$ED<4]"-S5G:TUS=5=G;F0S84LF(WA!.TEG M9TAX,#-R9W1W.&549&HY>G!V<71654%),EE9;#)%8W1,13!/4#%H2$U/5G5. M-F50>GA'>%),4%E:6'!T>D)$82MG;T-N;V](9TTF(WA!.W-J3C%E8D=42S R MD=N86)4 M<4HF(WA!.U994%!526=E,G552V-2.$UN:5)T431";#9&$EQ0TEN-TI9+W-N,GDO M2%=346HQ8V)66E)$2$M88RML-U,S4S-T24QD4E)955=.4C=+04(F(WA!.RMR M3W1X=S1):5!C2'DO2E!J:UI(<59F3$=$=S,O;DE,>35W=7)(>D1%=G=Y9S)L M,W0P2S%A3G9P,T@P1$Y8%=24T]X<5!O M3F-W0SE*>&)S:&DX>C9L8GI+>49':&%N>%4S52M'62]H0W9.=C)K>6%8>D'="66UR>6UG M-6(K1TI"6BM"1D@R3W!U.'DQ-FIT:4=J3&=O335S3#1#0F%M:'%+-6MW=#!' M6$9U;G1I8F1G2$8F(WA!.T-186EO>2M"9&1M:DE,=&-S-U9B0C=U,UAN3VYX M:&9%;G)G;D5C,D=M>E0T<5!*:'5R4E@Y+UIM:'!Y1D0O:VY-5V1U*W=3:D-4 M0G0F(WA!.U8P1T='8VU12&UO1E=R45E":VM.;F(T<&E9=%$P84\T85I6-6=X M2W@T<4119VIX>55Y4&DR5&]"-G!P3G=G,&@O5DY604E.97A(8UHF(WA!.TM- M=&YM9%)%*TIS:G1",#5.47-706I,."]I16@R,E!H;&=H>$)X9%IQ4$1K0VM8 M;F)Y;V)B4S5B:$EZ>6IQ>%EB-UIJ5'AM2G0R2%HF(WA!.S-A2$A-0F=';G)C M,W1W9V(T>$=".'=-:DU!1%HS.&E):3):,DXY95$R<3(Y<$M4161P52]8;5!4 M<4UU2T5P8U5H=7I#,6EL4W=7444F(WA!.VAM06]!4C-W.$QP8W-X>#!T;&8V M=6I.8V-1=$-U-7)6:FM*,$5X=5A*0E)83G)(4U=6=W@V2U!$-5IG>FQB:T=% M:G-R3'%I45-.2C8F(WA!.VEI3FAS36=!4S%N5$=3=F%A,GIX1U=294U02550 M9T%A06938WE"16=!0F]Y85%86%904G!43DA,3U4-'1C9W;$-S;SE18F-183598V4S:WE!5'94 M-#4F(WA!.S)K4C5"=T@X=5DU24)9-4I#;54V9F1)>#E-3E%$<&QS8V=$<6,R M33@P9EIZ,T54:T]Z2V].5C,W6F-#-"M315-.;5%X,TQY5VIE;$HF(WA!.U8R M1D%P-EDX5G5S;&IQ5S9%4#%U0T1K:UE-:E9$<"]-349"=7%-<&,R4%A':C-D M,49*3%!&5&Q88G)4-3578V1M,UIW,4U9:T%&-78F(WA!.V116&UK>CAN5C%1 M>54U0W1.:C!Y,$%41D]W36A,94\W3F1*;'5,>4=.66DU:6M(>&]09G9M4'=N M:S0K9FAH=65B,7IY>F)P<"MK=U$F(WA!.W,O>'-V2W X0FU::&E9>&5,-U%N M-&U1;$5A,7!H=C="-&UE;V-BD(W;FUI95999$HQ M05)1>3%"<7I(,G(F(WA!.S!Z5S5145AQ>')V1G@S4V1*8C9B07E&1D(U9VU1 M,#(R>79K-%IN3U-09S%7=VAT<%-P-45F,V%J,GEU57A4:7DP.#531$1T5C%/ M.74F(WA!.W!M85-O4W!O=&5N=FU0>F0S<#E01T%1075P83AA,7 Q4&)$=T)Y M=4%+:V-L>3=*1&(O2$LO=T)O.5-"9V]C,G-X049Y,EI:2DAF=%DF(WA!.W=1 M<$9W:&=0<51T,#)'*RM:1TM*7I,>3%Q:V0T=%%#5)H M=%1X1V)(D0T9FYN3SEQ-&Y99&YZ16-G2F5A3C56,6AR8C%52$]P;S%4=#%Z46E, M,78X04M'25-P3#E3,&95=$U6038F(WA!.S%:='E19&AL-$)C;D1Q65IE4U-8 M9#9';#139F%&2S1E075D1$A1=#=N-4(P9S9D-61T;&-C6G!W2G!.="]I1W=0 M,%HQ6%IU1'6MS5$MK8SA3<38K;7AP,WAO34),8F0Q&]T4E1*8DEY55%N='AQ8D96*T=P<&QW;',F(WA!.S1%34-0,&TU;#5$ M:3%&4%5:14)X.5)!2C!S,&AB-%1Y<#%)>7E)8T1H0RLT:V%O8TU">#9P-&I* M07-99V-L1S=S9$PQ*T-31DEL96@F(WA!.V]%03,U8EI'479K>6AK;G!J6E9V M3&9L13963T9647E-836A),E5$=WI66DUJ,D]#>D-G1G-D-6-80T,S=#%9:U8U&Q%*U1J4S%1-'%+ M5UA50D5O44E30CEP:G--<$)C=44Y:W1U-W%.2F92:E-R13 R-D0F(WA!.S4U M9$-/,6QY8V-$5F]R4F(V3%1,.4)%=G)88VA!.%9(9DQO0S)J5EEJ;&=E9V5L M-EAA=F0R.&MC:6XO4T%423%$>#,X37HT-&I)8TDF(WA!.S502V%I67AM,"\P M=E,P=$564654055R441P;69O9$%-9G9D9'%.45IL3G%B57IE>$9">$5.9%)+ M-%!)06EN435G-G9'2E)B245G30Q-&)F9V-X0FM,,"M(5'AG9&M, M-4LX=4QR9FUH4%8F(WA!.U1L85=V-S(T4&%Q-V]V,&XX33)N6BM%-5II*U1, M=&)7;D1P-DA/5#-63TMQ0C(W05HQ8C4Y9C)Q9S9$0W)S5F1I<54K861!6]13FER14@W.'$)K*VXR>5-';E5N=FM)0GAC'$Y,4Y9<'!I>B](53!*,BMI;55Z-74P>%E,05)8:V)5;&IL:V]X17!& M5#E/5'A4;W10874F(WA!.T1I2&MY2S$X>G)"3$E#2VM60G(Q*VI'5U1H9&)K M,$A%06]093-&>DQZ9TI+-VEP3S1Q92M9,&5)>71S:FEJ06)O5S5!&5%9Q3E!9<$8V6QO15=I85=L<4%$37=$6$5G<#A4+S!(8D\P,%=M M.$7=)4#!T6DMZ,G)!049X5&5-:SEJ5&(S>D4Q941I:EDF(WA!.S5H M,DA:*W-/1V1(:UAZ:$I"2D-Z239L6%%L6%%I:$1$66I.23EQ0T-!46I.261) M<%=&9&TS2'IY;D],1&PT2E5Y5S%V6DEI;U4W;G$F(WA!.TUX26MH45C+W1/2V1";%51-V]X0C)15GAQ,#!J0DQF#!&92M74G@F(WA!.T1M M5S)/241M=7114WAA5C)L:V)U,V@W1$EZ4&-Y:TLU3'!,=$EU8W)B26QE<#A- M06AE>6I(97E",#9DD8T3&---'(U'!)1FUT-5%!2VY9.6-R>354,$QL63E'3&]P8DQR=G(R>GEY9C-T2T%6,C(X M37AZ3WDU:V1'27DF(WA!.S(U34$Q-U505FQO5W(T-5%26F5K,&U,:$0P6#AS M+TM+,E9R*VQB>% Y3'5!0D%J1#=%9E55.3)Z;RMY.491-#5C,VQE,T\P94]F M0D4F(WA!.RMK8R].;GEI;6)K4%!,%8R2W5X5G!U,DMT159W0EAK9C5T M+VQM8F]395ED1VDO,&Q2>79R6E X061G6&9M;T@W6&IM=#%E;78F(WA!.S%" M,S-:6&%8:&YH;3A24W%Y061+1W K96%W=E5X;%DMM M3U1%0VXQ$]"4%0R5D153"]N17EH<4U",7E"3%II>%55<'0Y M6$U)0D0X=5!592M.1GE:66=54F,F(WA!.UAQ6%593$Y6*WA(8DEKF]3<$AA6#5S=G)19E5*04I%6&%R5F]&-F1C=$5A M,T1J-2MZ;U0Y634F(WA!.W-R,&985E41%DS M1C$F(WA!.S8PEED>FU4:4%G3%!.=G@K:U=5>71J2$9'' R5&)3 M5'A',3!K>3=I=GIP9T56059T4'5"0F5K:'EP248F(WA!.T1J26)-8S!/2TPQ M1%)H3&924G%(-V)N$%K M;5A*3G9Y*R],,E%4S M53=:3&E$9V-',VUL;C989&)G>$ML9#DT*S-T;$US46-V.'5$1S)R>35U-5-P M:%%2.'HX4E!A;5,F(WA!.S111GAW:4]A,SE%24Q.<$HU:3=%9RLQ1&E*9THO M34AI;T)+-S6)B94EN;6A225-4=G9L;D-K1VM485=V M6Q7>6-H5-(63!.5%$P.7-I0F96,"]A1T54-4(F(WA!.U Y M43%+5S1S,VI/-B]S4#-"*VI,235$>41RG8F(WA!.VMO:4Q-,'%*0T1(>6UC'9D8U8U>F-%1D0K,"]W1$1),U%:06Q(5SAH=&G5X:&IP M3%IR>3=O<5!Y9%=)2$5E2&IL:UE"=&]23FA5=3E-8C!$8U)K:T1C9SE25')H M:&LV3EA&6E%%65HR;V]*63E!370F(WA!.T]Z2FM79S929G!Q34-S1'AC:7%G M2'!8=FQ":T,T*V902'=Y.44Q;7ES-T=W-7AX04]A.'%E3DUJ34(U-U,U<%I* M,%-W3WEA-W5T444F(WA!.U9V0UI:6D=&23%"3F9E9W=19UI':'I,=C@X;UDX M9'E/=V4P95AV2T5.5I6;TM!54=B5VY63'%954XT<3=&6%EQ-T9867$W1EA9 M<3=&6%EQ-T97:4U64V9Z1#55,%!8-TYR6%4W6EI622M'4VQ(42LF(WA!.TMS M3GAL5U1"1UEO="M(57IX;7=8:5!N2#AM=DU':VAR;E)M8E5B2F0K0S=4;U X M058O87I66G1%665996TP=F)-8V=Q5WAE9DQD6&PF(WA!.W4U:FQ*5U)44F\R M0D)&4$5(34M734\U1V](47!P6C-+>G)VG98 M0F1SE!I<&1&2$DU M2W531C6-G9FA!05!G8W(T:7A*2T1L,5)98GAE M0V5O<4%M;F%U6'=X8E=W;$QO"LP93)$25%D:S5C9WAI>GEE>"M84$Q2 M#9.=%AV=5-065IM671"3$PY5S!81R]04GAF5'9*3SE&.'-A3F\V,'1,8TQ) M,S)P;6]84#A!6I*<#14-D]69S%U M5$8Y2F5983DK4D=O,G).4#5F=D)C061,868T2' W3TMJ-WAM=7DY;GDV8G4X M,#-B9R]I1$%.63@F(WA!.W1E83E+8R]P4WEN=#!"<'I)2FI0*WE7;WI$;&=- M3UED,6@W4GAZ1WA1149X3W(Q3$YX-S522T%C>4=9.3,R<')$97AS2T4P3UES M3-W46=:+TPF(WA!.S=6 M%-.9S-P4FYM-6]A,%!24FUB:C=/;% V=&Y2-C-T-D)(1$5F:C50 M6DEB84Y!3TE&9D4U=&-7;&A"-6$F(WA!.U5Y5EE)04UY07AB-&I&5SAA5C)+ M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMR84=L3W5+:#-( M9G!G,U9P-&\U058F(WA!.V1!>6YQ0T%18U1%2&UK4TDU2D)Q4&M$>6QQ0EDS M3VQW1FUR.&%,-F)B*S8P>DAL;SA2-D]81%@U;SAP1FI7;V9K8C56=4%F<3!L M>&$F(WA!.T4W,%)W-B]D24C=W,D0R:&HQ:35F>4@Q;R]A,4M!9DI74#E-4C):4'9# M>3EO269Z4VEO4'E$;4Y04XX=%%B,U9X8UA2.$-Y;U K1D9C=&HR64]P='A-=F(R M52]33T9K9&HK6&YL2WAO,$=M4D8F(WA!.W@P85=S:"\T66Y,-#9(14]L=4)K M-U-Z>2]I6D)&87A24G%K56%X<79254%!2#!$36U/3TUE46-357!3,TI8.%-E M;W)K>7AB05!H:70F(WA!.W)H,'A6,DMU>%8R2W5X5C)+=7A6,DMU>%8O+UH\ M+WAM<$=);6&UP.E1H=6UB;F%I;',^ M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z93 X,3!D8C M M-&0V,"TW9C1C+6)F,3,M-V)D.6-A96(T83DP/"]X;7!-33I);G-T86YC94E$ M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F4P.#$P9&(P M+31D-C M-V8T8RUB9C$S+3=B9#EC865B-&$Y,#PO>&UP34TZ1&]C=6UE;G1) M1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$ M,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/&UP M34TZ1&5R:79E9$9R;VT@&UP+F1I9#IC.# Q.38S M,BTX,# U+3-B-&(M.3!D92TY-38U.&)C.&-E,#D\+W-T4F5F.F1O8W5M96YT M240^"B @(" @(" @(" @(#QS=%)E9CIO&UP34TZ36%N:69E&UP34TZ26YG M&UP34TZ26YG M\V,5)"@>I<%0*>IJ12FL5R0-:U)".TC^,>((<5H3/7W&![\N?=S]NO@JV>?R MIY@X/Q"1%+"QR&7@DRDM/418NS-SD)3^"Q$UTV[EN_;MK!%35-:TB9 4"?8) MP]K)TXWQN+2;3;:IYM1P4$$)/_$0![XK<\@?OM_:/QV>>PX'C?(OD^^B+1QW M.*XU_IW"3S>B+'D.3W..N71B?S1V\E-1K<>N>VZ9DKHVW7%RXA29=X*9^V43 M/8?I3ZF7%X(NU/\ )MS&)*%^Y*Q]\"#R#]^[R%F:KP+P)@L.4=XY1RGDMQDI MXR'(5GAQ=M:HH*BM*]?8G4:7GZB;LS+]NIZ=*2"9K"E3Y2Q3XQ.6WOHC:J%@ MW2NJ'@932TE#93WE17/LD(AW+_O1?>7F[F9,-B?&'&X49-OT_&,EDV*D D++ MD,MLW?\ PTTSG_J4WHT O_I\C/#T53'>?6/W1,=#]!'3QQH&JH*RRR$C\*Z3J'ZE-[5#I0\JES/PM M$?\ OF%:L^A/I53M@L_NI,N+[1_\"-+B_P!X_P"_6Q<&[SW!,JB4Z7'!;8+) M0@D-]+>V[K5:]0=+H^H/> _MN4>KDIHG_P!\0BO?1!TO2D*=%W"2J4TOMC_P M#$X8']]#[D<=>8V'D?C_ ,7YNSN8G$TMM;9_$W)N(@"8@?K;J!#+[=/765)] M1.^4A:ZIN@<],B82TM!(/&?K+R[H)W;Z"]BNT^NROW5MPC K>:6!X>DC[X*3 MBO[\7%8Q!_XB>#N06$)V1W&0XIF[+*HK]!(ZV5[%9S!1U(7>3[5T[;-]2:ZI M]+-RH4I3+%25D>(!3^)B(=Q_09N&VTJJNTW5M]9Q#1;2%C_"I0>E/F=([H// MQ9^Z?]GOE1;2&S\CMQ')W?;48SG&'R&!E21Q_;^JDCEQ[D'I434U)M!UUZ>5 M;R:9ZL+%01_S&W D<_.4!'OBO=^^F/K-8V5U*K,^[2H,M;90N?+RI458]T'7 MQWFW'.66L=_QSD.%SEE,@>*YQ5[;7T4B^M5>VFE4BGXZDVUW^R7MD/6>I9J$ MD8%"@8A6Z;>O]C>4Q>:5ZF=3FEQM2"/!4HG\>O37D>D$#4'N15.]?92:%9,A;QR#YO MIHW!'\WOJ&-S];[12)^4V\NFJZPI)&EQ)GAP*=6/WQ:WI;]'/4#J!*X70N6N MAG\+Z"VX-Y)L+!)9N6V13 MY0S396Y5XS1B9$5A_+JJVY^M.[=P598]1RE: TZ$J*<9XDRTDGA%\]B?2-TJ MV8R&]RTKE7>)S2X4%:=/L6D8SX@Q5_S//2W?()[K-?5YF]VQF:ZO9Y+RZ9[D MDLTMQ/W)793U-3I#H55]?2?,//K4XHG%2B29=I/&)P-IM>V&Q2[I+@FAX*/;C&ZD:0TH!A]; MZN3H*?\ VR8?N"P\]C(^3EB!AG51,D+?(T53LFVK52Z?PJ1733NUP9J4"C;4 M?523*><^(GR,2#8J>M*BJJIF&$X:2@H)7WZ0,N$^<2!8B/ZFY95%'$1!0]&& MP=5IT"G\--&I*O10"3,3S[^,.AU)2@&?.,BX@$B&-MLS$^C$!5!K3U-!36ME MPH5J'E2/?&DD$8IPC&M["W4EAT!JK(5Z=?4U/M36YVK=/E]\9*2V4A)0D\X^.#%#MW,,R7B$"@_HMN8+M_F9?33EVQ[\1#.VWLUI"K*!#N*R;C\XD HX9#U#@^QZC3GUTR'E*!\\L.4OX M0TWZ*L2YZ3;,GPJ1&F@BL>2ZP1_;E[,=1R[HF[A_F+R?XNOH1 MAF40RX;+7-I&27%%EM-SVERA]T>-E.LMN;GW#MRH#UFK*BG*1.2%J"<,<0% M0V-T]*]A[X953[EMU,^@I,SZ:-67/23XYQ:GX-_=V\J<4FL<7Y@PF/Y]B%58 M+S,8R-<3R@ 'K<,Z))C;^0#U0K%6G1M3OLGZH-UV=Y-/NUL7&V3^*80X 3/' M!6J0[!%)^IWT&[5NR'+ATY>5;ZPXAI?G;)ES4I)2)_8Q<_X%^\;P3Y\2TBX= MSC'PYYW7N\6STT6)S\3E36.&QNG3ZS:?5X&D&K<;,ZR[.WTA'[144],[JDIE MYQ#;I[$(64J5WI!PCGEU#Z#]1NE]2MOOPUD,P(6A A:$"%H0(6A A:$"% MH0(6A A:$"%H0(6A CRF("$DT%1U(!]_QUXI24#4K*/4A1,D?%&,\L:UW$ * M"2Q44 _$^Q.O%F2->K2GMC)(!,I:G(K7^[G]R'P]]N,>1XQ@9X/(?E"-'ACX MSB+F-K##779)C?D.3C+1VRQL1NAC+2$=#0ZA+J!ULL6QTKI:=:*N^)']L*$D MS^'41JE/_=BRO1GZ9-\=77V:MUIVBVHMS2:A2%25(^;1@ 9]>-:;I+@RN:57;75.MX= M3K]OFH4MZK#%,0060=*2#@4G2 %8<\.8,=5^F?TR].>E##/RK":V\%2?UR@E M2%@X*$UK*9'' C*!D@6TR-M+;S".6*1&CDVQKM.X]1*IJRM['48O+J*5Y+K< MTK!!$S]W#MBP+=L13F:![H:4!FXEW\5DA"ENA]1IR4ZJE%($MMKF$Y &0/*&K66'U'P>!4/OAX38S"K; M07&+N+25XXPTK)-&!)+_ ,/;8BBGTTWF;A<"\IFN0XE)5A@FD.OLE8_4ERD0M0)SRGVS,.> MA9=4VEM7QIPC"Q/,,+#DKNU:=H[5YU-MVR/>(_Y>[F59]IHD-R!_39@U0!./S& MGKITH=>>I/3!_50G#F4\1X<.R#::)"B>>1AN[BUA+?,BB>3H M0.AV+_CN]M)2Z-RG:6Y+RGRC[X(MS#:B!YB)?QAP65ZC0[@"7+/M) _XSZZ2 MZBG4ER1RD/N@M44R@Y(_#(?=&3!E\AC+N&^Q>0NL7E+23OV&0L+F6UO+2XJ& M66WN(72:-E913KK?1./T;R*JF4I#B"""DD$$<01B#V@@PGW&Q6R]42Z&ZL(? MH7$Z5H6)I4GD0<#%D_VM?N]^6O$%];*?R1P))(K:#D2QHO-<+:[DC[[ M.X$.=MH4&YA)MF/L2=6_Z<==;G9Z=JWW)*JVWG J*AK1AP.DE6/ GQCG[UF^ MBBP7MRHO>P744=PQ4& #H49Y$!9*?^%/A'2?X7\[^,?.W$+7F?C'E5ARK!W> MUBUJX^ML'DBCE^DR>/<"YLKI _5'4'X5&K@;>W#8]U47[C8:I#C85I4 H$I6 M "4D3,B 1A'+[>>Q]W; NZK)NVB>IZN6I.I"@%HF0%)) FDD'&)F#JX5D.T$ MBH*@'V]NE-.64D@/R*H:"05F;> $9NA&<+0@0M"!"T($+0@0M"!"T($+0@0M M"!"T($8F TAV>*\>8F$B0Y\>$=*OIR^CDU:Z?=F M^2KU H+%,IORY3 ))22<<<)#A.*4[/.PYQY[R6[FO+RXFDFOVOII6OC<2L7> M283L99)'.,;5D0 E6Z D;:?X!CZZ10I2C(C&%-MI+8TI$AWD_?&*;'' M35F>,)**U928A3W+;6%2/X:W_,U;?Z8)*.W'V1L.L*RF(9%_#<\@6>RMY)QQ M])UAED8JSWNPD2) [)4QQO[UTXZ5QFUJ34.A/[H4S QDB>14)YD0=]%L) 7( M.D9?QAN6'%K1+N/'SX>R+65S2>^>/N3R6LI)LYF Z%' HQ_E(TKU5[?4P:IN MHZ[I1-J4EY9),I'&$NJNK5&SZCFG.6,;;)>-[;"#Z>UQ<,=TJ51S;[F"L M.O<)'J!Z:*L[EK*I>NL=7Z9S$Y>R-%OOK-3^LDI#?9&A_P!*6+6OT=S&DR,Q M+K+&K4D)^=E]"IW>GPT<_>JE+WKLDI4,I$Y0M*NCBE:TY2]W"-#+87'&DD2V M#WF,=SW+?^[]$HZT]1I215-7=04])NL P5DE78>1@TRXBK()\K MG \#&XLQ0^_KI:9J?22'$?E.![\_;"DE8 ]1)XPV,^;W'Q6%S.%,MC< M1$7\-0OTS.%>)@:T?92OQTKVWT*E;C34]#B#Y#_5+ ]TX5+:PU6.*:)^))\O M:!@8?]A:P-']8TI^IN(TD'H5$8^MQ38T\X9GD>XQ]MBBSRQM<@H(NJAA4TH67YATTX]HMU;M<$H M!#!G.,:.F2\5K4@:M)YPY_#'W*^7_MLR;"U:P UAI(.8[<,/"<8)6A0\I\XS'* M,G6<90M"!"T($+0@0M"!"T($+0@0M"!#"YOR[CO \LE@<;J"O_O&E M!Z=30:@,4[BE!(R,762\TPGY>F2 ,!P$8$N,QV5C6YE@:&=EVB:W=X)"3^4 MET%&I^-::,)K*NA466U!30.2@%#V&#E.\XVD!V6N$<=?X^ _2Y.27MIN$%^G MU",JCJ5DB1)00!\3_#6(JZ6J<_79"9GXD'3B>PS$' ZVX9+1GQ$9^+XCR#D< M4,]Y?PV=E*IE:.VB>,LA)4[I)&,FTK7H -:JJ]6RUN%EAM2WP9349@> P@C5 MW>EH5%" 5.#"'W;<4C2*.RL[.]N;>$"(200L(5IT)45WL?QKI%55U;[AJ 9K M5CD23^$([EY*2775MH6<9$XP^\-XBDS%+BTADCO(%VUECG42QL03!**;21[5 M]/;2G2T]?5,J;"L"9R(X]F&!^QAM7#?#="K0\4EI7(C \Q!)^'_$2V.<:ZNX M7./A4&Y6>NZR>A+"OYC$7Z"M=;#8'4GUZC$2Q[_"(DWUOH.VSTVE /G*62A_ M&)SYQX6QAM)9HPHN6MVN)I=@[0#59$4TKU0CWTG7.VLMM(T8.8DGV1'FV^H% M8'DH<)+6H #CV^^*Y.><;?"WT^P.%65E"TIZGY6]/2FDFB=.KTEQ:_;-V3<* M=.J4RF(J%F;F=@TDBOU"U)"@GIZ TTOFH#+8*0"GC#T]?TFY@ CC#5R/"LE$ MTF5P%Y<13K.OUEM %9)T1269(6&Q95 ]1I9I=P4JP**Y(26RGRJ.8)YG.4*U M)?J-7^4N*$J;*?*3P/:>4903D[6L=] T69QBE3SD+5DZ.0#\CE#U(H-: M=5H2^:9P%BK_ "G-"IY=T^<%TO6=;I9,V:D_"9S0K\1&^L\?#D+>#*6KB54( M6:,5$L)K%4[BJ1S \#P,N4?Q7&,9.36MO)+&UH]"3M967K\:5^!T859:AY"5I6.[&$YQU"EZ"HX1 MM&Y+;)9F2)F61U+;' ! 'J *'1#]H>-1I< T YB-S-('W@F?E,1!Y$D>^PN M1NHED62.**X4RNVX]M@[;%J!UI\-/W:J4TM>RRN6DJ*U*-K-QQ#%Y]$R"4O2PY:H)&A=8NTVAY%)& M';C#L\0\HY'PF+B_(^+92\P7(,/=+?X_*X^9K>[L[A9A(LD^.U+"U(<0I)21@0I.((]D(.\-F6?$<4_J7^F*Z=,[FYNG;B M2O:;BR=(F2U,SEE\&.&)*>.$6[6?;K*ZE:N4W$$@DJ"/F!Z BE.FK'-I?0-# MIF@?#W13C](J*F_B.??&=4?$?YZV1['W0@0M"!"T($+0@0M"!'E*2 M/=AH1 MF@ DSY0W\YGL;@,9?YG,7MKC<5BK.XO[^_O9!#:6EM:HT\]S/,S*L<4,2LS$ MD ==:JAVGHFB^\H)2!B3&='3U%PJ12TR2MQ2I #,GD(XU?W$/W(^3?=YS>\ MX7X:Y#/@? O"<[>6-L(H:R>2,MCYFMGS^3;?W4P\#(1:0@A6KW74F@U37K/O M8;@KU61Y&JT-'RR)!5_B...9D)E8WK7 ?NC[9409'0)RTC# M#+$@XSBO/$9SF+/LEQEEDU+ =VTG^EE/6GS1O1#4ZK3<+9M]"9H><95+)0U# MVC&.BE+4?-JUK T)PG&[?%\\R+R-:8O'62&K;;FXEE>>=4/Z4@#WP*MMDSD4CQ_A'O:<7Y\89.]EK&TC)5*6-D9'4,U2=TIKZ M:PJ;OMC6%-T[KBA_6N0RY"-=&I;)"$N(]/A^.<;23!$*J'TK(7J&@''"4%OXGXO;7:XQ;S MN7X>U@D2&79$B$GJ755'6I]-(JJ?4[K*=0)G+@(BG>EY>9]4L$-D*(*AB3!H M\^D5+:*&:,H%"DLU: $*#3II*D8"WL$=&,9(_GZ=/QT\:1XUC!0 HY]L1N[>W M:=W35$E 'EG^4Y?='ZYIB+3(\>@M%';FC(4V[_)+#&(@K1,& )%?0]=)=RM" M0V2G-7X1[M^XNT]Q+XQ2J6/#/.*LO-'CU+>\NI=]%ZH[@WHZ?E! -:D:-4:: MRI&IMM6@]F!YQ/5(^Z\-4I(/O!C68[G6'L9Y[8%9)%B=I'B^91\P+;E!!-"! M6E?71RJVU<'VDOD$)*A('W1C448K7-"%^9../\?&(KY1Y*EP_)(+C$R116&2 M4V^01.@$P']"= Q($E6H:]*4T];)M!%PM2FZX*-2R=2)\OS ]D*S]O0W;$H> M(4ZDF1.8$9.1FR"10\HP,D\E_<%?U"P22EMD5D_E8&@2X4FOL*ZQI6:52U6: MYA(I4_VUD>9N7WI,)=)6)2!3K 4$8>SC&PQ'D4W,,UCG;>7%9&,]E8[@?*5I MT EZK51^.B5?M+T7$U-L6E^D(G-/\,X-.HIT?JHP$\NTPWC<3Y7,WT]G+(3; M*EF+E1NB(0[B-PZ%J-ZZ50RU0T#350D>G(XP=%0D,>6-U/AUCDMKL"2ZE M9S"TLM#M$P%2A!( W'1!NX%:%L&2$ 3D.,N<$$$*<]08S,?/T]>WM>-F^5E) M^6BU-/B*G6)JU%>I)PG.%QC$#E&FR^-5L3D+1OFWVDR+^*%&H![^M-'J&L(K MFGQA)8/C.%.A;1\RDG(F7MAG\4FCEX:5*$26L4]L5ZU!C4HU1\0%.ER])6B_ M3!\JU)5[3/\ &%6Z4NFO1+(MC\8>O"<<@PUG'VV&^)S0_P#$?FZ?Q&D'<%8K M]P<7,2"A#6NK$G?-\(SA\8O.9GA>0L.0\=R%UALWA;J+(XK)VD%IN"M%PIPE*9X:P>(Q..&,@_@/]VL(][LH^Z$"%H0(6A C\EB/Y??XC7D M^4>@3SPC'GFV1EMIZ$4^8#K[=:]!K$ZC+#">/=SCTX R,S*.7K]Z7]PJXN[R M]^T#PUDK]VMHU;S5G\&))P%G4R0\'MKNU8@LZ,&OU!-%(C/OJO/5_>B0Z;!0 MNI"0!K5KTB?],NZ+P_2GT5>O#W^M+R@"G:F4-J1,JQ'F!Q )Q PRCG9\"\V:-OI[AJP[1T2GX 4&JL;^N-(W2-U#*TK?4@"8, M\1G'3/:S50RI2VD%BW*,T-JS0,I$B2W MU0"/:IZ&I8KT8Z-L;89$M848CFLZC)0VIQ;H0!/MG#LR_P!O]G8PO#D$MK"= M8W86D3(79"*AG8==Y7KZZ%38&R]Z#:%!(&8/V,(-OZGU%0]JI=3C,QYSE/B M(BVY\;XO!NB7H@@BNU"QS3.B2K$QV= P)(*^XULH=N.)6"Y(7UAQ*-[BPED*V\T\=J8&9^^( ?F4J0 M*Z51:O2.((D<. MV4+].R_?5):J GSI!5.6$^$-+CWW'_09:YAE%])N1D5C#,W67IM+]1\IU@W0 M:7/6]5*492(F?<9PL77IR2(XN^NK.[>)C**1J MA-/B0Q]??2O36]:@!ZJ2T2/RF(DOO3FE>?*O6;0^@'#.<'IXJ\LQOBTCOL5= MQ1]*,L8D=@%Z@2AJ+N]*Z?M)9:9ICU$U" )?TF*S[WV8Z*W_ "KR"J?LQY0P M_-'GWB;6)2W$F(ELIF>]BOJ6FL*6R)O;NFI2MN@ \R](!)X 3'OBV>T]EFPTXJZUH+?G@D'(YC(7,^::2+)75QODAE'R,K4^6VJ0#IS/V&GH:5#5 :5"<".?\ BA\T MEV1K*7 4F>4;RXG'=@N;2*6"XB9V21J*LD3,-\9'OC"XH# G3JGCC M@8>-MR/ \GY(<;#:V\XR%L(FCO8*36Q/1BR$*ZWJ^Z_XZ07;/[C"W3%553D,&1&,CG]C#CR^. M%O:R,C[[<)'/ T:54@,M2&7Y?S-_LTD4-5ZKX!$G22DS,9TKVA.E4]0)GP.? M*-6^/9A'6)E$@W$_"H]]&TU8$\02(6V:H!,P<>48<^,C6-JKO=@1U!(I^.M[ M58I2QP$&&ZI6L&TE[A7RUB&'R&.Z4Q2HO2A,3+I^*=5=:: MDN,_*B3:^J-=PIF+B#Y K0KG,8^PQ)6'CDM2,.4.;A7D[F/@SDN'\F<$RU[K54%]IZVD6H+0=6!..G'"7/CV3AA;TZ?V?J=:ZC M:%T8!I:MM4W%!)"#+2,""9^8J!&4N<=FGV@?=/Q#[KO#G'O(W%GLSD!;)C.9 M8&.XCGON-B)4;X75M=/-C;JH]UV)NN:FBI"0%))F01 M@3[1AV1P%ZS=+;QTFW]5;/KI.6Y#A])U((2M!D4Y\0" H<#!BCT'\!IW1%$? M="!"T($+0@1BR%J&AIZT]_\ 9\=8,)(45*RF8\VY\A\N2XXUX\QAE5;ELQ=6L@FR_;)!-MA(B9F)^4L%7WTP>H&\D;:LSJ MVP35. H1*@USEOU MVK;S5.H="\5G.9)/.9F??'<&QVNP[+VU3,T*4(#;8U2 3SGD(M3X-]G$MU@< M+R-X+>VO*$7$\J(BQH]3L?JM70]5^%=)S&WZFH83ZI.H'&EADNFB9 MH$3M!$C*HT1K0G>/?15RKI5JULK!&?\ +*)9V[MJRV%ARC2P"E)/F,C,G'E$ MGV'$L)EK/%760+7]_#V1,+R8,G;8JP0(3U&\T_AH[3U5#KFGS/#*9X\.$-"J MN];1U+S5. VPH&6D0XN0^.,9=XR*UL+''0G:^TQQ1,4>56%%!!J??65=5UI1 MH9;2#";:MTU--5EVH<<(F,)D3E ?\TX7#P'*?19.Q$KW*PR+.MO%$JB1RN]5 MV O0CTTW7/GD@_-).J8EW1.]@W YN:C]>C<(""01J)G(=^$,SD?.KGCF/N+B M!H[FVMHS/#!L5"#'3Y-J@-T(UHG7)7H2KR*( GPGXPN6[;S-Q> ="DO' G^< M";EOO%\UPYCLV/(I,/C8I \-C9.R12PC^61J,[5'PU(=)MQ+M#J74/J>(QDJ M0![ /QG!>NZ=;>54@K0V0.:4DGQ,1YYB^XKE7D[#PX_/W4KF'Y4D@N9DNIYF M $<:FH !8;NH/IK98-IKH;A\X\X7E?XP" .),/C;NW-LV6G<^60D:I8"6>/9 MA O083.V:K^70DAA8RR(P![,(WT4O*I1&][86V4E0/%$L$O;N%:-:M(6#U5TTG+3: M$S2RXIE)D22)C'AEE'B+5:'Q-?IJ=[)#'Q$;;'95 M0@DJ&4T*5'KHG56^QG34+J4(2KBF4B?XQF=NVY2#Y,!S*8>N&RGD8+'/8X)D M(14D'_$-I#T/\=,^KM.W:>;RZR:#EI F/P]T'WZ M*TA?G(E/L_A&CRMCRS'9A.19#"202Q$N]S9 L.XO]MV6/YQVE]":U'KI0H*N MRU-$;535(4VK#2OEQ$SACR]D'JRU6&NM)IZ27SLTD2E/ X\!!1>.[VQ\BXB* M;*[)Y8D[%U8L P6053ONK4.XA:^O34-[MIZG:E>6Z*:6U'4E8XC/2)?8PQ:Q MU^T^1G!7/NX<8W>5X[?<:MIH(#)DL%(ZHT;*6N+%"^YC%U^>V"CKT)&DVBNM M-=W4N.R9N0$Y_E69<>2O<8SI;DU<' MP:*J7#(X2QCVFM[:6R+VLBS1M3;(* M,P-!TZ4*TUK0ZZA_2\"E0X1N:==2^$N@A0X1HVL7*-12/0$&E3U_AZ'2@*A, M\84Q4I!QB)_(_&;F6.+,6*DW^+*R+"JC_G;?>#/;N>A-5-0/CIZ[5N[*%JH* MD_Y9Z8G_ $JE@H?C#OVS=T(*J)T_H.G.?PG@?MV0Z>(S6^8LHI]JJC1*2M07 MBD5*M&_0T=#T/XZ1[VAVAJ"W,Z@? B>8[#"5>T.T-04&>H'P(GF.^'FEDD(9 MZ5)H5!7U4&A ].O72 I]2R$\(055"G"$Y#CWQ!?GKD,/#N"YO/A>YO+3!^2(7N)1:V&0OIDAQ/)X8 M6^16PLU$F-.MO(17Y>ER=NWU>T+@WZ /R@ 0I'#2#\1 G,_SB@OU)]/'NIFU MS7TC,[^VK6% #49!4TZC(R.$\>4?T(,?D;;)VEG?V-S!=65];P75K/;R)-%/ M:W$2S0312)5)(I86#!E)J#JTJ%:TA0R(!]L81Q0+(\S/)MBABA4M)-(:@*D:BK'VT%K;0@K60EM*223 MV1XA+A6%)!4I2@D#/,R&$<$G[K'W5Y/[O/N8Y%=\5O,G<\"\>WUQP3@&-MS- M<65\N/O3;Y7/Q1!NT\F9O8BZNHW=I%%2*:I]OKKZFB3@29G2%_%I(*9@2!D)B)U_;ZY?9W MKV_C[DMC%;\MP,AG"W2LLUW:OM*(4F)>1D'MUH-0!6TS(N*WZ8N MP@MK-%@!9(FB82KO7JP)WH.GK[Z+W]]L@L-I"4GD!"KM6T7.HN;50_K4G5F9 MX8'" 1Y#G..; M>(XWR7?R7AR$EDF'G18Q9E/J#M_JB.1B0HC!;\OKHM5TBZM.I;B@$]IB2M@W MFKVO3"GT%1?$S,D#E[Y8P$//./8>"[NK);GN&%3$Y8+M)DH&8CK_ (G2)4K9 M;)1J\R1%C=M72N=80^I$@K'V<(#+RQQ/CV+QDF1^IMUN((W<-'LW*%'J:4^4 M:6MH7:XO5R:-&I;*SQG#[#2;@DNN-Z"GC+ P(,!FOKB/*R-_15J6MHB[V:($ M@7,D:^KGK0GJ!J;'/38;-(D>-C# M>W4@NX2\-K+BQKZ? Z]J%L-)+*P"Z$STB6'89\8(:R79 M(&D3E/*?;$E65O/SINW4 KZZ:-4\RXHOOID MEL>664U8Y9&'Q;6?T#K,YIXXQ*6/C@@@2\420"&W>-XV5A_3:@8,I ]&!.X_ M'3.J5N.N&G,E:E@@]H[>["4-VKIBT^7 2$P_N.GMI^HO13(2(]_4);(*1_EZ M[V'6A]=->[C4KY-.(3G+BHY^$%M!7YCB#SB1\6GZDRS74:-%)\ACDC!%Q'3; M60,M0I'PZ_#30K5?* ML$ZQC,'X3V04J/4;1^FI25 SFDR_&&3G>'XYS\8GW!.VN0LY(94I#)=Q M;(^Y;R*Y2:-D #$K0U^(U%]RLE58;LND>"@K$).,E3$P>4-JOM[]DJUAX* D M=)QQ!$P8U&9XXO'+O]0"RR8"]9C=1Q;Q]%(_S17"!:@1/_/[+H];[L;LQ\J2 M!<#,'M'#G"A074W-D, I%:@#23^;F._[X1QUM)"LL)X]R,A4[E M850JU:,"/?7HJW4N%"DR6#C/WQO%4ZE90H26#C/WQHS_ *BAB@;:SBM* ]:M[ :8*ZI;M1Y3 M(&6 AB+J5./^4R!Y0!OW#WHY+:YF-)%;%XR">%(M@VRS["'D/\K@L* ]:ZLM MTPI#:O14L2K'B"3/)/ =G:(POB5JI$MRFC29\1.!3P_'Q#!;V@B:&2"SM+EP M5*J8S$&2E0 61W8#X&HU,%77%2U.SFDK4!WS_E]T1TJD6XLME)T2REA*4=MW M[(7WA3>>/M^3P]S3)27GDSP=#9X)Y;BY8S97@TB&#CF4^=V>6XM!"]K,U204 M6I^8:L3TLW*;I;W+;6.J55-F:2M6I2DF4L29X91R7^J+I6=C;K:W)0-H:L=X M&M"&T!#;2@5 I2E/E&K058 8DX1>7;49C('8_($*%BVTJQ)KUINZ]>E=2LB: M/TCB4A(&]?T[#]PJX/RNZGIJ*NKVYT[$<;OC3+8.TY?AVEL8NSC+GNY*69 M1+,\S=1.^Y6+]QU+,33J=41O"*[Y954\X5J<4"!PE.9'OCMNY0L4SZ+;2)2F MFIV/33+AY0/#*)%S'D&YXMYLM.;X>;]&MEN+*2>6%8T>YLU([[;AM$<;(*4] M]$;:A=3:52FJI2XI20#\)PP[9PA72TLFE5350!2M,CQGAQCH)^W;G'&?,&"L M,_99!9H)[>42,[!B)XU"E?DD*;C2O32Q;*S4LH<&EQ.!GP,4WZ@4-7MY];+* M ID+&DCE[(UGFS!3"VOKRVRYMYX;>0M$&4AQ #VU54)9EE4=?QTEWFGJWG"\ M% ( ,_PPE"QT[NB5O-M/4Y*"O,CGG[(KL>;*X[+XWZC((3'<)/)&RL.Z&D:0 M;ZTIT:G7TTV6EMH4AMQ4E@@F8_G%JFVZ*KMSOI-'%$@>4A+"#&XAY(FL(X.T M\-O&8P) "@W-3U!%?E'^W3F15LL^9,@)<(@F^;314J45 J7/"&URWS%C;.\E M'UCRR L\K1N@C#^M" 1T'II,J:TO%0:4#@>,H5;'L*J?8'Z8"3@)SG*(EN_N M%"1W-E;W0[;][;&S(2*BH:H8D48:17;NMC](R([YP^*?I9,H?<1YA+'&!FY# M]P,/%VOI;[*QQ_4R=]MUPKF5B.J[ 2?04TH4=567(Z+>TXM?'#CWXB7:8E"F MV#25+;94_N.R/*#A%E;QK(9+A:">X )JZR5&R(?C73XM M6R@Z!57B1<.2!D/][F?=#MH:)JT-_+4I*^W^' "!;S.;S_*Y#%->32VID*2S M.\C!NM6BC-?FJ/S= *>AU(5#;[;9D:FFTIT_:<*GSKR$^D^<#F1CX# M*-S867;4Q!>BJL<04?,$5:4]J#16H?U'63QF8Q"P\H^K,I'P_CR[(V605NS: MX^T0FXOCVB0/[<*&MPQZ_FDZBOPT4IU#6NI>/Z;>/>3E[(WAM\22Q+'[H>5D M(+:S:SDB81R1QPVT!4!@1T+*032/=ZMI!?4XZ^'TJ\P)*C^'?V1MJ*).C4U* M$=\?*BS*4WN!$\H+.KEAO J>J$^G7KHAA8@=0/PTS*BH96" M$M@JGB<1!1]UM0(2F9XPY@U]-;RVHN3=1RIVVBEBC9-C5#+^7H''32013-NI M>T:%@SF"9S_E"44,-N!XITK!F"#$96N"R'CK(7>3Q4C2XUW,F1LG!(6SF&Z6 M6. #8#&Q))!Z#3N?N5-NNE;I*T!-8!)"_P#&,@3GC]\.!531WRC32U?]_'2K MM!P'LEP@J>,W./Y7QN*6.\MKF"X@';+A7%6H H05K0=-0K=V:NRW@MJ;6AU* ML>'OB);P7K)<-6A8"3,Z9Y2.^MXKE\%<.\=W$Q9Y+&[<@QRHNX M@6\K>U0%]M*]+?%W8FF=4@7- !2<@M S!/\ 4.?&%-F^5%PJ$TB]/S4>/D[P%R+@?D/AN7OD@MK?/8O(6D3,6,E0(IU60;**2 M/3UJ=.FT[B]?9[S=0#,K2X!W8'[Q!?9?4^U;EVM64-.'2[3NI)F!PF"<^R&_ MSO&97&DW;-90UET27/[39F0>,LA[85[+ M54]PJ]*% !(GC @Y2<;( MD5 %+D/^7X:PM&[;K=*YYAE:4H5Y@3DG3F9]V<:;7;+;752FFVQ(# GWSB9/ MV^_)W)_M)^[C@OF/,Y*3$\&Y'=G@/)^-H]-_&>1W,5LF1RIW+ \N(O7CN0Q! MV!6H=3EL;J'0VR\4S=&5+6VH>JX/A4")*2D'A.7LBJ/U*=&&=[=/[B0D*?H$ M:J.4SI(/YB#A\2_ZL_9WJ8.=+FVCGCD$T5Q#%.DZG2LA4^8C>:]CV%H0(XSOWQ_N6BYM]SE MKXDQ60,F%\-8MMT3*O?/Z1,Y@#U F66>!XQ4'@9XK:\M;F.X M$4^5D6SE$9_J2*%+JX]C2FH)N*%N,+:4G4VR-0GD.$HO#:*-:J5;]1_>>F9_B(D?EG!K#D]C [9HV-\8T"&1QMO&0 "W[98&M/6FFI9-P5%M?4@,:Z>9 MG+\L^,X3=RT24LSU25+VP9_@[R1F?!W&L=@K#(F<75)HXK1]C(PC7<6AHQC5 MCZ]=(E;>*D53M8V"$+5//+A#(JMEVG<5*T*I*5.RA^^(WRWG3&YM MFB:S@COH?Z3NZH)05]&&W^4'12X+J'V@ZEN6H8'A#OM>P7:0^1U1:G/3C'E! MY;GM81VKD*54 #=4&@]Q4T!TE-.UH:"%3U@P<')9MR-4%SUII<9M3:W02 4#&'<_:F@CR2( ]D#SG<9E\GDN] M>232)+,>VY,CJ%'2A/50#_OU*UNK*"DI-# 2DA.(P!B/JRR7.HJPNGGZ(SSS M]D:RYX_5XL?)&424O/+/(CU-I#'OGB#"E1(].GPT<:NB="JI!GID 1\1,@? M 0XJ*TJ;;TU QE/V1Y38N.!U^D7Y(U.U8T(&T"H0U_D7V^&MS=6IQ,WOB)XP MWZ])]3RQJHKJ1)'AH9Y>_L,$+#OD=#51[!:]=&UMI4@+R3+,Y1H2X6P 2Q62QC@;YXX@^R7=3H)/CI/?J4&F":8@)#DEE61,ICPA28? MDJ:LY80_4L;>U@2\>_2&3;MMX[DIO1*5,:)4LQ;WZ5TV%53KSIITM%2)S44S ME/F3E"NPC6DF<.&RO,+?1D-=6Z2O%&8]TB[Q>/C$T2Q74B,XA>-EB.Y&,BF,_,"0_P#3>O3WTWZI M9;67&00G4#CGACEPQ$:74:E>F8EKA,$,,-[#&@$=ED)8(CMJ:!(F0"OHO]3_ M &:8FXW7''6W5GSN,A1]I!^Z"-02E/I)R&$29#:)*RL:$"IVBH*L1ZCIZ'3/ M=?4V)#.$E;ZD@@8&-U!!0J *$4ITZ?[SI.=V%/=]ULKVV:BNJ%)34L()"L/,!PSB\OAWV6XF7#.OD"\ M@DM+^VV&RLB^^$W 3Z>629Z*[1,0:#W&J]45!?D7=+]4M-.E!PDKS$RSR [ M/?'-7=/U(U5-&NW86&^5D<* !6J@^OPTB4-_9ME24E0"E$1*EKW/1 M4CYT+$U'W#"!RY5X^O6SUI97%KV8,;9R9.\#"B;C)2%6K2E I('K74K6/<;7 M[>D%[+2-8)^QA;5T= M.\5)-SD'J*-%%6@/L1IWT=[9MK/IIQ4L3BW S0GTDX@IFX<,. M21VG[H9_*_&N*G5DS5ZUV2 Z@3R6ZI(K ILV,&Z,!I9LF[JYA8/F'[5_'V3N[PWN:XI8_Z$SDTKE[ MF2]XPL=C%<3DDL6NK%8GJ?6M??74/HKNIS=>QV*JI,ZQD^FO+-*4D9=A$WXAQ?D/*<2 MGO*B /OC^;]Y7YQ<^<_+OE?R?R&]18 M.']79$X)]9UQ#+!DEM.'8,(?5PN0SDEA(]P4E01Q(ZNQ5)( "SQT- 9$'4_' M3=:%-;TN(0GR$DD2S!X'NA)W%;ZEY *S/")IX9D(DY!8FYO[D3M;]@%Y&:"/ MIM( )/Y@-,>_4[G[E+MQ[H];JRR-S8Q6[35 ^L@$R/ YR[XCBYQF9N\A=PMFE*VZ@4[116F;JL=8F5OE&G@U54+5,A M88D5=L\.>,1S<:BB+YE+2._^,;? 09/'H][+86%Q)++LB&_MS2J*HY!D+, " M*^NB=Q72U"A3H<<2D)F<)@>R"ZE-/M)6PE(TSGGC/OG&QD.=EY':R*T5M#V# M$8;01SSE&._8'F*Q(03ZG11*;>FUK29K7JG-4P)\Y#$^$&&WJ=HA3J4G#MG] MXB0>,Q64$TGZI!=2W;7#L+V_B1HXE6E(DVCMK7X@?XZ;%W-2ZV/E%(# 2/(@ MD$]IX^!]D95-:NFQ844@_;MA_7./M98TO+>P@E>$H2!;1.)8 ?F7:4-*@UKZ MZ;#50ZA9IW7%)2J?YB)*YYQ@BXU)1Z@42KN&7LCQDP=M):?J&'6^L\E%(9TB M3>8I8Z@NA@8E/E7X >FLDW)Y#_REP+3E&H:23*8/ ZL\8VM+#GZF.N)$X-E\ MC>TN(KAENY%D5X;F.8*MNP<,-@(>+KII;EH*5@)#J7$K2- E(I(^(2X MY& ^*1T*49@]G\(ED97)11LPALP1U+"Y4UIZ]!73'-%2+4 5.2Y:8231TJE2 M"ER_W3#MQ=U6.(=J*20 %MSL2*K4 T/PTA^JTC4IUQ*0E).) [ M!",7FFPI;S@2$@G$^R#3\5>+[],5-RNY6VM9X(6-NQG*7FU0#N$9-2U1_'4> MM[D>I-P4[M,[II$.S4,,<#EAEXQ7W>V[J9=:+*VM2FUJD1(:9GM@Z/'_ )[B MR7',?@\XCV^;QBK:I)<2*$R**0D$CL0:NJ_ #TTD=2*N\M4:;K; $I$_&<^$ M_P 8JENWHTOY]RX6U0%"Z=13GI/'@<#]\3MPRUAM.12\C6&0KRN$V&2C5A); M3W4:-/#=LG50PBW(2*=*=-(W26[K>*ZJN02IUQ3:IC.8![N,1;NAU:+6W:7G M=3]&06SD4IG+3D,)X_C U_=U@\-#:>/.+VW'OU:_Y'S:#(/# A80V6(DCOI) M6"E=D2R[13X?'4@MVZALEQK*ND2&UN,+.9,]04F0F3B=4^X1*_0#<-S375]7 M6U1 31+;!5(?&A8Y6,\:-G.*W]Y>XO'XZ[K2I":E!\Q!$^'#^4::[?PM%_;HPM;C/9[O,\EMTGCDM;:[AM,SCB1P&4S^$6LV;NBF%NIGEI.MQ!*0J?,S49'@,HCGEGC5L%A<9DLM)$, MI+9]N&.%@D-O9M$J(FR@"D;?F-*EJDG2]5UVA:6M>*I>498?;WP\[%ND7"X. M4U*#\LE4S/,JG,X_= 3\KQ%U/=20MLD@BJ0X8-Z5/K3=[?'4CV:K;9:"DX.' M.+!6>KITM)=D0\8NA_9C\I?IG(/)_AE998;>]QEGS#%;S59+^QD7&Y4*"#M) M@[9-/6FKQ?2GN>H367&R5;DZ0M)=0C#!94$J//%,N,L(YM__ .@^QT?(VK?C M0_Z@X\MAQ7$HT^HB8R$B5<./LZ$?J)OH>[W&[FVN_I7^UOK2E/7\-7=QCE_J M'R^O\WIS\8KI_==\K?\ A5]C7G?+VLTD62S?&H>&XYH)##,MSS*^@PH=9#0T M6WN)"0.M*ZCWJC5+H]JK6DR#B@CVD1,/0BQN;AZK6RB;25-,.I>20[H.$QS';$XXKBU_CK)[^4[OIHXU2W(J92H "E1 MZM74>55[I:NI%*W^6@ MM.2V07)GM!69 ZLPE0*(RX)%6Z#XZ:UJM=+4)6M0.)PGWQE?=Q5],VE^D4"@ M3G+NAXZ56$2-4U 90 U170KK&MI/J-B:!/B/NG!+; M^^JJX50IM1*@1SE :\RL,?C1)"L5P8G%4 MG+D^H .WTKZ'TTC4J7@^-!D1S M,HGNRU3]6D*64Z^^($O%FEFD191;VZ2+4+_>:,FKJY;;MH#[:?%/H2@*(UND M<*9ZRH M3[N[N@L[<24CU%'4)]T2IC."RY2T6+$PR7CS1;MP9=B&0?SBE=-Y-QJB\5J& M"52D!RAG7:Y4N*Z]01P$^/=&K@\8YVUR2XYDM3)'%)(7$&X)O/HT@8+NI^ _ MAI4?OC;B#-*PK"?FPP'<81&':1#/S0<'I' 88^R&5S[Q,>)V]MF+?(K(,A([ MSV[0QJ$G]'>,DUZ$Z7K'NK]Q6*-U(.E&!259#@9CWPW*Y":A2EL$^54B#V\1 M$>8G%W4[RN]\\R6](X$9$V*O4G:"?0G_ ':7JRK:;2 &P"K$GC&@/5#"0EF: MIY^$?FRD:PSUM,'T5">.8)S$XUI4ME ]0R,Y?;.,_*"&Q#7=O.LEK=D;9$:.-+*=_D% M W55E'^W1*B*ZHBG=20^WF""2M(Q]WW0ILMU"1J \I[1A&3X]X?G),K>2XKC M.3S5IW2;I[2TFN9$2>L@N$,.Y7!;J:#6Z_UZ:^C0R'=-2E. $SEA(@ D=DX+ MUU?;[0WJK:AMA:\M1&?OB?8<)96D/\ @5GF8X9;***0@H:. M2M !U&V0(%U%VZ-R55"5I>*M(!G+'[HCW,EO#8WD 5FV$[YY7 8"./XU]=1_ M7IW);5.UX*'*!A.M2Q,CL $P2H\HB3<>U*EQ2[MK5I9\VH$8<,O'A&:O%HL[ MD,R]8(<]@A:WV&[,,<=M<6Q+R&&2,MM+,W3?[Z6W.J2J^R4S%?+T75%"3)6: M3B#C@9$$0CU=WJZ2E32))+#LPHF=XQBKBQ06\EM2WO[ M8@CLWL:@7" -3;U8$?'3_P!MN4K3;*::27"H+(GSPGV3 RSPBKF^K;6VV^.- MU>(<0%I.&*3.67:#&TYQQ&WY9' ME=/7>5'\VPR];ESJ/("/$:IG#A.$3;&XZVPU*RD?Y91Q']0Q^Z!F\J^3<[X? MQL."LVMLUR*]MU2SEF"Q6RVW;[;W>05=PBJIJ*@&HU'%BH+BSN12*X:**>*M M0((GR!)]TQ$];%V7;M_U8O%1K32)4-4L#.<\,)\.$XKF3F7+6R&=69-OZSDX M98Y9B)%>.6;N7^0C(]#0;17KM]M27<*FC:/HVU[4R$*G(2\\O*,0G,\>47%. MWK*W0TZ:57F9;(4!A(_E2>9X\IQY>6^=6.0Q\?=E@EN8%6V0(=M*BC1AQ7<6 M:I)]*Z*6*BN=56>K6(.G@9@_<3!K9>W'Z:N*TI4&CC,^$-?AWC?#XX;D[>)9'289R&2VAE9TCH4BN]C>M/EU8CHLM^S M[ZIO1F&GU!"L1B,3S[HAGKTU=M]]&KH[7MJ5\HTE]HX @I4G5@3_ $3[91TN M]Q?T^M5K2M:?R]C_ ']OI\==1<)_X91QTDOY35PE[IQS_?\ J)>:R\<^UKQS MQ>"4QMS/RIC7N8PX'>M>-X;)9':R="Z+=R1$_ @:AGJW7A5$Q:3^=95[)1;2E2P?3P@E\)9+EG:2"2AB:&6&CBDC!T;:!05+#447 M&H50MA#J<%3!PRP.,2(XII%6I:?BTD?=!,<.PLN;O[7]6$UACHIED#K!W-[Q MD*0Z_+T)]],)*&D/ (,YC$RR'9##W'5%"5%L J&0GG#SYSPG&XV6TDL)Q)0I>VN2IVQ 'T!]:Z5EK#*= 42VX)&7+^(AE4SRZ] *DZ5). M1QQ'X1-'#.0ODX\#RS("'%6\4$D-^LK=7N[)^RX5?E50!UJ=.&@=4&0[,! $ MB>0U.YS_ (:.O.*J6BXVJ2",N<,_:S3EGKU,UB%+="Y3E(B<\H&#F/%I M+O"=UOZ?T^_>Q*!9 O4=M@ ?F_CIG5VN4TR 2<8F>PWI+%QT#$*E+L[Q ?A'XK3TUMJJJI86IUO4693!G"35NNI!GG!K_;7XEY# MS')7!PS/>8Z&1+<31)O&T'YU8"O;"5ZUT3IFGZM2G&TZ22)Q"?4[>MMV_0)3 M<" \9E,SX1O_ #]Q.'P7=7N2N(I+W(S02=JU1'E@D=*A'"H&'R[NH]]8+H'? MG44B%!+CID2<@.<-W9V]V=V6L2,F&\1+XCS$5=ECE'M#!% M#//]4JHTLB$AG+2J(@ P992K_/Z_AK!;BW&T^B20 >&&/=AA!M+[2B?3E*') M;Y+ I2,/ 8XRK.E S-4BHI3YM)+M+>2M9PY"/6CYNR&*%3,VRAC'054HWH/6ND!YU=D"UI#I7JTI))ECG[8SJ@Q2(]>O=2A MGD2![R8Z*/VI^'7L-C=6O)/'TXL3;JB9_)X]F@D0Q_T0DL\921Z4% #T.I(Z M#4K%^W2Y2W"A+M$M<_4*#IQ!/%)RYQS$^M'<]J4I/[%=C\PE7]M"C.8..(EA MXQ;OSCP1XNRN,GEO>#\;O1M9Z28:R9]S U96$(?>=3WU@Z*;49LKUVH*9 J$ MIR"4SQSR BBFV.I.\[?5H^5N=6DY?W%REXDB45E>4/$?%\#.TF+X?;X&W@B/ M]6R2.".?N24^9E4& J*?&E=VH1L%10(JZF MG4G2XI"DRD,R)CP,6,VOI[!ZJ7AE]P3IE?ZNM]%4/4-R8;7;5C2X!/$?U<9*'9!!ZYTK"W&ZL#Y, M_%+EASPB7O!3YN[YUE,1R^U:RR<>*M[E657,-\L$AJ+=WJ"*=2 =-#J%;K6] M8:"OVV]JMIJUI,I:D'3J$P.)E($Q%75.XVVDM*5V#I:*I:3A,3Q.67;%?>7Q?(.6W=WE^2W5U>I>.?U/(7$4T,\ MD>_N&VLTHUK?W?2T[_I4RTFL.*0%!6/-4IR[C[(M]8?V2RT@H[($ M@CX0)2GS,@.<0]Y)\CX#"W=IQ^.P@I:V$QMUMT,ETTK!88C.(QO"*E?EKZZ> M^T=LW.[4RKH^X0%+EC@D 8RF3CWB)!VEMFZ7,O5KJRD>HG,X$8DRQYX90+5^ MO(>632&PM&6&&:JB_D%NJT).X15#;.OK74U6VGH;:D(<6"X4XZ36_%/RS4K\(D3B/DO$\. )AG[DV?5WC;UQLS* ME?).T3PD -)_341]PCK&_4[;_3'Z_N'T'Z7^JUW=/H?H/J/S?'M?^S76+YK_ M *3\W^;Y?5XZ9QPK^0>^=_:I'U?7].7_ !:?OCEZ_P#4F94Y!/MGXI,SB%3S M[.D1.4.[;B,=&S**[MJA@.GOJ$^L#AIKG1.-YEI4YY9IB\_T1*+-SO%LN,ZDK8_N<9Y2XQ:)P[!Y&RP R= MSA)+A(UC,RQJ.Z\=06[*GJS@=:#3)I6:@T^MQN:>.'"(HO\ =&'JWY9#\G. MX3[8W/E*SQ4_'K3.8*5.Q+%%^H8QU"7L+(M""I >%&(^;XZ5*FE873AUOX)8 MCB/Y0D[5J;B+@JAK0<"=*Y>50..<\QR@(K?)^4.;MD,=!9CB_#[(LL82IEN9 MH9 *;6JS&Z(J?CHRI%%34:4,J4^^1,I$PA.'/,G\8D-A+C%T0^H) D1,@$G MCV1)7%N3]9Z5UI=;HG4!8D1+GB?9$U9F.[R/';.U[:-$R]UV5' CCH!M9S\NYCHA<%3 M'RP[X;-O73TEW<>F0YE(G,P*?+;86U^]FM&?=M2C DN_K_@H/II*80II9*OA M'W1-ED>+U*'S@)8]PC*XSXIR-W>VN3F2>5'I(8;)=\I=>A'HU!1O32R*A;[' MI2_1/+.4)=[W3;V4+0D@.)XJP$7D_8=XYFP,,$RXMK7"S2R27CW#)'>=QXD+ M+(IV#:R^Y]SIX;=I6@M*'$GTR,<<8YV?4GNL7)PM)<"JD-^33/3F98#CXQ.G MW7^/_"7*,1:.^(6'+P7S36T+7,K;0$ MB$ 5CT8[5W */74LT>WF[53)80E2@D=LX5Z>WO-)]5<\>)@NOM@^T6]\]9^R MM1M]&-L9 ;< MH,@8EA3V]-."HVU<&F_7??)8*<-*4X$^!,L^$4Y_^^>DIZQVF%$GU$8))GB1 MS&F+ ?M2_;;^UGQ=S=K7 MRX>EN0+J-)PUJ$AW"4A[(@'K']4_5C>#&BE?:H[2L2 :;TK\51;+A<%Q[ V< M&/P^,L<;:Q(JQ065O!;PQJHVJ%6*-4 H-6RLUAVY8D)8M#-,TA D"$H"L.9$ MB3%,;A=+E=G347-UQY\XE2B23[9QM;ZUAF@9"QH01U/0?P^&C]VME+=J1QBI M(4@H/$4I96V,@666YEE>[MED01W=I :R(5)KW? MF!%.I .N4G7;:%&B]U%):TH]4E4Q@0?"<6DZ(UZBMQ=>J3"0-)(Q"CECRPBK M7RAF[*TLKC&MDHA=R!MN!N&9F$2MNW6KJI,6VOY2=4-J=J55MOQ>?2H/A7G4 MD8"?PS$R)2D)9Q=;:="_4OBMITJ+*\-7#R^4X8>W*)%\#7^$Y[?6< :MQC?F MFM75XV'8 W;E,B>!&6/&#=BXU9-=V]U#C;=9H8C LL4)658B#11(K!A0GUKIJ MV79]PN[::5MMU3"3D"J4^9QS$\#A%4JO<%>IDT[SI4RHS(../C&;G\1<66(O MKIQ/+$D<+-"S5 A20=TA:$D!16M"?QTZ[]TOW):-O.7+4L)U)D%9@"4^(GC+ M$]N)@C;*MJIN*&4R]0Y=_"&-?X'%7,=AF+&V_4,A5+R-"3)]5'M&X2I(W;]& M]2/743OUZVV&Z8..%UT26!-6F4IDA() !$I#,0\6KM7L.KI*LZ&DS2-(TD9R MD1$4^:>*9WD&-@?'16V%@6V82BTV/=QG;NDC:..D:[U!%?4:,XD'IS?[;17!-/4O.+J%.8:E&1QRD008JB MY?B;;'JUV@C^9#ZU M)/KI]IM*ZQD>A,&>*% ^XQVA_Z MJNO_ "5_ZMW?\U_Y?_U??_-WO] ?4;_S?FW:ZE_NCW_IE^[S'K_M?J983]*> M7?'SR?M"/_6W]DE^E_J+TI?X?F=/W1SN_P#J.[B1/)GVW0"G;/!N9ON;H _Z M[8!J'TJ%]=1_UG\U=1SX-J^\197Z,0&Q>5@^8NTY\)KQCGXXBR2SV-G.%9GC MK0D G?11N/J*D^NJ[7;4EMQYN8 /W1TRL]<^M80I1T0?G@3!VV1R4<9LH9Y( MI8TFN6 MT_EV.!4LO\ '4,WAQUVX(0J9:.(!/;G+G"W>*I%);5OH6/6RPQ. M646]8?@?T> M?)MB5?(.0 MSBX"RR02[Q^0-C);M;L8YW1]BW4TL:[067KUZD:?-?8[9140KAK#3B I)"LI MC( Y\H<%+<':ES0I(4H @@B<\,_Q@H0QUM) M)'#<3LK2I,TB%E;>U?7TTU$TU.FC4ZDJ%4% \P4GEVCB(QH;TNJ]=FG&L)F" M!F")YRX0:'-,IC^,\7Q6,A$=]]?:VX3M*-ZO-M)9O5CN)]-:*WT6FTK60=6$ M,"P4M5=KP]6.:FPVX9SRD/NB!Y/$V2RE]^MO;23/)(DB1M XC$;$$;1MVDTZ M=-(593OI,FIG6> Y^$28C>])1TW[1 ZAP=P!H2?]FERQ4;J5I2\A0Y815_J_O6J90XJD=PE(XY881:-Q_P MUF;?(PMQ]+FPPLD327UF 8UE,B;54.M II0C4JT5E4XW\PRDD RE%*+[U$HW M*8KKEI=KD+D,03+N[X%/R%XBSD/D#])N[Z\DQ$ZO%(SSS,89[EG$:E2"-P)% M#6ND*\TJG%);D3+.6<3CM#?MI=VH*VF0T*M&)$ADF4R>6&<-&S^U+E7&[Z2Z MY$D64QJF2[2 D]YX0VZ&.DA'>&PC<*ZCB^*71OEHE/J9Z9@*]F<+PZWV:]L! MNT+2A\C3-*IB?@)#L,#G]VGVJ>*>?\=$TG%;+%7GT AN\I90"UF^KV%NZ)MR M]I(0@W%J@DZSVUN%^UUDPAQ+RRG3*YN+?%6:0&ZMW:)V4Q3SQ$GI3KTI M34JU_4P6ZD14W&G1Z1S)F@GG(D2G%M*J\);I"I:'FB$!1*Y!(F,,")D&"N^S M;P_Y:\#^2;3,Y.[K;6LD1"VR7 MI 95#R0B<"+:BBI(Z#3+JNI5BN]WIWK>V M6GDDS*]()'>,^56:*,HA'>H24B# 4(U*3575+5\ZIQ3E IN0Q)$\/#G'+:[;! ML@N;B'*7TZHK(2K2?-V ' F6,L8E;PIS:RY#D,]]'DL&&;B0TXVAW@"H"&/U+L%1;K:TW\N\TRG#4I!3//F #& MRG\M\NN^>3<8QOT@L\5%+'D)X%ENIII =P-N "-^U"0-'=P;YW%25CJF75(: M!,B#A+V'&$:BV!;F]L,7BK<$W6TF9D$S/"JXM!0I(Q$ID2Y1M/22[5#:* MAEF=*HI(6 HI(.4CID?;C$*^0^=\>S>%O,E_J*QO\A:1W.4AF-S!'/9"6-^U M:VDA*H'3;1D;YC4=-5DW+N*Y7&N=N]>_):E%7F,L\<)RB1]F[7O-HO3-O-)4 M)HED)*BVK0<1B3+MYQ2US7-9_DW)+[)08&^R"I=31":T#17)4+2KR*@4[:;A M3U]-0]<+A05;ZGJRH9;<5_41C+ 9?PCI#MNV6FS6AJD-0TAS2"0J1 ),S@<< M>/M@B_M3BY+'>9&_NX8+9%WR+!DOJ&OHHVF&\))9Q&19=@Z:KOUO_:7VF&:- M2EO),YMRTF0P,B>!XX2B'.O#MN5;_1:6DMZ0"4D!,Y<9F4HM7X89Y;2WN+AD MDCE^8%VEQ"1C( YJ5.22@,;?YRZD[ MTUY?W4MUAC!-%IT &KN[0_S=+2TZ-*:9EL(2!(R3P\>9XQ MT7V<@5%*PTDI#;:0)#MYP%7*'R,\YK#(@D+O6NT%"/4$@=2=6(LZ:1IH24#( M >,6#M":5MN84#*0\8BJY9HTD'8F4*"IV L?X] 3[:>K0"U ZDF'VY1NK$.(IG$JD06U M>R1G[H[0/JY?_P#'#]7L;N?^6+=2A_\ X_[=?C^3KKH3ZCG_ *(:\=?[/_X7 M\(^>?T&__N@]+#TO]6^[YS/V119_ZDJUGM.6_;'FNU_R\_'^>8_NM79W8K_& M7;QDT-"4E!'^.DWK"WKKZ,?_ ):_<4?QB6OHR/@(HI#$U)! IJ JZ@=4%MI\R)Y1T?ME4E! G*6$'-]O/E#!66:M M[22\AAQDC!\CDI)=M)%*[(A7V:O4_AJ)]PV.I8JDUCVH"8Z\O;/#BSW;F"G^I+.P4;PQZ#H:TTH/[6<;N#5,RLNMEM)65 "4\9")( MIW&V&U!*0F1PE.&QX'YC@QS)K*_MDFFRE[#/3&&VF6 M1Y8B\4BT=9'8U*Q&GI^/II""Z<4OI@R.>?VPA(VC0W"CNCU34I*D.ZA@#(@\ M!VQ'.#Y/;\KR5G9S9"._OH^Q;2I'(O\ 3^G95!,2ENW51Z^^FK<%N**4F9U' MPSX0ZJRVFT4CKK*0AKS*_P"UC%@6,P&#Q.$Q5_DZU J!J5TL4!(9]99GRB$.H=/0LDBH6^GBCW!=\BIZT&EUC=:J$>A,I)XX1!' M_HQ/"!:61%F66V?//@,H$S[H/-UUE<%;X9IY;=+M56ZK0@G4Z;S1:ZNAIV M'&TJKELI]02\@.D"83E/M&,6Y?MMLIK:I%S2E:4ID"9DZ1B03,$B.@_[?/'N M'P?'+;-\^S[94Y+'AB,A<_U[&9DJ8 CM'T=B*'4.T-D2U5AS29$]N$N G.*! M]4-TU57<%T&WJ?TDMND#2,%">!F/NC<\DY]/A;-.,X?(0Y:[GM9[:Z%C-W); M6"63_EEF2(-3U4 ZG)JN>8LC=,DZC/$#,8'.$:R;6%6!=[T@H;:4% J$@HC. M4Y<)S@@?M\XYG?"AM^1\LFN%FS5F]W$DKEL>KNG=MDF>4+(&G#4IM/Y=;K/3 MMVM\5U9@3CCE$9=4;G;.H@5:K,@*0RK299X$SE*>4XT_._N&XUR7F5U8<2Y/ MC\!RU8YHIFQ$Z1I]6V\R->(CFMP""I]"*Z;>Z]XT547D!P)2%$#$HI342WG2D[,0>\5=B"P)]],U^E0]5)J*LZI''E**S=1]W*OS":5HE25$'AAG$Y7> M37%I-=F139VL;RN8?G;9&I)10@.YR1T&EJLW93;;I?\ +K2H#*13GRY?;'"( M3I[?45M2EE(,U&640'FO*/);R+)V^&QKVLMR'DMLG=R5,6XCM6\<93H@1:GX M%M1G4=0ZRKPKZE(0X[YD)Q6$]\I < ,9R,3A9>G=E9J&WJQ6HI:!*>!.(QQG MGX0Z^%\AOVXM9Y#E5U%++)<2V\DW:2);!S5DBFVD_P!$>@8]0-)=1>E.OJ:; M*G+<5:$FW*^)-E<=+/ MB8X)(9!).Q_(I(("L*5J/\=6 M$V37%ZC;](R7A.7/PCH%L>Z"II6RR9$RP'. 5Y;>8\37"ITV H$# U/J*&O0 M4.K(6)BJ])*E\<8LA96:K0DJXXQ$%W6. 7+0G9(S$&I-0OKZ TT^V)*<]$*\ MP$/9HC66PK%(ADRY7%Y"2XLPK12HOS(R_F 8!B*'TTY&:"MI_3?/F;*AB(VU M=2*:C=*E3/HN>Y!,=MGZ$O\ Y!/T'MBG_EM^F[5#_P#Q]^7;Z[M=%/05_P"C M?H_F_9I?_HQ\[W[HG_[@OW*>'^H]4_\ ^3/[HIV_]1[Q1\CX<^WGE"0;OT7R M'R#!RW!6JQ)G..O/'WFI55,N+Z>U=)/65HI>I*G'0D+'M*#^$2M]&]T%/?ZV MA5IG4)9';Y"YE_VL8Y(L=90R7@A-)08I*#T!)!&U:4^:NH,??6ALK&!G'1]# MRVJE82 1J/WP^^ 8#)9G-6ME;K/!;Q3"6XV%XXE4/3^H1^>@.D._W&GHJ)3[ MA27")#B6WX;)AK:PRDBW\UG8);PK/M[33E=JR!SZ M-'6@'0Z@%+]7ZZJA@N(<4HGR]\\>R'FU2H+04_*(FOO'<-MD+6.X:W&)R;GL ME56WAM]RU):H]_C[UTX:?<3CC"M /S;8Q)F=7^R-0H4%W _I$PV^+\6BXMS2 M23'V]HUJ;B)8VJ)&85] 1U_RTI72\*N=E3ZY5ZPQEPP@_0T:6:L2^&)6\FX3 M)IQ3D%[<9.:U2:*'(-7.<_M M[(7*E3+K4FSH*.79*&)]L*Y.VYEAATXMUJHGWD413Z;C(24RD 0KX@)P]=(E33M.H2RDF28J,_67.VUCE2Z MAM*EJ,L\YY06?A^VM\MQH8NVBM;JXP]W/&\AHO7VTO4+*5T& MD&:TX<(@O?[E52W45;BBEMX _P W> M4 J]H8 >X'+UI4Z8M[8JF:D+_P"3.<^WE%D.@QM=ZM3MG5YZISXE*$E# "8, MI2X\X#C/>8Y[[ 3W\TZ6-XRR,\'2-7:@;9M9NC >OMIOH9L>V/M\;?2VF(21.ZA'XPEC<*36G0?QT9L M^U'4.BL"G$.)4G*0[9Y8Q6JU[CZD;(=%95*:34/J&E!F4>4\3('"?.*O,CX+ MR_&/)N3M?&IMKCBN*NI);6.1%AF-O$FZ,RR4H\X<4)]]2$[;ZMM27'BIPD@Z MB<9=L_PBXM#U"I+EM.F5N,!NL>;DK3,XG#RXY1,ZL;9 M1W>,Q;I62*&7M&-)!2)7<+TH!HPY355(LU"FVU,D RFJV7=PT^ MUJ.E0DKR?(,R2)SD58C'E$E_:=!Q_F')\EG;V]&"2&>&=SD[I$:422Q&.W>. M8EVC2GM[Z6;37L?-*2VE.F0)!)P]_"&EUN=KMOV5J@90'@X")I& ,C,@Y3,& M?]YO*N3-Q*RGCY'@\''#;;<0EE=J1>RQ0B.U=4'SF547=3TZZ3^H.Y$,T8;' ME,L C$GAE.*\] [59J6^.?.L/O!;AUZP !,S./&*,L':YJ3D%QFK;(SMEOJG MGNYH7<"]OFLXH T# M;R!*>!2!*61X2$3AQ3,9VSS$F1OL=+?7)BQC!8;'#>FH[O#5 M [3I2T\D!/#.<^)G,PS;U0VU^A%'3NAMA.$D\CQYQ*T_D+/YR\[E]B8K"-2( MS-$&8+'0)M6&I'S >O2FF,]M^@8"G6GRZ\K'3@![>R&8WM:W6YD^@^IU9QD9 M9YYP9?ACF\6-QUG;VMK&KFA$]RO:[LP=@K/-N^9:'TU"VY&*FFKG%J*2#P!R MRBO_ %&VRNY*<]1Q29?TR/#D1!_XP6&4PUM>Y:_-Q-&HFG6UE*VD;N.@81@$ MJH^)TFI^5-$XY4*4%I3@$\?''C%/KL:JAN/R5.V)A4@2,3 7>7?*>:X%G/TC MCN2M;BVR]U%#+VP[+!;7$])1&2VU9@@I7UTWMJ;3I-U"IK;EZ@;:2N0!D%$) MF <)RGG(^,65V'L"W[FLPK;BVIJJ:!(E+, 8XSC?Y/E0CL$O8G9HQ!'(BS-4 M%U1-U>HJS,NHQIMN"KNIIEI""%$>7.4S+.-MKV\I-*MYKPJ(XU)C$>UXT)C^8F11UKZ5T]6]II:NZ;?;AZGHMI6HK.! M5GA*6'#G#/WI6VS8UR9<<8#[Y&&J>0..((C;\TQ.7\2<#,T');[-16X2*:V= MU1J2S!)*"-@>VH?K7T T]TV]BJT4+ZVVGW/RH,P#C@9SEEPA.VU=+?O_ '$? MF*)NG4DS"D3,^_43%>?F=\GE[1,C(^ZWNHF D04C<$GMNC)ZH/3KUJ-2?L1* M+>\*5P$+!F)C,#\>Z+<;"--05"J8 (*9<\L9Q7?RC"WEM/-.RB9"Q(()92/ M3J0!U%.NK1V>X,/-);'E4!%IK/<&'6DMC RACM=-%$K/"UTF\J8(AU 8BIV4 MH%TXPRE;A"5:#*W_]8_O4D^M^Z:Y8R_NZN^*U?WR/';\Z^PSGF3M+;OWG MCS/\7YHFU:M':6^23'9.0'U 6POY*_AIM]6*,5.U_F_SMN(/_> B6_ILNIMW M4ZF8G)+H*>\YC[HX4S9RVL_=MYH5CAWQSIV^Y' $9-O3N%E )VU]]->[VR@=;)6?,DSD3GV0Y M+4"V^"?A(@F/'' .4^E[F-+D]Q)V+5+56JD45@/AIA7:NI6SZ%L;_S" M<"2 ,.?&'14TS?H!;RPE!RQQ,/KR1B+WAZQ0""ZOD2"".$S.S]IY"0)26Z= MM=(5OIO5J=#ZDMK5YC(2GV000M"606CJ2,,X';*^2+[CV5@DMX;>.[BGMW6, MQ"98TJ"SRES0EO3^.GM1[98KZ4A:E%N1QG+'A(=D;/G"UYA+5#8Y=YIY-RSO M6&4F QMVPB>*U00M+"'J8P%-"05^7X'2[;MJ4E"I-2@J55($P5&8!X<(Q57K M6GTP $'E%E'V<\ X]#@1D%%]*^1C7)PQ.BSW G<;8D6H-$7^?KUTPZIVJNE\ M>%1IFSY!I&>DG'WPV=XW2LH;4W3TY :423J,@ 1CX\HNZX!PKCV1X+"+RT2Q MR]U8M!D;] (Y+=T#;7"@ @$>VG +1K8"E2"R,3A%*MR[FNM#?M:5ZZ1#@(3F M".,?KQG977B'*WEKM"%5.O0CTT3(5;$Z)@H,:] MT/(WG1H=;2I+Z>'+[XBOSU?<0Y;;9NWNTMKZ".V%SWVC60QSQEID=5?.<= +%25C-H]1Y1]8D9F? ME,I?C HWE]=+89#&A6AR%M<5M9+;_EI89K=PU"$V$&0K0T^.I(8I635-5Q.J MF4GS!7F!"AV\IP?IZYE3Z[*PF:\0/MX1>?\ M?<^XOSNQN\-S*QO+R[6$XZ2 MYC::1;JU6$P;7:K$3*PI4Z\M=&EJZ/4+GF;04E//2N/9SD,K7%]#;_J2V4-+2=6/=D $OQT-O;7NNY*+6A4Q* M6'*&/>_J.>MNZE5]+3_IM+(053U3& PF9##G T<<^UCB7VZ>0\TO-9(9^,Y. MWNKC"RS]R=I9=Q-MVIG2@EV@JZ>Q((TTD;=N6U;^^Y7R+"FR$SYS!'N!B9KG MURNG5G;U)3[=21>6UCU1*4DRDHRGP)$CR,57_TKQG_(^FH^NBJBY5CE2ZMHALD);*B%&?+F.R+C=)+, M_06=FOK:9OYE: 5$$8JD)S 5.@ W." M:L2-,RXTC:&W/GSH<*2=))G]N42;7&D%.MRJ/E4#A/[>Z"]L\#?X/!I>99[9 MH12299WB2<32('!H/F" GT%-0U=5+=J_EF 4J4<)8X#^40M4W*FN-R^6HPK6 M+*6/,+E;&1)XW5E,(9GE-R6H%D(_E]M;^G]0* 586 M?TO36)'M$A(=_&)'V3=T4M.XIM0-*6R)>S$'E&ZS>%ER5[@.'PS3QRW:++/, M*&-52N[>4)H@VZ;6V5Z':R\K2V=#I0D'MXXQII[HW2MO74B:4K($N[^<3IPN MX/B>TRD'URRRFU4P J7@DE"[D;:6%&D>G^>FNYNFN_U"7:)$W"2@D"8E/[@( MBC=-K/4*K:>0E26D+&KA(3\W/@(%SF//<_RE\ACLC,YCR$D\,\2ETW;Y"3L. MX!6H>E*:E6V66FI:E%X"BJH1)8)Q /=E*<3'M;9UGV_2(J&426 # @<_YCRS M@MZ.*V4T60L!"+JRMG(I/\ LB>-N6"U7^G%R2DM.H(2LIGX'BMJ?52L.LI$Y@S,NT9Q*E+97;:CUM8 M<:2)@@S,AV0WN+X2&VS]TV21I%B#K(C&J@J01VE _)_A73J37MO-M 2]*4_] ML*=XKUNVU/RBI*5*7\^V#3^U_A6&\@?<-X@X[!;,Z-S"PR\T9 *?38/=EI6* MFH"HMEJ1^F%!37+>5(E(FM#J52\3%:NO6X;IMCI'>[J%@.BG0V.^W\E?\]NNL.@?*^G^7T]/X1PPT_P";GPUZOQB%_N6\;VWE M_P #^6_&MQ +C_6?CSD^$A1MI!NY\7<&Q<;B &CO1&P_$:;^[:%=PVS4VYN? MJ+;D.^''LRY(LF[K;>%D!MFI;4>X*$\NR/YJV7M[S"Y?)\O,;?A ME/+I%,K4A6#B5%)':#+[X[9[?52W2UTU>V M00\PA<_]Y(5^,%?X3N.'9:PQV$R,T=KE+N1H!*5!=2YVHWS@*1U]NNHBWDS> M:>K55T\S2"7=VP\*1/J2I6L'09^R#2\11WOC?E7Z%>=C,X#+7B6UJY0LR2[] M[. VW:OM3K[:9KUV7Z@>T:73@L<#D 1QG!N]45:Y;?B(*1-)!D1@9@XY1/7 MECAQSJM>6UA (XWC;9+"ICEM@2=A#49C3X:U5 74*^81@Y[/?"-M:XM,I%+4 MKFH^,C[XK[\D<$R&1RCH>,X:R@MF8Q3Q6VVX:&A"B4@%NC=1I;M-X3;$$.NO M^H?RS\HQX1(HMK-:XA:=!:YX$6CL;M&[:V;Z\ MXA+14,,,X OR?9P<2Y-:(&@M&L9XYKZT.PLQE/RAJ$GJ?\M)#C"%#Y=I,UZ< MAP(Q\<(L;M2O%VM*BI4TK$DGLB#G/36X;CN- M-<*@Z*=2@H'">8D<8TWA3[B>.9=(+2>>\@N,G(6M()(@\%L%4(805%:NXZ#U M.D#IIOE=@*D5@(2N9&>$S/MA7ZH=*KU:GS4,)]1I/Q$2GSF<88WWI0CEG',7 M-93V\%[B)WG,MV"4-K=1 2,58?TF!44)H:_QULZC;@;OK0>;,E)5[I'G#G^G MC_HU]=*TDN.LZ9 '#S))$QGD,(J.Q7 ,9Y&S,.'Y4(K'"QR+;]ZTD%S/D9E. MU))9%!I&[$#;Z=-52O-54LU8>:.@IP!3(J)YSB_%SW&[M>U+K:$ERJ(F0J:0 M@'@!G.#I\=_8/P_CL5ARK$8=GR1B=HU5XX8F65#VKB6V?='*RJ:5H":]-*]O MVYNR]4::I0==9E-,S/[S/P]T5E 3MU&=VMMXM5>IE]!"S,SX MCLSB5=E==-MU-&E#:PE\)QD%!1,L<9>WMB/LQ]N.=XO8=X20P.8Q-<0[X7V2 ML!N1=I#;!TIIF7"[N-O!-4 H@2SA\4'56VWBHTXJ3.0,CB.<>?'>#O>IGGBZR@AS#'WP+QN.RC4^% .I$Y<>_N@N MO%'AWFG!ITSN/@BD.=D3Z>SG*1F)IA\UU< J&6.).HKZ]-(5VH;GM4O% M4M=SF%)+D+Z)?I6E,5'S=+,HXI/ <01#)XQRE M+#E,V$YQ>""=XC!9YB3=''?B.@A3N48+=D#YPQ&X^FG/<[(NNM2:[;:1Z6J: MV_Z)YF6'DGERXP>NM(EFT,&W36M1R[<9^[^476?M0^-XN4^9L_S;Z9&M."\> MN(X9F52_UV:86L;JY-!(;>-^@ZT-=6-^ES;S-QW8\X\F571,)6H_[RBD>^?& M.?/US;E%LV7068+'S594*U)Y(2G5[-0E'15MD^F_(:_4;]M>NVFZGK\>G\-= M()(U]DHY*37Z<_S:Y_C&7)8M(%!D H#\I^9?YE/7T8"FBR@%JFH33R@TJ>A M(29*3QC^?S^ZQ]N%QX,^^;S!8QX^*TP'.\H?)?&'A18[:2QY9(\]['"JU >' M*Q3H5]B/;5.M\43UBW!4L.*)0X\MQ.$O*M16!F?AG*?NCK1]/>\3N3I_35TQ M\S1M(84WJF5%L:-4^&H)G*1SS@#.,V]VF9QS4%P))>*L4G[H%C+XOWJOH12U"%I4GXCC(\IP4W$/)5O>V]KQ MDR[Q& 1,)-Q978 (ZTH::6*&]%,D*Q3WQ#M]VF[3N.7J0VI( 2K$YX< M^$3#P&*[AGR4UQBKPQ2V#RQ,*/&&2(]R.(J*U8*3Z>NEJMIVKHR76U!$AE*? M\(CO<[R*A+3#3R4+0L3/,$\<1 M9'C>1_P#%5M>7V$P^J1RLT,,QCMKYE8F.V:*I#%">A]--ZH7\B2EI0)M"FR<,@58D?@(FM^K745A46SIRSQ[XNZ^QW[BIO'/- M<1#DKV+(P28B!)9>YR'),A!:/QGD5L M);4JI6.SDD^9XP0#695/0]*GVT\;T^S/X9Q6/8]M%L0U9*8GY^ MD,B9_%+ >7EXF("\@IFN+8'$Y+@$&2M1'!W[>[F$ZK*2I?NKM52Q5QTU'5X9 M<0=+"2@)$P3$H;5\1%OC3S+CL=SN#&8E+^#$VV1B6=YY7F@W-*@ M[L,@C(")2M>NF@NU.4?IUM2H?++,]!()[SQ'LA\;MV.[6;97451;-0&Y2"9' ML&<=!G_F'XKA.-<>ML;D;'-93(V5K!:K:R[A&ZP1[WNT]8S4$?,1UU*5/U(: ML5$BDI*?U4A,@0K3+_ND1RN5TFW#=;[6.UC+E+0H?69J3F)F6DS \88G*>3W MV9@7+KGK6"]NKJ,C$-;!PD->L:S0R';5NOKJ)=QW&IOE2JY^D1,D:)@Y]LAE MW0\]N[^(%Y!C[^]LYY\[$_=ON_%;7D=P?H@0 M:@R25 C*BE1U]=0Y>-H/5#IK'W- )G*7XZOPB4K.[2L50:ID :""H8$R[I#. M/#Q\;V&""7)62C$8JY$L9VMV+V6*1@7;?7=#04KZ=*Z:3J&*)U27"%!,O'#Q M@SNH4[Q>;97I>=1+M2"G[^,&+:\AAN)+"]401130?U%,O2VC*AAM*_(22!3H M.FCC>XO7NE,EAC'X<,9=HD.45?JK!54RWFR%N*G@0)3XX@SG#MY#RW'6. RM M\JA9L78=P2R#:DMQ/&3:1CW+2,PZ>NK+U6Z*.^V]O;M. 'T-^99!(!(,AIYX M<\(:]JLSKMU;0]-"5+Q)Y#XC TX[BUC?\86PR%O!8_+<2, MR(37H>TM/0G55=_HH=RW,6:U@IKF"&CA,**5$STX2G,O2BGKK>S MTMW>U:/7<;F&4DXI)U2$Y X>TP\6.OMI*&*!=,M*M0!7Z@D,1(RTSE P9_Q M7%^J36>0Q#B[Q,PNKJ&1 =\45"SR-050TJ?X:2-L5MX:KC;ZE*T.9', =GV, M3M:-^-/4:7*>H0/53( *!..4H@3S%CL-D<:ZX5K42P5#K$M?GIM6/I[ _Y: MF.V4ZZ&K14+,TF67'_9$G[#JZZGK Y7A1;7D2>'.*]N2P-?QWN%D:6WNX).] M;743[9K>1#42QBG\C?YC4UVAT4JF[@@!3"A)22,%#D>^+,4 2D(K$R+2A(B& MC8_H_+[BXX[R")FRUFJ+-'/'M:60 4O;*5E!8,1ZJ>FE]\5]C:1=+4J5$XHZ M=)G(?T*$\^PC&#E3.B:#K.A;0DHC^GO'XB.K[]I_PS<>,OMUBSF0DG?)QHGS7BC*SX;EUQ;Q M;KJ7A?(Y%%O-,PKOAQ&50'K^19W/OJ"NL]@55M,7FG3/TTZ5R'#RXGNE%LOI M,WDNS;L1X;+Y?L&:"/) M8V#(S&%I(BH>[AB,G:)('4#J=-&HH+Z/S8DAZ'^;T/OTUKJ;2AIKUT8B>$' Q0/3&A))[!*)_\6702021@O5 MI69-P)9E6K G65 P#(I.$^4,;>FWV'+NI*M]$XNG"D$Z=)BF-[V>\Y4NH"0%JP$N_4?#3FH":=L)6J?MB!=X=/KTE:RE*PGGRPS MSCY]RD]GSCBV)R?#[FUQ=WC\E']9);=J&2:T;Y3:>Q:I]-%+TVVO3Z4@2)P7 MZ54U?8[RN@NREN,+$P%3.69Q@"N>>#+'F>)3/929I++%R+)=6MP=\D%S"/FD MDBD8.T+-Z, 1J/JNRN7"H+C:E)0@&+669O)+("Q:XF075A:J5C#2 H9)57ND2>@ZTJ=$+$FJ=NJ&6%"6 MLR!/E[APRX1;?;UV9KJ$*>_NZ 3/XLOXQL/MMSO!L?<126F9GCG"1W5O!=JS MW@EC4,\=34F .>@KHU>$71FN4Y7("%9!2!Y3+++B82MWERX6PT5O2%Z@H$3R M!&:10M(F2IZ>^C*KDN MC;0E1GJ(PBGMMV'>Z.]5%U?96AI.HZI2F,V!U\$ M^/K^SX[_ *IM[(Y:\66-YL0=S70C9PH54)!#J#N]*G3)W"'ZRH]1(2II)D!+ M,<\.Z)KW_N*F9J/V69;9TX+P GWY0?GB+B.1_P!88;D.0&5LL7=3QF[M1'). M+>(J6*/%,2B.&Z=*:2F[9K(="2D2D1**Y;YOM(BP/VZB#*ZQ"3I. )/>G$B# M]Y)AK&IRKY!\;C+''I(DZ106QFD+?(94<",,B_#6BI>IZ)"O4 TI'8(JU:J^ MY5 50I2553CO:92G/A.7? B\U\W<,BOHN+V\\]_C<9,\S74DH>*XN)"IECVJ M0LG5>OL-0_NBZ5EG-\J*3]R<3I?6D3PX"( XSG*4+'_I= M7N#YAT:JCC,'[91L\#Y.SO+(\7-Y%!/3L^.0V-[]>] MT$%AU92F>4R!S/#&*X]3:5FVV!B\6QOTG7S( @!029XB7.0)G!FV_BC%93.8 M[D=O!;/'%:;K:0TVQ-*21LCW;-RBE#[>VK06?Z0K'>=U,;TM:4FV/,I7\,TZ MB5''S2)D1PY179>\[FS0+M^M?IJ5,XYY=G9#ZS/$[*WM]Q1-R15J**"R*#6@ MZ5)&IQW?TEL]GM*DAMO2EE4_*."<8;U-<%O. DG7JPQ[8K,\_>>/$/!,MR'C M.7LUDY4+<0/-#8*5=+@;2HG W2-&K&HIZZY=[WHK:QN1UNTT@]1#F*DR EVB M+>]).F&_=S-TUZIE.)M25 XJ7B > RD9?RBF/D6T# M^4,?D/"+.9I\[#<0R7!,@,:E0:-T(8$U--NG:$U5%3AH*!8GEQ$.2U;B>04V M]:5!N6<8'B;PC<>;?)O$.$8EFL\Y>96UM([^VB)EBMA.K73RLH'_ "T4&YC7 MITT^]@4C]\W)3V#4335C@\IQ$\YRX'""W4GJ(QTZV57;EJ9*I_1( )&).0$Y MXSCM X#Q>PX9QC!\6QD:16. P]ABK9(P%7MV=O%#N*KTW.4W$^I)UU\VW9:7 M;MF9L]( &VD# "0RE^$?/M?KK67V]U-XKE%;]0ZI9),SB2<^S*'KI7?'7-_&7*K.&^X]SKCF5P&1@EB#@K?VLL"3BM:2V\D@=#ZAU!'4 M:2[U;&[Y97[>L8K0I(/$&1 ,*^W;W4[;W#37BF40ZRXE0D3P(P[B,(_G5_<) MX3SWV[>9/(7AWFT1CR?#N0WF.261I+>'(XYG-QA\K;K+L$D5_BY8I.@*AF(' MIJDESH*NU7!VWNI(?:41EC+@GVZ[?N3:E/=:,I5ZB$D@2Q.(,^9!! M&(AL<3-N9[:UQ^043/)W5M))E:"9E%"@ ;43'2I2^REN7G C+Y"F%-M-->2)9QN0%DC=XIY'W#;V8U(;NUI M2@T7M:KAZJ44X+BQP(!2!VGE!QOTJ=02]\)X?R,-KBV Y?F,A%]/^I6N%,AC M2]N3+-DG@KZ]A4#!0/<]=+%VK[)2L%M8:_&?<(.HJD)&O2E+8& M9D#!=\'L\7QB[5^^)[V*([IKIF6X:@_,QD/3TU'+M=5"JULI$IX "0'8!*&Y M?357*F]-((8)X8CW05'C+GMIE[N3#SR%GOIQ:QLCEA SC8IVN2O0FO3IIST- MTN*BA"]24*4!A/#W1#6\=L.T3 KVQ)+2=1X3ECP@@\5<#@=V5[[7D:R&XC&V MLB(SJQ 4=#2O0#KIYH>524Q,RLY]L1;7,_ZBI]6@(5*1Y$XP3=MR+C_D/ VM MK)<+8M$\3Z:9F"C^Y%O2K*W7J.FB=-=4N@^H)@'C_.(?>LMPVU=%5*&] MP_-#(N_:5(ZUZCKHVFN M]12@VD)FDCX1CAW1OLFXQ9:U5>_1M.2)4)I&'<2GA$ >1OM0LN<<.R'!\!>I M>YF6T57%M%=XQKJRFNL?/;1C=+&XD:8.QJKKMZK MHM:-N4-X4E\N3;,L)\?^U%=NN_4RFVW2.VNG<4AY*5 *2K@1@/MG%\EG99&W MFBQ$N'C&+MVL[6W:-U>W2T2U0)L@3J'68=?;4UL[<(K&V&UGT0$B4S+(<)YQ MR_KUTM2E==ZQ-0M2E$GXB22 B:7'*T36V6QR2VU^J# M=#=QL6*)V_57/6FDK>VW[;2-34E!=R(4 1EGQE$P]&'=Y"X-M;6JEI6LS.AQ M0*4SQ$L09F7**H_&7DGQECLODLEQV"RF/ZW-;+;/:E4,891#V@P=60*>AU5Z MMH :]3P=2//*4R.X"+W[HVOO"OM[+%Q<6/T 2H'OG/(SB6\QYI_TW=W)C@MK MRXRUZ1#C[)8]UK \:T;M>P4GU '73NIE &H*$I(X"9,N$6%;KF&6TI"&TI,A) M,@)=T-^ZO)N/1Q3Y1WN&[Q.Q6+()R"$B2)B6JQ]#ZU]-*K%,FZ*4U1)"$E,I MD2PXDG*%1-,U=,& $Z!/O''+/N@YOMT\-9BWP(\IWF;EM)LW+!!%;]V9[^WD MN6I!:)$6[JQQ4JQ%-NENS;W<;;5T5MVYK4 I*CI^$F9X $1"M1?['N[;52 MF^,-H;9)0E 2"I($I*D)$9SGRBX'QO->S8''-D8$MKU[6)KFWB8M#%,84+K% M4 ",-Z >FNI?0&X7A[:U&W=0M#H; TF8'PC&4@,>Z*&[C9I&+@\BB5JIPLR, M/#+VXN;"X1DK_3<#H=Q&VAH>AU,6]+6FXVEUH %9;4,N8A#I5Z7 3E%57G/[ M:<-S_P J83-Y?$7$7ZE(;,WEJJRVZQPQ,1-=*-O]4@>K5ZG7)+J/T[KF]TK4 MA!;]59P D")X<.$70Z;=;ZC9>QS;J1PN.)E))..,S*9)P[H&WE_VC^'^(Y/. MQWF5O[?(2B081+ZY$4'>$ 9S"#(00['Y5^/IIC4]H8M=8IJM<*5 R2)@##/E M/LG.)KVSU\WWN1FG4U3#Y1)DX0F O>#-EQC,C+=M]7(D1F M9G#1K(:HB@DEXP0#[Z<]/06RI1-;H40/8MR9W$E@UC24'1,R $B=>4X[L6-H)>+\->XB;OW5ZVQLO?QEC3M00E8T(K4LWP MU<3Z7>G+3UT=WY5(0JD;26V@I *2ORE2DS$A(83'&<4.^OCJ91(;I^F-F6?5 MUAU\I5E(*"4$#GG(\LHZ"[8*A,:J11%;=2E>M!4^Y &KS-*]5)>/$QS()*2& MCC(9QF:V0(6A C%EB9E8G8"*E34]#_+[#_'6"=:'II_M'.,5)UI\WQSPCFM_ M?J_;_M?*/%,7]VO$\5+<\F\>8M,)Y!M,:\ZW>3X=W&ELLL(HUVSRX*[F?N,2 MI%O(3Z)34)]5K"^PS_J.VA.H*"701$3/9QQ9#Z*$6NF#BODV10RF29@$'_ YD]T3CMRN8#2!4.DOD M<)??A! >-^)V\BQY//2-DLI+L,5Q=.9NV"2NR,$!!MH:FFHRW7?5H6:&W#TJ M),YI0)3XS/&'%6)3+YQ.('MQP@KN.8*>)?K+2W[W;(51VP(W'I0#T &F-1T] M94K^8;EH'/,^Z&W<+@TH>@ZO3J'B(<]QP[*W\GZD^(5(W4P[8DWFC+\S57I_ MMTXT)?DE.A,Q^/;*$MF_4-,CY1+Y*@9S)E'IP[A=]@+])+6TGFD-T;M7(D#P MAC\JU -&1O\ #1OTZM* EL)TSF3Q ]D:[]?Z:Y4I0ZM(1HTRY\S$M9!N4W65 MLX9'NH@ LB[F8Q,%6G;;Y/E+5_AI31<#--,OU-79E]\,BF39F:-QQ 03B.WO MS@C/&.3M[17^MMY#=*PA-K*%C+RMZ&-Y"J$'\#I2I:;4V2D +)R,13O*D=>$ MJ522V1,*X2'.4S[H*2PPUW:V)Y'>/%9VD2L[V[/)M6$J:.9AMB5C_$:7&&VT MLR4DAP>S[XA>HN"'GA:FDE542!/"4YY*J=)C5[IVG2R\%33AA*1]XA\V?8-=?*S]EN 2:5> M.!.$L9Y<)#""!\;XWAOFS@%ORCF79L[>P:.:YL4C2>ZNKDK1?2JO#O0UHU0/ M;1M=IHKE3+JZHRIV\0D8G'L\.<15NRJOW3K=/[%MXJ4'9A))DD)!'.9!QY>, M%)XSX]P_Q[BKOD^*E./QT!55M58]J1W7:/Z5*IT]SK?0"W6FF->A2DM)X,9L?W)V5C+EG9$N)HKT0V*,RI'+$JJ6. M\M4;0?A[:*67J6KU7*]*U>BA1$B!/ ]\N'."*NCMQJJ1'IR3Y9F9.?LB&_/W MD:T\C<:EC@M[#)Q20HD$6^,J]P$=9PLA*E@I) 'J?AI!W/U!=W$LKIUJ*,I$ M '#VQ)G2K9U1M6XAQQ2VW)G41.4B1_"*@[YLY;3WN+Q%GA\;):2$".&)>[%) M"0=S$P,>A]Q74-76LJ:QXL"QV9>+_ '*I*:Q*OE2HZ0!F M!S/; A9='Q-M=+9WC93*WN_8E JQLQ)#S*!2)/AZG\-%V:9"GVS4A+;">4R? M?F3$[T*Q4NM_,(**5!$SS[LO&!NR?+X.'2W&7YM.F3NGF,6&QUK1A!>;BL0, M9V&0[Q4]#J5;7:G+SHIK CTVFTS<6Y/$9DB4QAR)$2K3V5V](316 >DS(>HM M9TS3QQ$\XLA^QRXY+SO-67Z]F=F4S!FGPF/N%N([6PM80K1R30*>V[ 'I\M3 M\=/[:5UMZ[FYMY!6MZ82523IX3,P>?9%/OJ19L.UV%.4C,PRF3BDF96<9RF? M?A%\7&?'N+@@L)LQ:662RMDI'UYMB:EJ;^SW"PC4^WIJW.V.D]C=::N5Q#;C MX,Q.9_E',:[;ON-54NMTJG&Z-1^$88=LHG#$010PC9"8U%5 &T4'3\IIZ'V MU;#:]MIZ:D2XT$)0CR@#D![(83[BE+(DJ9QQC(O+B)8F1S_*0U*>E.M.HT=O M-WI&$$.S"1.> RX\8#3*SASB"/(F:Q^&QUWE) B_1PDQLW0J3105(Z@FOJ-4 M3ZV7RS,O.UK25:R#ID!.?_:A^;:MM97/M4%-(K4H"1RSXX'[HHN^X?F4N7Y9 M=7TN4:>V65I('GE<&(JP 2/YR*U!]#U&J(WNZN5]25F9\\D]D^)EP'C'4'I3 MM]%OL#-+Z"0_I 4$B8.&>('M@1K7QURK[@N?X7QSPJ"&XSF?O+:VEGE;;;6% MDYI=9.=J2=E;2V8R5H=Q7XZ?/3/;MTW;N>GL5$4FJ?6 E1*O3PS*B 3I&1D) MQ-%XW?9^E>SJK==]+@H:=M1"$2+BU<$("BD$D\R)".K?POXCQ/A?QOP_QSQZ M.%<=Q;!V>-$P)$E[=Q*6NK^>BC=-=W#,[$_\5/;7:#:FVZ;:FV*;;]O2E*&D M@*E.1)Q4<<<3SCAYO?===OC=M7NBZ*4I^H<)$\P,DC##!.&'?$MP).I8RE"" M.FTUZU_]T:[MY8Y*H\/,K;*2+6"25IK[C%_%+A$4;6DMRK$FAU3G?6V7=IW,TX2"P MLE3:C,B7+*4YSCJWT$ZN46]]K(MKY_ZLRG2L2EB.(Q.!GA %V44=HE+:+L;# MM(555]P)!WLI)9U(I6M#ZZC9U:W5?J'4#%@:.KKJ(I!)D()?P=G3?8XPWBEW MLKNXCK0](Q*SQD[ZFI#4U%'4&WHIJU-0W_;6E)([98Q-6W[@NOMA;)_4$60> M++C$7,<4%[);@.1L@)"E]P]:UITIUKI*L[M.ZQH! [(C;>C5@IK6MHI25$>6"MUW#7J9 M-(E:@]IEX\(R.6\XIH:K''[_XUUBFG0F3P C"RW2Z( M:**Q2OP\8C*:.WQ5S*EW$R/)*)A+<)UV1GY>RO0*& ]AK*GNK1*@H9'C^$.Q ME;M>UJ:/E2)2';SB6LMF+=N+0QXB]O88;JWF22SN6:XM+R1E'25)@Y6,'\NT MBFE)FZTQF$' @YY'"&+06Q2;VIRJ2DK2L&8P*>[MBL#RQRW+8R2/CM_;"W1\ M@DJ74BCKIHU;B@2M298SG.8'VY1 O*=Y<^+,UA>[#;WV(0NG8C1T,<@D>&[BEC(HGR]1 MI2L=]54H&^XS/) ^,&6E MCK,UM>PNHE@EH2F_8PZ"5NOL1738O=?4E[Y)M4@HR(^W."59TIMSCR:_T@9) MFDY'[")MXOQ>#E&!RG+"U]):PVUU=7?<$ZVEE<*O;V=PC:_<29+CEJM_87VHSJZ%5 4N4B\UXB9[\O"+$;5L]%=7OEWFP%J M;G.6/"?WQ =QR3D.3^HOIIU[44[ MY8+SI!*AP,CV9?=V1):+1;J313-MN%#:9"8\G>2AM=[JGO3H0M:5''C[\AXPT;OTL&YG M ^60253$L !GC/\ "(+Y3YZQ[R8[!W'H9F?+")&L&R;-M^D#3Z==:D :1@D89&,6 MRY[/@L'D[J><30@232W'XC_*Z.I]*5!ZZO'1;S6_1,_(+!*3',M-.Y;:AVGKFL2)$*&(_@8= M>+Y4+A)7@N$I:2-;7<+U5H+F.C21R)7<*JP(]B"-2);]_5-N0A]QPAD)F1AG MC.$BIMKVOX<58CM'"&YFO)>$FMKV:WR=H[6(874,4I,Z.&VA.W1F)9A331W? MU>I;G3N?)KFX$JPE+'VPIT6U[LI:/T5:5<>'VE ,_@ZL: ==1I06U3RP\V 7E'2 >1Y M=_NSCISM^STM@M K%) 2$C5,9(EB?=_*.@3]N_[66\5<"C\G.<P(6A A:$"%H0(QKFFU 0#60 5^)_V:&@KRP(Q@:]$N1, MH%O[KOM@\??=7XAS_BOG6/C*WMM-<<\[IL'.V.$_[BOM]YY]M7E/DGBKR'B)<;G,#=O^FWT<,HQ7)^;5U4M**V MUN!*TH!(R,QF"#/''&&'P'E8P61CCDB,,>2G$,P3T1B".Y0>G73'W)9OW2C5 M(@K:3,3X]D3#M>Z>FI;C#^:IU M#K=(]2D+)(U*,Y0^JA#-6V9@*,N,2QP;RI?8-9)5=E+2!K,I91%MUV+34U47UL@R5.9QB;N*9:UBLSD\C<+/ M*HW#ZCYRP)_*/Q/QT%W%?HS"C*41_>:)Y=1\M2I*4=F$1EY0\CXNPN([Z^B5 MDA"]C;^5Q7HA%:;*::CUR73NS\QFSJJB6'*5LI<) )_JYP* MOEGZ*WO\JYC^JMLB9I(KMHP5!DZND;&NT:37;K5)JE4[:U%E1F!_")HV3ZZZ M=E,]#CXFEXSF+U;"\4DO%%9,XHTRD@=M VEM 2 M3^X6[RU3*9J S5SES,/CJ#LZAW;MYUVB0D7>F:*T'(ZI8R[Y"+.\EA?'F9FQ M?+>(?17<-ZL+WMG:,C&>0;'6=("%"@4Z]=+5OJ*2_ .(:":O(KEYI\\3^$5 MHKENJB9>LU\#C:FR0A2N Q$M0)G/A!X^&>=0S\#S7#)^)28Z6YL+B3<\1!NI MID>*VG6U(=&"*1U##UT]UUML3;7*8L(*2!,D&2-';1JJR=E(X MHQMKM?\ RU7ZYJ0JZ*%.R?35(>7@2>1/+E%^.ENZ;==;$U44;*=:DZ H#S'B M22>Z NY!D,V\<.1XU;?J^4DC+W<%C))#;P6+KM[\+OUW"GS =2!IPT%!2.3: MN+A;8$S,IF9C(*EX]@B<;;1TY(7= ]$3./%1R$#OS#F>1Y=GK3@/&K@G&=Y5S-UN;LQA#2:$$'T!4 MUZ]6.I2L6WZ6QVQ>YKLF59IFTGB>1^W 1(E@ME':*9=ZKFPI]*9H[#PPYY=P MB?\ "1OQ_'0XVS/82U@C6.,'UW'<2QZ@LY8DZC*X*392U&9]WNABW M!:;I5*JW_,5J,S]N4;6PYOE.-W_ZI'?733V:">(6KL1$P8,E:D+T8#6I-H9J M="6D)0K6)$X&8@A5;=H[M3?)J;3Z;AD=0S'&+N_M/^[^\S\.#7/W=Y(\.+[5 MUCHV0M))M6CA'.U7:E2VE.@O-;05H;2XKR9@&0,L,.PQS>ZZ?3U3TM>_66Q* M$$K,E]F.![!$\\[^XQL#EH<]8VCV^$RM\EIG6FF(%J2"L-Y*8R5WD44_ :? MK>[*JKH33U+BEA2B/-P&$L?;$7[9Z6)J*+Y&H*7*Y!FDX3D /*.P$8=\19>< MLRV8SLW)>)7Z-:(K7-ZME.\L3QDF<231R?(1(!4?"NF=6T]13NJ4PK2E8(F# MEJPG[YQ(-+MR@M5+\A=F?U%D)&H2,\L.Z 5^X7[E;#,Y&\QD60>YRB*UC-"( MZI;S+\CD&E-RT/\ EIO5HJ*JG%'3I]4#!3JNS##*9.64HLGTPZ5.6ZD3='&@ MB@'FU3'PC'GE!$_MN_:'=^6LZ_F[R=A&' N/Y&.XXEC+^)A_JK)V\C2)E&B8 M4?&VK1U4, &>AZC5GOI[Z$)W'7HW)?T$6JF4C2VK .*SRD<$RE.8F3$*?5I] M0])M&S#9&R:D+O%6PM-0XB2\XME3KA(4HDX]IC<#T'\!HQ'D M?="!"T($+0@0M"!'G(I8+05HP/J!Z?QUZ"1EG TI5\48YB=A1DZ>]&7_ #UK M0"TF:<51[(.)*7/"*^OOV^Q;A/WF>-)\+=06N%\F\>M[J;@7-V1#+C,@R;AC M\B5$[;>7$(2FZ#'#2/:HX>^)5Z6]4[STRO#3M M(ZK]I<,G4S.7$@ C'+O$<2OEOPKY%^WWR9G/'?D[ 7G'N4-D+!4J"1JG5]M%?97U6ZX-E#XSQ&.?(D2[>,=;=L;LL MVZK33[@VA4)J:!21ZYD4*23PT+"5J.HB<@J6/ $P[^+9J&[LTA,P[D3(7BK1 MJ GK0^M*>VHBO=O6R^70GRJ!QB;[#5&I8$R.Z_V M1.G%N8SXL6R-*VP?2GEV0=KK73W!HS Q'*" M#P/EDW@$,EX@%M"L:Q=T$2-_&M#ZZ\-0Y\)F $X X3B.[CLM+)+C2)ZE3)EE M#:YWG\AF,7=I&;>XFAC:YB,G556'YP"&/0CVT0)U.I;J=4BK&7 99_;"%"S6 MUJWK]1 (,I2YDQ!-KS7,@VTG<6!V=6EBC:1$G6$"@8:4'[-2H*PDJ4D# X8' MAE#H8I?G $J;YRF,IYYC"'OF>;19+&+%EYX+8&.D4)(V1L3T:K_\1TBBBJW* MD%A*E!)X1NH-OJI*DKI$J4J>)_"(.S_).,16-[%DLC;,K[TMQ&YD>1R/RQA MWSU T\+9:;PNH;72-+F)%4Q( =O9#_M]%7JJ$*ITR(EJF0!XS([8P/'7.L]A M)C+#D,MDZK.;>-&N[5,?;F@CBW=R(2S%5]:4KIQ7*G:IE>I3I0PX 2%?$HY MJ$LA/G!C=NV;7>&?1J&664F6H^514>)XD#NBS7Q#]RO+Y;;"W^,N63)89?FN M,AH5XT MSQP "9DF>1D.<9'GS*IYIMVS\]]]5),T(R#=;>&$1*VX(J=2"X% W4Z2[M;' M;>U\ZTF:YYB1D>X3]\;>FUO3L17[0&@EH Z!F3/G_$1'^%PF!L\786G'8;2: M2RQ9BR[%-1T%*W475(%.VZE92)*F2< 91*K+EL^2"G MEH2ZAT2&!G(R.7+.&/QKBUOQ"2\MIQ)]6=LMW<24:5KJ3<2D#A 1 "*C\2=* M-UN[E^2A]!'I9(2,!I',!3.2%B>!^Q\()W[ M;?)47&\MAOUT=B.[B6WAEC8FX1F7IW%CW^O^6DJN8I*6N=7B4))Q .$S[Q$8 M]5-JN7FVO+MLU*3YB")"79.47PX2/QMR[@EMBK];.1\M:J)9\C$BPH94"_U) M=NU96<#U(-*:5;#56E3J4+49*YI5R[HYHW6HW9MOX_A;+ 8^TPN%Q\6-Q6/M;>TLK&T$5O:6-O!$$B@@@C 5%5 M1UIZGK[ZZ*4]MI*&E124"4LT[:0$A(D"!W1R(J[A75])SGV1O6A9E*,I(^.]06_#WH-&0"RG4WYG(+.?K&2L$QECH /P&LH]C[H0( M6A A:$"%H0(6A A:$"-?/$'/\ 5,->2@JL-RH53D,9.6VR0N:=:BA M.H\WITYM^\J980I+%QD-+FD*E(SD<1@92.(SB7^EO6._]*[TU64ZE/V<*/JL ME2M*M22F8&(U"8(F")@81QJ?<1]L'F+[./(E[Q/R;A9H81-(,!R>R@F;C/*[ M0-MANL5>4:);ETIW+=J2(WL10FFV[]HU]DKG+1<4*DDX+TD)*9Y@Y2_XB1QC MJ=TJZK[?WS0)O#%4VV\1BUK\P,ID%.!G/#+'A#I'I@$LG(Q9>RW^AKTAM13Z@P_ 0XH)7,H&Q6!]W%3_#I[ MZ2'&DEN9,C"^_5&F6"WBGESAPPFQK'2+Z>6E))5=D;K3JM#0&ND=U%4 ?-K1 MP&<&6+CZD]29=A'\H^7$0%XR*-UWT I[G633Q0 5,HU M#L'OA3:J:58 6TV5C(ZY''&RG;$X*?+-#&7[E"MK7V42 MW!^517UH=%J>DJOF$BOJ4L!1E+\WL3G[8/MJ=3YE+DG@.<1=AI>09B^NKP<> MP]HL)DBMX;R<21K*M295$5N03Z4-1Z:>UP:M=OI44ZJJH652*BE,B1RQ,:$W M!YQPEI00$X9Y^R-[87O,+.5C=C"S71F06ME#!<1 =:%^Z&:J*.I)4C2954]@ M?0/0^82SI.I9*3X2Y\I&##::BK2=;B9?A[8,GQER>[X[@[E..,/ C&A"[*%J^FE*GO2*BH-.I*E MZQ@.V8EA+C";:K*^S>&UU;2"4B0!!.![YY1'?C"/D7*L/=1+$ <1W0Y=SU=GH7VZ%FG"UK$YR_E, M8QERV'#L!R9\KFDCO>],LP:\V2!(E!(9%?*^T_+41])242.G D]ISRC\^0/*N(N+AIN-XZ*6%;&&%YH8TV*T! M4U*QQG;11_CK%NFN%Q_0JUEMM6D:5=F.1,HT6/;%716]51<72I0<)"9DSGAG M/MG I9#.WN3O+^XNWVSRS&44&U3$1_3"CU'OI]4ML8HV&VV1- 3+QXSA=2Z M D8)&7='I9WJ;X))0 %D5I>F^JTZ^I7X:TU=*HH4A&.? 5]YSP,F9KZ5Y;C8!>2K' M4)D3X@Q'.ZNI%%L"OTW0(2VX"4F>?@ 8?7,? =OXB^EO&E/UEO)"9(;C:9%> M!P'$8,M>H'MI.?=?4[^L=20V$6P]2G-[:Z9"1\NH&13.4B,.$%%XM\CY# MD%I^DVH=;1C;TCBD+R33LJ(5B@# AB% 'S#\*^FC#M6X\L6^R,:JU4C@.!PX M#/ \8A?>VTZ6SO&YND>N 9S TA(),R3AQ.,']XC^QB]\F-7"$Y'D$;,LD(RK2GNP8\*H(3:"]?;5LND'0>MNP9W!NM*FZ=LI5H4)ZP M,2""G0I#CHP2W/RDHD,5#&1!D(N!PN#QV L[ M7%XFUMK#&V%LEK96%G EO;V\$:!(T2./;& J@>PZZO'3,4%OH$T]J90TP )! M*0D2[@!%$JRJN-RKUW.YO+=J7%$J4HDDDG$DDF-] 26D&T@ J 2/7IZZ/A,D M)F9J(@@%%2U&4A&3H1G"T($+0@0M"!"T($+0@0M"!"T($>;1J_K4?^Z2O^T: M!Q$N$>2[X_#P(4VG<0"#U8^H]*D_CK6L23A,>,9)Y9CMQB%?-_@KQ9Y_X1D> M ^5>)8OE/'[^)P(KR&,75C/M(COL?? "YL+N ]4DC8$'UZ:1[_MVV;@H%4M> MRAP*3G+S#M"LP?&'%M;=U\VG(T9)(956XC?XA@*'5?*G9ZW'#\ MLJ0!^$Y_8'QB]])OF@=8:65H?<4!I*2,"/CE"\S6LT>+OG6K%,I8#EAGC'@>(X2>Z MB>*S$LL9#&6Z9W,;*0>A=F%:ZS%[N#+"DN.%*#P3A,>$;57BJ?4$M-ITSXH' M\(<&2-R]O'C[9%,?3ZBX6B$@FK1;5H.M*'211!A+IJGB=7Y4G'Q@^[ZXQGG& M*8K"&T M8A]8*I'$BT7> '?:*=#\=&/5JUOS>5_E\R3RY""S-*R^I6N>')1 M'W&/3%8/Z%OJKPF^NKAM^XUWQL1M[48!HL8'0TUJK[F:L>BQ^DR@2[".9[8. M,L-TH(9*@>,R3]YC=O(\(>2=UCM46O;EJ(X]E3Z#U(TF)2ER2&@2\3F,S.-O MHI6H*S=[(CF[N)>0O)',]UCN.K.SFVZ->I9A7<6IZG36K*)Q2E5-:X@$F G&DN<5 M>\KG.3R$C0K:1M!+"ZM5%)-)(QT66I^/0:WM5K5K;4Q3R4I9U:AQ/(\O"#;2 MF:%9;;&"Y@?;A#D\4^/([[*Y3)KR:QBM)I%MA99$PPVCK;5[RHLIW1RE1U(Z M'VTH7.M56T3;#C;;3CX;LJVH_20\YK,Y(F0GA_*&=Y MWP/%>/9NP_0FEO;#E2ZEQB952I (49D M\0"<_P ((VN\.5%-ZM!*>9 RC?>%O'W&>5Y&WMLW+KG5BH-*R5--ZOB Q4>0)P C*_W2IH;:BZT2FTM- M@E>LIDD GGC/#LCH!^V/P1%X#XA-=70'U&52.Z:.4B);.,@,(J$T,A 'MK?0 M6U1;+RZE*4*Q65!)^\B.>?6/J2]U*O:*2U$$TZM)D09]\AA U^=? 7EOSOS7 MZ/QSA;_._47+4:W66.SLN^[$37]W016T25^8_,:>@TCVW:NZ=RWY-!9K=4/M M*5+U@E9;QS)(24CVQ+O3_JML7IAMU3FY*EAJK0CX%*3K40,@DG4?9%EWV9?M MV87P3%9\P\FWT?+>?,D3I8@N_&\"_;4N+2"8%K^Z#D@RRB@H-H'KJ\G3'Z<[ M;M9U%RW%HJ[SJU)(!"4)D)((U$*(,S.0G/+"*;]?/JJO/4IU=IVV#0[9T@$# M3ZKB@22K6$I6E)$AIGP[3%HT5O" "B[10* IHH4=%"J.@ 'I3TU:8M(8:2PV M EL2$A@/9%. ZIU1)E,\>/MSC,[$8%.OP_,:T_$^^MH D)2C"9TZ3E'HJ!: MTKUI_LZ:&4>SPERC]:$>0M"!"T($+0@0M"!"T($+0@0M"!"T($?&%0=>*$Q* M/1G'B4K[$?C30]12< "1'BD!6/&,6XMFFBD0JC;UVD/&LBLI!!5@RL"I!UB5 M)5,/(ULD?#*??A'@#B %LJTO YSBK?[O/VH_MP^Z6*^S@X^_C;R5;<+ MLH;1+BZ:I0Y[#KV;+*P&3JY(1R">NHSW5TMLVXB:NWE-'68G 2!/:D&7B,8G M/IWU_P!X;#=;:J"NNHDJ'E49D2/!9!D.P@^$9?'\7'E7 M@%@6DCY?X\MKRXO+:%6KW10W5C>6+RPR-=6TL5XG:Z;+JWF57A<>X(!U %]VVX^_ZM* "TJ\CLIW=.K$@T!IK"N^8JEEQT*U\ .'9'M12EQ$@D]DHT?+N8+B ML3<6^/DC>:6)QN1PQ#&M*4).E;;]BFWI D. A MGUES988]6M6 UJ&9D)DX>^,N'I>6TEU"TJJVZ=9&.^5:>@D>NT^M-:',6%H9 M4$DCRRX> A:HJEIVE#M/3J6WS F(OO\ VLN&>+?*=[F8\1PJ\M.6<:@M;NXR M]U ;JU*/*$"P7)7M12CX'K7258-H7J_7#Y/TG:AY63B05) )ER\OVQBCWU1] M0+IMI"V:2I"*1TA*F =*@2@2F,9CC[^,7^R>#%)E>2RLJQ"0J MI 2XD%#VJ>M!ZZL]MGZ9V'4MOWUXII3BMN:@HCE\0^^.;]'U)N=E4^;20:Q_ M_F&2M';B"!E+$'NB8N.@$ZC.$KTU'!9!C*555?RGITZ"G^ROIK/%S/ Q MZ!HRCUUE A:$"%H0(6A A:$"%H0(6A A:$"%H0(6A A:$"%H0(6A A:$"/.5 MML;MZ[5)_P M>*2I0*4_$8\*M(U,!D5E>H8. 0005H00=8.(;+?I5 M4E)[8V-%?]YDR7P@./._V#?:W]R,-P?)GBCCUSF9 PCY1A(VP?(XF;<3)^JX M\0S2L"U:2!P=,J[=/]G7Y1>73)#X$M22I)Y\#(^(B1-L=6-_;5(;HZUPTP/P MJDL#NU D>!E%0OEO]@?% W%WX*\O38Q0LC18/R'8RY2$"I*Q1YW$1P7B +T# M203'XDZAR_\ 0>J<6IVROC3B0A4_9/28LMM?ZOJVF0BFW#3J6UDI3>DF6$_* M2B6$_P T5VE%8^$VZJJ*1>K-^21WXN+P@: M,[PCSQX\G-CS;P_Y'PZH6DN)9,_]P"9/;/*&C-Y!RUJ* M)CGQDQ8T6]M)TE45_*XFA0 K\*Z;7^C*4JD^M2TCD1+^,.8;N74C T$:D;JJ92(9PY3E MX0V,CE;Z_>M]9##S8>RHW42-=9HV42J:^I]M.6AV[N:Y!)ME"\ZVL I(00"#VR B-K]UTZ M76,N)K[DS\X@G4D.)5CQ \\S%@/B[]E/[B>42VS&YO;G/YJ M.(#5:TH)9I*4_C6:-M?3Y;:.3]]<54$?E25)'NEAXQ5G M?GU=[\W>XJGMA3;:0SP0$J,CVJ!^Z+2^"^,^%>-L9'@^!\2X[P_"P +#C\'C M;?'QT%:&1+>)1*WON=F/7KJ:;/M[;-@831VRG0T4>7ZBU I/Z8SA'(0SY!F8 MS=90(6A A:$"%H0(6A A:$"%H0(6A A:$"%H0(6A A:$"%H0(6A A:$"%H0( M6A C\O\ E;^&A'HSC#?\R_F]O3T_]NM+F7#QC$_%Q\(^K^<_P/\ VZUM?#^7 M/A!@_!Q\8_(_^\_Q_P!VCJLA\64%$?'PSC7C\LO\5_-^7\I_M_\ V]-8IR&? MC&^HRAKY?\C?_+OJ/_US^Q_\7XZ:NZ/A1_Y3C_=\,HVVKXU?W.']O/CG B>4 MO[\W_P#3+\X_^HW_ %/Y1_<_'X?AJ)KIE_\ )<^. M4&ZGA\,?(/['\W\W]O\ B=%T_%PSXQZ/[(SXY=\94?JGY_4? EFT:5&*,OXYQF:UQG"T($+0@0M"!"T($+0@0M"!"T($+0@1__V0$! end GRAPHIC 6 tv524860_img-macular.jpg GRAPHIC begin 644 tv524860_img-macular.jpg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

T8A?IWEO=N M2'R]34".VH>&@ZMV@5QF.*.$_+%%Z:1VYV1+G5F([$K3;!=P.=6'I/(=^2< .U8I(I#-]PZZ)!1B!X2U>@RI4@8GS'>D4Y=&^L M!HF*TW#[A5C8^7*17N (/6N!#M\A'B**&\](:7$Z471O/TQ3 , 0!)VDY 4 M .>-'Q"%@@8/GUS[UH-WMG EQ^6M%O=1ZL132?X->.7*M:V+Q21 M@>7M:,ITM':T_:Y>)_AECH?I;9G1M%WM0SY'L) _'L.>+P -/!1Z$4Q2X#0N:X4<%,R2AQ2U/:EG IG7(_'(5P2FUM*UQ;RJATJO ) M(XEJ[=:'/(]0,:N:'YJR6MQT_(5':Z6P@[0U9$(%0 .E3F<^N>)X8Q'6O$(>YNQ?%H;YFFJ/;++]M M83422&I";75V76XH<*K[;E:45 M5,G6M:UI@KHUCJ@;68;R:()YA=*E74Z5 MHN1K4 ' >XV0'C:WQ41=K>/N &!_RN(1^>]=)XO(E0Q ^-,A]0H22?G@6WM2 M^(AXJ%+)(;60.8ZC42NK.VN(DF\[2\=)5TTH<_$-0[<:1]7J=*O@Y)E':QW, M769@\\4X;"]A$1>DQL?*,<:E@3J"Z20*FM">W"F[MG=1U*YG[T19&$N+9J%S MK,AB4DZAGH=1X3AVVZN8F^8Z!PH$KCN8B^D8H\G!*EQLU_LXD MGVB[>,("?MIBQA*9DJO:":X-MKF*?\YNI-)1*(-8=XJ=B0WY)"-T7]Y0/9S$ MZ&D8@JQ) )KW?$G#YMDV2!O2P:1DJ=/*1.YSS62N)4F]O$^Y2XAF5XF0:2IZ MY]:U-<#1[4Z-QTM)S!0>.!X@9!*L\+DN0 0<^V@[<,C,TYA+ "!HU8)?N8?+G,D= M4)-06%:USI3$\.IP\&#$JN(3'*7QFA6">2.E9G6M1X213]-0<-(FN9CQ2FY< MXXRG4.2"7$RYZ0*#NPQB\6>:23NC)I0('*UR[L56B@TIV?@,&!K4FFM) *M- M%CB68 ^-4SK3J?F<3,:TC)+W2NA.B0U*Y!F4U$BU[:*P)RIE6HQO1HRS6OU0 M.'%?B[.0:U;Z5IU[32@[3@N&-C_,@IY\<)VB)U45:FNIJD:N)76F6+$DFIZDGJ2:U M)/:3AB0!D@)#4KYC"T7LK_U1O&OQ1B\YWOP_RVO=E_WAO5O_ *:;SB (W@M4 M\96%\-S.RM>6%U'J5#J0:HVZQR!6!J*%=NVVQ;G:F$@"2F!/-'6MVZ#.I"]#'%.0\ M3]7^$;1SS@UXM]M&[Q1R20E@]SM=^BQF\VJ^0>.&ZL9'TMJH&&EA4-CB%U;3 M;?=26]R"QK'D \"!D1V$*][7/'>,!8:&B$[IL3([KH HIJ>H)R[0,8AOVN); M0TYJQ6\KXPZF%*>W-5ENFWLAE0)4%60 ?S^E?EAK$.H X'!2_72B-TE<&BJ5 M]LLEBFN))5*B(GK7J 3EB*1VI_3XJS>G[N9C1=D^'.G%+-Y%+N=]=3K&S)$/ M$2,J*?EV@8F(8U@C_>'%$W-W+O6XO$9T-#OWNXXS#5UW:J@Y([8*ZW8*9-K-5/757-OE3"^XB-*U3RUD)N1BBUW6KK0+_ &RF77L.$EW& MYY3.QN;F&R-L#XCQX+']^WW<7TDNP.0S%,>GBPR1EK<2"\^I-=/)8][GUW9F M* +X1I6O9EV#$EG$TQDD8ZO@E6\22"4RUH",D'N)Y#%,020 I\/6@(/\F#61 ML#JTR53N+B1T9>*T!'WKA]_*+2/+4'R4BN0[S3&DL#'Y41+KNY9;#0''#@N= MC=M$Y9696KTU,03\/AC2YMF3-:&T! "DVW<;MKP7M<&]J:)YH-T6-9(P9O+" MDJ,R!U8G+IB!T<\6D1XX8JW=6"_,4+NER^4%P>T.P0UYIHV9'RJV0(J M#_-I^.)@QC,6#%5"[W-S8Q$]KB0[/!$XTCD$3W:T.D%FH-)/93&Q("BCN8I6 MZG U66:V@99'AC \O,LA6H6H!)I2BCK7&([F20X I3>F QF1IH%KQZY^L4/I MWLMUL&T3"7E^\6SK$5?Q;%9R#1)?NN82ZE0E8E.=#J[L679]I-V\7,U-(-/< MN<[KO0C:Z"+5JYX+K(FN)KFXEFF=I))G>21W9FD=W;6[.S$EV+9U.>.EQ1B. M ,;Y5SBY=-)*9)'5%5$F^H?V(_C./%1MR7V.,@JU12E>VN8^7QQY8)X(+R!O MV$2_U^K^,8E8@KK)*6)$$OV/+R^"JD%30@@CKD1TI3/&U<*');AW-=K/M ]P MT?*K"U]*N:7:C?\ ;[<1\8W6YE\6[V4*T&USR2, ;VRC7]D>KQBG5261Z>%C3.HHO]7&62M!T4-0CW1QEG6IP2:!E**)ETVW;C4U-,.U/^WW4*J"T@4Z M0?A\?XL);N'6<,E=-DO6VS1*ZM#P4BXN8YXGTC5E0J"*TKGVTZ8'@CJ,50>U0-JNY[2X>,'1'(C:2>B_!NO4XFNXFEH9Q(4%A>RP"I=A7\$?@NF MW#(M$#L4:VWS[)Y();AFT%64%C2CYM0'XXT?;B740*8E,K M8R01B65P+G"IIS*9+*X^ZU^85DMU)4+(00&%>O9XL*P R0QTQ6AECF<>H:'M M4.2W07!.DQ4J5,1;37LH!C:;2QM' T*W;&W4!%YJY\D*OMS'W'V0D\QF6@&> MK\>[!UG'$R/J$&B&N-SE:_Z.CM7/@D7>]AM[F1'N)-$@8550"=-

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end GRAPHIC 7 tv524860_chrt-line.jpg GRAPHIC begin 644 tv524860_chrt-line.jpg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